>>I'D LIKE TO CALL TO ORDER THE
56th MEETING OF THE NIH ADVISORY
COMMITTEE ON WOMEN'S HEALTH AND
I'M SAMIA NOURSI AND THE
EXECUTIVE SECRETARY OF THIS
COMMITTEE.
THE MEETING IS OPEN TO THE
PUBLIC VIA LIVE BROADCAST ON THE
NIH VIDEOCAST NETWORK AND
RECORDED FOR ARCHIVES AND FUTURE
ON DEMAND VIEWING BY THE PUBLIC.
IF YOU'RE A MEMBER OF THE PUBLIC
YOU MAY SUBMIT YOUR QUESTIONS IN
WRITING TO ME AT
SAMIA.NOURSI@NIH.gov AND YOU'LL
RECEIVE A RESPONSE FROM ME
DIRECTLY.
WE ARE ALL PARTICIPATING
REMOTELY.
THE ADVISORY COMMITTEE AND OUR
INVITED GUEST PRESENTERS ARE
PARTICIPATING THROUGH ZOOM AND
NOW I'M GOING TO TURN TO OUR
MEMBERS.
YOU ARE SPECIAL GOVERNMENT
EMPLOYEES, SGES WHICH MEANS YOUR
SUBJECT TO THE SAME ETHIC RULES
APPLIED TO GOVERNMENT EMPLOYEES.
THESE RULES ARE DESCRIBED IN THE
PAMPHLET ENTITLED STANDARDS OF
ETHICAL CONDUCT FOR EMPLOYEE OF
THE EXECUTIVE BRANCH.
YOU RECEIVED A COPY OF THIS
DOCUMENT WHEN YOU WERE
APPOINTED.
AT EVERY MEETING WE'D LIKE TO
REVIEW THE STEPS WE TAKE AND THE
PROCESS WE FOLLOW TO IDENTIFY
AND ADDRESS ANY CONFLICT BETWEEN
YOUR RESPONSIBILITY AND PUBLIC
INTEREST.
AS YOU KNOW, BEFORE EVERY
MEETING YOU PROVIDE US WITH A
GREAT DEAL OF INFORMATION ABOUT
YOUR PROFESSIONAL, PERSONAL AND
FINANCIAL INTERESTS.
WE USE THIS AS THE FOUNDATION
FOR ASSESSING WHETHER YOU HAVE
REAL, POTENTIAL OR APPARENT
CONFLICTS OF INTEREST THAT COULD
COMPROMISE YOUR ABILITY TO BE
OBJECTIVE ON GIVING ADVISE
DURING COMMITTEE MEETINGS.
IF THE NEED FOR YOUR INDIVIDUAL
SERVICE ARE PLAYED AND POTENTIAL
CONFLICTS OF INTERESTS WE HAVE
IDENTIFIED, WE WILL ISSUE YOU A
WAIVER OR RECUSE YOU FROM A
PARTICULAR PORTION OF THE
MEETING.
WE USUALLY WAIVE CONFLICTS OF
INTEREST FOR GENERAL MATTERS
BECAUSE WE BELIEVE YOUR ABILITY
TO BE OBJECTIVE WILL NOT BE
AFFECTED BY YOUR FINANCIAL
INTERESTS.
WE ALSO RELY A GREAT DEAL.
YOU NEED TO BE ATTENTIVE DURING
THE MEETINGS TO THE POSSIBILITY
THAT AN ISSUE WOULD ARISE THAT
COULD AFFECT OR APPEAR TO AFFECT
YOUR FINANCIAL INTERESTS WITH
RESPECT TO A SPECIFIC PARTY OR
MATTER.
IF THIS HAPPENS, YOU'LL BE ASKED
TO ASKED TO RECUSE YOURSELF FROM
THAT PORTION OF THE MEETING.
BEFORE INTRODUCTION I'LL BRIEFLY
REVIEW BEST PRACTICES FOR OUR
ZOOM PARTICIPANTS.
PLEASE MUTE YOUR MIC IF NOT
SPEAKING AND WHEN SPEAK STATE
YOUR NAME BEFORE MAKING
COMMENTS, MOTIONS OR
RECOMMENDATIONS.
FOR OUR RECORDING PURPOSES.
TRY TO USE A HEADSET WITH A MIC
WHEN SPEAKING.
THAT WILL USUALLY PROVIDE THE
LEAST AMOUNT OF AUDIO FEEDBACK.
TURN OFF YOUR VIDEO IF YOU ARE
NOT SPEAKING TO PRESERVE
INTERNET BANDWIDTH.
IF YOU HAVE A QUESTION OR WOULD
LIKE TO MAKE A COMMENT, PLEASE
UTILIZE THE CHAT FEATURE.
THE ZOOM CHAT WILL BE KEPT AS
PART OF THE OFFICIAL MEETING
RECORD.
WE WILL BE VOTING -- DURING THE
VOTE A MULTIPLE CHOICE QUESTION
WILL APPEAR ON YOUR SCREEN.
PLEASE SELECT YOUR RESPONSE.
I WOULD LIKE NOW TO WELCOME OUR
NEWEST ACRWH MEMBERS.
DR. GARNET ANDERSON DIRECTOR OF
PUBLIC HEALTH SCIENCES DIVISION
AND 40th ANNIVERSARY ENDOWED
CHAIR AT FRED HUTCHINSON CANCER
RESEARCH CENTER.
WELCOME.
DR. IRENE ANINYE.
WELCOME.
AND DR. AMANDA BRUEGL IN THE
OREGON HEALTH SCIENCE UNIVERSITY
SCHOOL OF MEDICINE.
WELCOME.
WE LOOK FORWARD TO WORKING
CLOSELY WITH YOU IN THE COMING
YEARS.
I WOULD ALSO LIKE TO STATE
FAREWELL TO THE ACRWH MEMBERS
THAT WILL BE RETIRING THIS YEAR.
DR. ROGER FILLINGGIM.
DR. GELLAR, DR. LANGER,
DR. McCARTHY AND DR. RIOS.
YOUR FEEDBACK HAS BEEN
INVALUABLE TO OUR OFFICE AND I
HOPE WE'LL CONTINUE TO WORK
TOGETHER IN THE FUTURE.
AS I GO THROUGH THE ROSTER, WHEN
YOU HEAR YOUR NAME, PLEASE
UNMUTE YOUR MIC AND INTRODUCE
YOURSELVES BY NAME AND WHAT
INSTITUTION YOU REPRESENT.
STARTING WITH DR. ANDERSON.
>> SOCIETY FOR WOMEN'S HEALTH
RESEARCH.
>> THANK YOU.
DR. BRUEGL.
>> SHE HASN'T JOINED YET.
>> OKAY.
DR. FILLINGGIM.
>> HI, UNIVERSITY OF FLORIDA.
>> DR. GELLAR.
>> ABOUT MORNING, PROFESSOR OF
OBSTETRICS AND GYNECOLOGY
UNIVERSITY OF ILLINOIS, CHICAGO.
>> THANK YOU.
>> UNIVERSITY OF MICHIGAN ANN
ARBOR.
>> THANK YOU.
DR. KLINE.
>> HI, I AM AT THE JOHNS HOPKINS
BLOOMBERG SCHOOL OF PUBLIC
HEALTH IN BALTIMORE.
>> DR. LANGER.
>> I AM AT THE HARVARD CHAN
SCHOOL OF PUBLIC HEALTH.
>> DR. McCARTHY.
>> I'M DR. McGREGOR AN ASSOCIATE
PROFESSOR.
>> DR. REGENSTEINER.
>> I'M PROFESSOR OF MEDICINE AT
THE UNIVERSITY OF COLORADO,
SCHOOL OF MEDICINE, DIRECTOR OF
THE FAMILY CENTER FOR WOMEN'S
HEALTH RESEARCH.
>> THANK YOU.
DR. ROBINSON.
>> I'M MICHELLE ROBINSON.
I'M A DEAN AT THE UNIVERSITY OF
ALABAMA BIRMINGHAM.
>> THANK YOU, DR. ROBINSON.
>> DR. SAVOSKI.
>> I'M AT THE UNIVERSITY OF
PITTSBURGH, THANK YOU.
>> DR. SHAW.
>> THEY HAVEN'T JOINED YET.
>> DR. SIMON.
>> DR. TEMPLETON.
>> THEY HAVEN'T JOINED YET.
>> WE HAVE A QUORUM.
WE HAVE MORE HOUSEKEEPING ITEMS
BEFORE MOVING ON WITH THE
MEETING.
YOU WERE SENT THE MINUTES FROM
OUR LAST MEETING OCTOBER 21,
2021.
IT'S FOR YOUR REVIEW.
IS THEY ARE MOTION ON THE TABLE
TO ACCEPT THE OCTOBER 21, 2021
MINUTES AS WRITTEN?
>> I MOVE TO ACCEPT THE MINUTES.
>> THANK YOU, DR. REGENSTEINER.
SUBMITTED.
DO I HEAR A SECOND.
>> SECOND.
>> THANK YOU, DR. KLINE.
WE'LL SECOND THE MOTION.
THE POLL HAS BEEN OPEN.
IF YOU ARE IN FAVOR, OPPOSED OR
ABSTAIN RECORD YOUR RESPONSE
NOW.
YOU'LL HAVE 30 SECONDS TO
RESPOND.
SO THE POLL HAS CLOSED.
DO WE HAVE THE VOTE, SARAH?
>> YES, WITH NINE FAVOR.
>> THANK YOU.
THE OCTOBER 21, 2021 MEETING
MINUTES HAVE BEEN ACCEPTED WITH
EIGHT IN FAVOR.
NOW, I'D LIKE TO SHARE WITH YOU
SOME GOOD NEWS.
IN OCTOBER 2015 THE GOVERNMENT
ACCOUNTABILITY OFFICE, GAO,
RELEASED A REPORT CALLED BETTER
OVERSIGHT TO ENSURE CONTINUING
PROGRESS WITH WOMEN IN HEALTH
RESEARCH.
THAT WAS A GAO1613.
IN THAT REPORT THEY REPORTED ON
THE EXEMPTION OF THE NIH EFFORTS
TO INCLUDE AND MONITOR WOMEN'S
ENROLLMENT IN WOMEN IN CLINICAL
RESEARCH AND ASSESSMENT ON HOW
NIH-FUNDED CLINICAL STUDIES ARE
DESIGNED AND CONDUCTED TO
ANALYZE POTENTIAL SEX
DIFFERENCES WHEN APPLICABLE.
THEY RECOMMENDED THE NIH REPORT
MORE DETAILED DATA ON WOMEN'S
ENROLLMENT IN NIH-FUNDED
RESEARCH AND COLLECT AND ANALYZE
AND REPORT DATA ON THE EXTENT TO
WHICH THESE STUDIES INCLUDE
ANALYSIS OF POTENTIAL
DIFFERENCES BETWEEN MEN AND
WOMEN.
NIH AGREED WITH GAO'S REPORT AND
RECOMMENDATIONS AND IMPLEMENTED
THE FIVE RECOMMENDATIONS.
WITH THE RELEASE OF THE NIH
REPORT OF THE ADVISORY COMMITTEE
ON RESEARCH ON WOMEN'S HEALTH,
FISCAL YEAR 20 19-2020 AND NOW
ALL THE RECOMMENDATIONS ARE
OFFICIALLY CLOSED BY GAO.
I'D LIKE TO THANK ALL WHO WORKED
TO CLEAR THIS AND OUR COLLEAGUES
FROM OER.
NOW, I WOULD LIKE TO INTRODUCE
THE CHAIR OF THIS COMMITTEE AND
THE DIRECTOR OF ORWH DR. JANINE
CLAYTON.
DR. CLAYTON.
>> THANK YOU, DR. NOURSI AND
GOOD MORNING, EVERYONE.
LET ME BRING UP THE SLIDES HERE.
IT'S MY PLEASURE TO BE WITH YOU
HERE TODAY.
>> SARAH, CAN YOU CONFIRM YOU
HAVE THE CORRECT VIEW THERE?
>> CORRECT.
>> GREAT.
THANK YOU SO MUCH, EVERYONE AND
GOOD MORNING.
THIS IS ONE AN IMPORTANT PART OF
WHAT WE DO EVERY YEAR AT THE
ADVISORY COMMITTEE MEETING IS TO
PROVIDE FOR YOU A REPORT ON OUR
PROGRESS FROM THE PREVIOUS
MEETING AND OVERALL.
SO OUR DIRECTOR'S REPORT I'M
MRIEFD TO DELIVER THAT TODAY.
-- PLEASED TO DELIVER THAT
TODAY.
I WANT TO WELCOME EVERYONE FROM
THE PUBLIC AND ADVISORY
COMMITTEE MEMBERS AND ORWH
MEMBERS AND NIH COLLEAGUES AS
WELL AS MEMBERS OF THE GENERAL
PUBLIC TO THE MEETING.
WE'RE STILL ADJUSTING TO THE
WORLD WE'RE LIVING IN NOW AND
WE'RE ALL HOPEFUL THINGS WILL
CONTINUE TO IMPROVE.
I HOPE WE WILL BE ABLE TO BE
TOGETHER IN PERSON AT OUR NEXT
MEETING.
MANY OF YOU HAVE JUGGLED LOTS OF
RESPONSIBILITIES AT HOME AND AT
WORK AND WANT TO ACKNOWLEDGE
YOUR CONTRIBUTIONS AND
RESILIENCE AS WE MOVE THROUGH
THIS.
HERE'S AN OUTLINE OF MY REMARKS.
I'LL TALK ABOUT SLEEP AND
PROVIDE ORWH UPDATES AND TALK
ABOUT OUR SCIENTIFIC
COLLABORATIONS AT A HIGH LEVEL
AND WHAT'S NEW IN SEX AND
GENDER, SCIENCE CAREERS FROM THE
ORWH PERSPECTIVE AND TALK ABOUT
OUR PROGRAM'S FUNDING WHETHER I
DO EACH FALL AND THEN I'LL
CLOSE.
BEFORE I BEGIN, IT IS WITH GREAT
SADNESS I SHARE WITH YOU THE
NEWS THAT WE LOST DR. REBECCA
DEL CARMEN-WIGGINS.
SHE WAS A VALUED MEMBER OF TEAM
ORWH AND SHE WORKED ON THE BASIC
TRANSLATIONAL SECTION AN
IMPORTANT ROLE RELATED TO POLICY
IMPLEMENTATION.
SHE WAS A CO-LEAD FOR THE SCORE
PROGRAM AND HAD SPENT OVER 30
YEARS AT NIH.
I HAD THE PRIVILEGE OF GIVING
HER HER 30-YEAR PIN WHEN WE WERE
STILL IN THE OFFICE.
HER MENTAL HEALTH EXPERTISE WAS
WIDELY RECOGNIZED AND
REPRESENTED THE ADOLESCENT BRAIN
COGNITIVE DEVELOPMENT STUDY.
WE REALLY MISS REBECCA.
WE ENJOYED HER POSITIVITY AND
CALM MANNER AND CHEERFUL
DEMEANOR AND HELPFULNESS AND
WILL MISS HER GREATLY.
I'D LIKE TO SHARE A POEM THAT
REMINDS US OF REBECCA ENTITLED
SOMETHING BEAUTIFUL RENANZ.
THE TIDE RECEDES BUT LEAVES
BEHIND GREAT SEA SHELLS ON THE
SAND.
THE SUN GOES DOWN BUT GENTLE
WARMTH STILL LINGERS ON THE
LAND.
THE MUSIC STOPS AND YET IT ECHOS
SWEET GRAINS FOR EVERY JOY THAT
PASSES SOMETHING BEAUTIFUL
REMAINS.
NOW, WE KNOW SLEEP MATTERS AND
THE CIRCADIAN RHYTHM AND THE
24-HOUR CYCLE OUR BODY OPERATE
ON ARE IMPORTANT AND IT WORKS IN
EVERY CELL OF THE BODY.
THE FORMER DIRECTOR OF THE
NATIONAL CENTER FOR SLEEP
DISORDERS AT NIH, SAID QUOTE,
WHEN PEOPLE DON'T GET ENOUGH
SLEEP, THEY DON'T GET A STRONG
CIRCADIAN RHYTHM AND IF WE DON'T
HAVE A STRONG CIRCADIAN RHYTHM
THE CELLS IN OUR BODY DON'T GET
ENOUGH ENERGY.
THAT SUMS UP HOW IMPORTANT SLEEP
IS TO ALL OF US AND THIS IS ONE
OF HIS SLIDES WHICH I USED OVER
AND OVER BECAUSE IT HIGHLIGHTS
HOW IMPORTANT SLEEP IS TO SO
MANY OTHER HEALTH CONDITIONS AND
ISSUES.
IT'S LINKED TO HYPERTENSION,
DEPRESSION, HEART DISEASE AND
OBESITY WHICH ARE IN TURN LINKED
TO OTHER FACTORS AND RISKS SUCH
AS DIABETES AND KIDNEY DISEASE
OR EVEN CHRONIC PAIN AND
FATIGUE.
IF WE LOOK AT THIS SLEEP THROUGH
A LENS OF THINGS THAT AFFECT ALL
OF US, ACTIVITY, PSYCHOSOCIAL
STRESS, GOOD OR NOT SO GOOD
DIETS AND OUR CONNECT TO OUR
SOCIAL NETWORK, WE KNOW ALL THIS
CAN AFFECT OUR SLEEP QUALITY.
IF WE ADD THE LAYER OF DIMENSION
OF A SEX AND GENDER LENS ON TOP
OF THAT, WE REALIZE THAT
PUBERTY, MENSTRUATION, MENOPAUSE
AND FEMALE SPECIFIC STAGES OF
LIFE ADD A LAYER OF COMPLEXITY.
WE KNOW HOW IMPORTANT SLEEP TO
FEELING GOOD AND PERFORMING OUR
BEST BUT I WANT TO ADD PROPER
SLEEP IS CENTRAL TO GOOD HEALTH.
SLEEP DEFICIENCY IS LINKED TO
MANY CONDITIONS AS A MENTIONED.
IN FACT, IT WAS THE SLEEP AID
AMBIEN TO LOWER THE DOSAGE FOR
WOMEN THAT BROUGHT THE ATTENTION
TO SLEEP AND SLEEP DISORDERS TO
THE GENERAL PUBLIC'S ATTENTION.
THIS SLIDE HIGHLIGHTS SOME OF
THE DIFFERENCES BETWEEN MEN AND
WOMEN AND THIS HIGHLIGHTS THE
LIFE COURSE OF WOMEN FROM LEFT
TO RIGHT.
THE CHILDHOOD THROUGH PUBERTY,
REPRODUCTIVE YEARS, PERI
PERIMENOPAUSE AND WOMEN HAVE
DISTINCT SLEEP CHALLENGES AND
RESPOND DIFFERENTLY TO SLEEP
DISORDERS.
IN THE RED YOU CAN SEE WAKE
AFTER SLEEP ONSET AND YOU CAN
SEE FROM CHILDHOOD TO ADULTS,
THAT WAKING AFTER SLEEP ONSET
INCREASES THE TOTAL SLEEP TIME
DECREASES THAT'S THE LIGHT BLUE
BAR AND AT THE BOTTOM YOU SEE
ESTROGEN AND PROGESTERONE LEVELS
AND HOW THEY CHANGE AND IT'S
IMPORTANT TO CONSIDER THE
HORMONAL AND LIFE STAGE CHANGES
AS WE APPROACH SLEEP RESEARCH
HERE AT NIH.
IT'S MY PLEASURE TO INTRODUCE TO
YOU ALL DR. BROWN THE DIRECTOR
OF THE NATIONAL CENTER ON SLEEP
DISORDERS RESEARCH HOW MUCH IN
THE NATIONAL HEART, LUNG AND
BLOOD INSTITUTE AND THEY HAVE A
NEW PLAN THAT TARGETS SEX
DIFFERENCES AND SETS HIGH
PRIORITY RESEARCH AREAS.
WE'RE PARTICULARLY EXCITED TO
SEE UNDER THE GOALS BEYOND
STUDYING SLEEP AND CIRCADIAN
RHYTHM MECHANISMS UNDERLYING
HEALTH DISEASE AND UNDERSTANDING
SLEEP'S ROLE IN HEALTH
DISPARITIES INCLUDING WOMEN'S
HEALTH AND WE SEE THAT GOAL 4
SETS OUT HOW PRIORITY RESEARCH
AREAS THAT INCLUDE SEX AND
GENDER DIFFERENCES.
HERE'S A QUOTE FROM THE PLAN
WHICH INCORPORATES CROSS-CUTTING
PRIORITIES ADDRESSING MINORITY
HEALTH DISPARITIES AND SEX AS A
VARIABLE ARTICULATED IN THE PLAN
AS IS INCLUSION ACROSS THE LIFE
SPAN AND THE OPIOID EPIDEMIC AND
ITS SLEEP CONSEQUENCES.
NOW MOVE TO ORWH AND NIH
UPDATES.
SO WE HAVE LEADERSHIP UPDATES TO
SHARE WITH YOU.
AS YOU KNOW, DR. LAWRENCE TABAK
IS NOW THE ACTING NIH DISTRICT.
DR. TARA SCHWETS IS THE ACTING
PRINCIPLE INVESTIGATOR AND DR.
DRDR.
DR. AKLIN IS THE ASSOCIATE DEEP
-- DIRECTOR AND WE WELCOME A
NEW DIRECTOR OF NIDCR.
ANOTHER IMPORTANT UPDATE IS OUR
RANKING FROM NIH AS A HIGH
PERFORMER IN THE GLOBAL HEALTH
5050 REPORT.
THIS SAY REPORT THAT ASSESSES
GENDER-RELATED POLICIES,
PRACTICES AND OUTCOMES OF THE
200 LEADING ORGANIZATIONS ACTIVE
AND GLOBAL AND EXAMINED WHETHER
AND HOW THEY'RE ADDRESSING
EQUALITY AND OPPORTUNITY AND
THOSE WHO BENEFIT FROM THE
GLOBAL HEALTH SYSTEM AND NIH WAS
ONE OF 37 HIGH-PERFORMING
ORGANIZATIONS PUTTING IT IN THE
TOP 30% OF ORGANIZATIONS.
WE CERTAINLY STILL HAVE WORK TO
DO BUT WE ARE SO PLEASED THAT IN
TERMS OF OUR COMMITMENT TO
GENDER EQUALITY, PUBLIC
DEFINITION OF GENDER AND THE
OTHER VARIABLES IN TEAL ON THE
BOTTOM RIGHT, THESE ARE THE
AREAS WHERE NIH PERFORMED WELL
AND WE SCORED HIGHLY.
I'M PLEASED TO SHARE THIS
INFORMATION WITH YOU AND LOOK
FORWARD TO CONTINUING TO IMPROVE
OUR PERFORMANCE THERE.
SIMILARLY, AS YOU HEARD FROM
DR. NOURSI, THE NIH REPORT OF
THE ADVISORY COMMITTEE ON
RESEARCH ON WOMEN'S HEALTH, THIS
GROUP FISCAL YEARS 2019, 2020
KNOWN AS THE BIENNIAL REPORT WAS
RELEASED.
THANK YOU ADVISORY COMMITTEE
MEMBERS FOR YOUR AMAZING WORK IN
CREATING THIS IMPORTANT
DOCUMENT.
IT HIGHLIGHTS EACH OF THE 27
INSTITUTES AND CENTER'S EFFORTS
RELATED TO WOMEN'S HEALTH OR
ORWH'S ACTIVITIES, INCLUSION
POLICIES AND PRESENTS
INFORMATION ON NIH'S WOMEN'S
HEALTH RESEARCH FUNDING
EXPENDITURES.
AND FOR THE FIRST TIME WE HAVE A
NEW SECTION ON THE NIH WORKFORCE
AND NIH GRANTEES.
I'M GOING TO SHARE A LITTLE BIT
OF THAT NEW INFORMATION WITH
YOU.
HERE YOU CAN SEE THIS FIGURE
WHICH REPRESENTS FISCAL YEAR
2020 DATA ON THE SCIENTIFIC AND
INFRASTRUCTURE MAKEUP OF THE NIH
WORKFORCE.
EXTRAMURAL ON THE LEFT AND
INTRAMURAL ON THE RIGHT.
THE DARK BLUE BARS REPRESENT IN
SCIENTIFIC OCCUPATIONS.
THE ORANGE BARS REPRESENT MALES
IN SCIENTIFIC OCCUPATIONS AND
THE LIGHTER BARS REPRESENT
INFRASTRUCTURE OCCUPATIONS.
YOU CAN SEE IN THE EXTRAMURAL
SIDE THERE'S GREATER NUMBERS OF
FEMALES IN THE EXTRAMURAL
WORKFORCE AT NIH THAN MALES.
IT'S MORE DIVERSE FROM A GENDER
PERSPECTIVE.
BUT IF YOU LOOK AT INTRAMURAL,
WE SEE THE OPPOSITE PATTERN WITH
GREATER NUMBER OF MALES IN
SCIENTIFIC OCCUPATIONS MORE
SIMILAR WHAT WE SEE AND THOUGHT
IT WAS IMPORTANT TO SHARE THE
DIFFERENCES BY EXTRAMURAL AND
INTRAMURAL AND THAT DATA IS
INCLUDED IN THE BIENNIAL REPORT.
HERE'S DATA ON GRANTEES ON
INVESTIGATORS THAT WE FUND AND
THIS IS JUST WOMEN IN THIS
GRAPH.
WE SEE GREATER PARITY IN CAREERS
IN THE MIDDLE RESEARCH CAREERS
AND WE SEE PARITY BEYOND 50%
WOMEN ARE GETTING MORE OF THOSE
K AWARDS THAN MEN AND HAVE FOR
SEVERAL YEARS.
THESE ARE FOUR YEARS SUMMARIZED
IN THE SLIDE.
YOU CAN SEE AN INCREASE IN THE
PROPORTION OF WOMEN GRANTEES OR
CENTER GRANTS INCREASED 26% OVER
THE LAST FOUR YEARS.
A SOMEWHAT SMALLER INCREASE IN
RPGs, 9.4%.
NO CHANGE IN SPIR, BUSINESS AND
INNOVATION AWARDS HERE.
HERE WE'RE LOOKING AT WOMEN
RESEARCHERS AND RO1 EQUIVALENT
GRANT SUCCESS FOR OVER A
FOUR-YEAR PERIOD BY RACE AND
ETHNICITY.
SO 2016 ON THE LEFT, 2020 ON THE
RIGHT.
AND WHAT YOU CAN SEE IS THAT FOR
RO1 EQUIVALENT GRANTS BY WAY OF
BACKGROUND THE SUCCEED RATES
AMONG WOMEN GENERALLY IS LOWER
THAN THAT OF MEN AND THEN FOR
FEMALES FROM UNDER REPRESENTED
RACIAL AND ETHNIC GROUPS WERE
GENERALLY LOWER THAN THAT OF ALL
FEMALE INVESTIGATORS COMBINED.
BLACK FEMALE INVESTIGATORS SAW
THE LOWEST SUCCESS RATE FROM
UNDER REPRESENTED GROUPS RANGING
FROM 12% AND 18.1%.
THESE ARE QUITE UNSTABLE AND
CHANGING OVER FOUR YEARS AND THE
ONSET OF THE PANDEMIC IS HERE AS
WELL.
WE SAW DIFFERENCES IN THE
SUCCESS RATE OF ASIAN
INVESTIGATORS THAT WENT UP AND
BACK DOWN AND THEN HISPANIC
FEMALE INVESTIGATORS DID
INCREASE OVER TIME.
I WANTED TO SHARE WITH YOU THIS
D
DISAGGREGATED DATA AND THIS IT
THE TYPE OF THE ICEBERG IN THE
INFORMATION IN THE BINE -- BUY
REPORT AND WE LOOKED AT THE
POLICIES AND CAREER ISSUES AND
SUMMARIZED SOME OF THE WAYS ORWH
HAS ADVANCED EFFORTS.
TAKE A LOOK AT THAT PUBLICATION
AND YOU'LL GET A NICE SUMMARY OF
INFORMATION AND ADVANCES WE WANT
TO BRING TO YOUR ATTENTION THREE
INCLUSION-RELATED REPORTS.
THE GAO REPORT DR. NOURSI
SUMMARIZED FOR YOU IS LISTED
HERE, A NATIONAL ACADEMIES OF
AND ENGINEERING REPORT ON SEX
AND GENDER TERMINOLOGY AND
GENDER IDENTITY AND SEXUAL
ORIENTATION AND OUTLINED GUIDING
PRINCIPLES AND I DO WANT TO CITE
AN EQUATOR NETWORK STUDIED WITH
SEX AND GENDER CONCEPTS INTO
PUBLISHED REPORTING GUIDELINES
AND LOOKED AT 407 GUIDELINES,
57% ALMOST 58% MENTIONED AT
LEAST ONE SEX AND GENDER RELATED
WORD, 13.8 MENTIONED SEX, 11%
MENTIONED GENDER.
ONLY THE SEX AND GENDER EQUITY
AND RESEARCH GUIDELINES MET THE
CRITERIA FOR CORRECT USE OF SEX
AND GENDER CONTEXT AND THIS
REPORT RECOMMENDED THAT THEY
SHOULD ENCOURAGE DEVELOPERS TO
UPDATE GUIDANCE AND PROVIDE MORE
OPERATIVE INFORMATION AND YOU'LL
HEAR FROM THE NIH INCLUSION
OFFICER TODAY FOR A FULL REPORT
ON NIH INCLUSION.
NEXT WE'LL MOVE INTO THE
SCIENTIFIC COLLABORATIONS I'D
LIKE TO SHARE WITH YOU.
THE NIH APPROVE INITIATIVE.
YOU HEARD ABOUT BEFORE WE'RE NOW
IN YEAR THREE.
AN NIH WIDE PROGRAMS THAT SEEKS
TO PREVENT MATERNAL DEATHS AND
HEALTH EQUITY BEFORE AND AFTER
PREGNANCY AND AFTER THE YEARS WE
FOCUSSED ON BIOLOGICAL AND
BEHAVIORAL AND SOCIAL, CULTURAL
AND OTHER STRUCTURES
CONTRIBUTING TO MORBIDITY AND
MORTALITY AND LEADING CAUSES
MUCH DEATH LIKE CARDIOVASCULAR
DISEASE AND INFECTIONS SUCH AS
COVID-19, IMPORTANTLY MENTAL
HEALTH CONDITIONS, SUBSTANCE
USE, DIABETES AND OBESITY HAVE
BEEN AREAS OF FOCUS OVER THE
LAST SEVERAL YEARS.
WE ALSO INCORPORATED
GEOGRAPHICAL DIFFERENCES AND THE
IMPORTANCE IN OBSTETRICAL HEALTH
AND SOCIAL DETERMINATES OF
HEALTH.
WE HAVE CONTRIBUTED OVER $20
MILLION SUPPORTING 58 AWARDS AND
THE RECIPIENTS HAVE BEEN AT 43
INSTITUTIONS ACROSS 21 STATES.
AND THE FY22 NIH BUDGET INCLUDES
THE GROUP AND WE'LL WORK WITH
THE TASK FORCE I HAVE THE
PRIVILEGE OF CO-CHAIRING WITH
THE DIRECTOR OF NICHD AND ONE OF
THE O.D. DIRECTORS.
HERE'S A LITTLE BIT OF A CLOSER
LOOK AT SOME OF THE FUNDING
ACTIVITIES FOR THE GROUP AND THE
SPECIFIC NOTICES OF SPECIAL
INTEREST AND OUR ORWH EFFORTS IN
IMPROVE.
FOR FY21 WE FOCUSSED ON
INEQUITIES IN BIRTH OUTCOMES
WITH NICHD.
OPIOID USE WITH NIDA, COVID-19
AND PREGNANCY WITH NHLBI AND
RACIAL DISCRIMINATION WITH NIMH
AND WE FOCUSSED ON WELLNESS AND
PREVENTIVE SERVICES LAST YEAR
WITH A DIGITAL TOOL FOR
LIBRARIANS AND LIBRARY PATRONS
AND HELPS TO GET INFORMATION
ABOUT PREVENTION INTO THE PUBLIC
IN A MORE ACCESSIBLE WAY.
WE HEARD FROM THE IMPROVE
GRANTEES IN FEBRUARY AND IN
JANUARY HAD A WORKSHOP ON
TECHNOLOGY TO IMPROVE MATERNAL
HEALTH IN THE COMMUNITY.
AND THE INTERSTITIAL SLIDES
YOU'LL HAVE MORE DETAILS ABOUT
ACTIVITIES.
IN ADDITION, WE COLLABORATED
WITH THE NATIONAL INSTITUTE OF
MEDICAL SCIENCES AND THEIR IDEA
STATES PROGRAM TO DEVELOP A
WOMEN'S HEALTH RESEARCH PROGRAM
AS PART OF IDEA STATE.
AND TO HAVE ISSUED TWO FUNDING
OPPORTUNITIES AND HIGHLIGHTED
THE FUNDING HERE ABOUT $9
MILLION AWARDED IN 18 IDEA
STATES WITH 34 GRANTS AND ORWH
FUNDED EIGHT OF SHOWS.
MANY INSTITUTES AND CENTERS
WORKED TOGETHER ON THAT AND THE
TOPICS ARE LISTED HERE.
YOU CAN SEE THEY RANGE FROM
SEXUAL AND REPRODUCTIVE HEALTH
TO FETAL GROWTH AND INCLUDE
MATERNAL OBESITY.
MATERNAL HEALTH WAS PRIORITIZED
IN THE WOMEN'S HEALTH PROGRAM.
I'LL HIGHLIGHT TWO OF THOSE
HERE.
AT MARSHALL UNIVERSITY THEY'RE
LOOKING AT THE RISK OF MATERNAL
IN PREGNANT WOMEN AND WITH
OBESITY-SOCIE
OBESITY-ASSOCIATED METABOLIC
DISORDER AND IN LSU, THEY'RE
LOOKING AT WHETHER WEIGHT LOSS
AND EARLY PREGNANCY CAN ALTER
GENETIC PROGRAMMING AND
ATTENUATE THE RISK FOR ADULT
ONSET METABOLIC DISEASE IN
FEMALE OFFSPRING IN A MOUSE
MODEL.
THIS YEAR MARKS THE FIFTH
ENFORCE ANNIVERSARY OF THE UNDER
STUDIED POPULATIONS OF WOMEN.
WE NOW INCLUDE INFORMATION ABOUT
THE U3 FRAMEWORK.
A PAGE FOR RESEARCHERS WITH
DETAILS ABOUT THE FUNDING
OPPORTUNITY ANNOUNCEMENTS AND
EASY TO NAVIGATE TILES THAT
EXPLORE PREVIOUS AND CURRENT
PROJECTS AS WELL AS THE U3
HEALTH LECTURE SERIES.
THIS MAP IS ALSO INCLUDED
HIGHLIGHTING THE SITES OF U3
INVESTIGATORS AN YOU CAN LOOK AT
PROJECTS BY THE U3 POPULATIONS
AND SO THIS INFORMATION IS
AVAILABLE TO YOU AND WE WILL BE
FEATURING A U3 INVESTIGATOR
QUARTERLY ON OUR WEBSITE.
HERE WE'RE FEATURING THE WARTON
DISTINGUISHED CHAIR AND
GYNECOLOGY AND PROFESSOR AND
CHAIR OF DEPARTMENT OF
GYNECOLOGY AND REPRODUCTIVE
MEDICINE AT UNIVERSITY OF TEXAS
AND THE ANDERSON CANCER CENTER.
MATERNAL MORBIDITY AND MORTALITY
IS AN AREA WE HAVE A TOPIC WE
HAVE BEEN PRIORITIZING AND I'M
PLEASED TO SHARE MORE DETAILS
WITH YOU ABOUT THE PATHWAYS TO
PREVENTION PROGRAM OR P2P A
PROGRAM LED BY THE NIH OFFICE OF
DISEASE PREVENTION.
WE'RE COLLABORATING WITH OTHER
INSTITUTES AND CENTERS THAT HAVE
PLAYED A LEADING ROLE IN
IDENTIFYING THIS AREA AS AN AREA
OF IMPORTANCE FOR PREVENTION
RESEARCH AND WILL BE HOST
WORKSHOP AT THE END OF THIS YEAR
IDENTIFYING RISKS AND
INTERVENTIONS TO OPTIMIZE POST
PARTUM HEALTH.
WE KNOW 60% OF MATERNAL DEATHS
ARE PREVENTIBLE AND OVER HALF
OCCUR AFTER THE DAY OF DELIVERY
AND UP TO THE YEAR FIRST YEAR
POSTPART
POSTPARTUM.
HERE'S A SCHEMATIC OF THE
PROCESS AND WE'RE HERE WHERE THE
CONTENT AREA OF EXPERTS HAVE
BEEN MEETING AND LEADING UP TO
OUR P2P WORKSHOP.
AS PART OF THE COMPONENTS OF THE
P2P WORKSHOP AND NIH PORTFOLIO
ANALYSIS HAS PERFORMED, A
SYSTEMATIC REVIEW AND REPORT IS
GENERATED, PRESENTATIONS AND
AUDIENCE PARTICIPATION ARE
INCLUDED AND THE PANEL REPORT IS
GENERATE AN INDEPENDENT PANEL.
I WANT TO SHARE WITH YOU THE
QUESTIONS BEING USED TO FRAME
THE WORKSHOP AND ARC SYSTEMATIC
EVIDENCE REVIEW.
THE QUESTIONS ARE AT A BIRTH'S
ENTRY INTO PRE-NATAL CARE WHAT
COMBINATIONS OF FACTORS HAVE THE
GREATEST AFFECT ON POSTPART UM
OUTCOME AND DO THEY VARY BY RACE
AND ETHNICITY AND THE QUESTIONS
WERE ASKED IMMEDIATELY BEFORE
AND AFTER DELIVERY AND BEFORE
RELEASE FROM CARE.
PLEASE STAY TUNED AND WE'LL BE
ABLE TO SHARE INFORMATION ABOUT
THE EXACT DATE OF THAT WORKSHOP
WITH YOU WHEN THAT IS AVAILABLE.
NEXT I'D LIKE TO SHARE WHAT'S
NEW IN SEX AND GENDER.
AND I'M GOING TO HIGHLIGHT ONE
OF OURSELF AND GENDER RO1
INVESTIGATORS, DR. JULIE SIMARD
SHE'S PERFORMING CUTTING-EDGE
RESEARCH AND UNCOVERING SEX AND
GENDER END CRITICAL AREA AND
LOOKING AT THE OVERRELIANCE IN
THE POTENTIAL INCLUSIVE BIAS
THAT MAY RESULT IN PERPETUATING
DIAGNOSTIC DELAYS AND POOR
MANAGEMENT FOR CERTAIN PATIENTS
BASED ON OUR EVIDENCE BASE AND
CLINICIANS USE SHORTCUTS IN
DECISION MAKING FOR CONDITIONS
THAT DO NOT HAVE DEFINITIVE
DIAGNOSTIC TESTS AND RESEARCH
SHOWS REPEATED ERRORS CAN LEAD
TO CONFIRMATION BIAS IN EVIDENCE
BASED BASED MEDICINE.
SHE'S LOOKING AT WHEN PATIENTS
DEVIATE FROM THE NORM BY SEX,
GENDER, RACE AND ETHNICITY
AFFECTS DO THEY HAVE ON THE
PATIENT'S DIAGNOSES AND WHAT ARE
CLINICIANS PERSPECTIVES
REGARDING THESE DIFFERENTIAL
DIAGNOSES.
WE KNOW HYPERTENSION AS A
SPECIFIC TOPIC HAS A
DISPROPORTIONATE IMPACT ON
AFRICAN AMERICAN WOMEN.
AMONG AFRICAN AMERICAN WOMEN
AGES 20 YEARS AND OLDER, NEARLY
50%, HALF, HAVE HEART DISEASE
AND MORE THAN 50% OF BLACK WOMEN
OVER 20 HAVE HYPERTENSION.
THIS TRANSLATES TO AFRICAN
AMERICAN WOMEN BEING TWICE AS
LIKELY TO HAVE STROKE AS
COMPARED TO NON-HISPANIC WHITE
WOMEN AND THE DATA ARE
PARTICULARLY DISTURBING TO ME
AND I HOLD THEM UP IN AS MANY
STUDIES AS I CAN TO BRING
ATTENTION TO THIS AREA.
DR. GARY GIBBONS THE DIRECTOR OF
NHLBI WILL BE SPEAKING TODAY AND
THIS NHLBI RESEARCH DEMONSTRATE
THE PANDEMIC HAS BEEN LINKED TO
INCREASES IN BLOOD PRESSURE
GREATEST AMONG WOMEN.
THE BAR GRAPH SHOWS WOMEN AND
MEN AND THE RED BAR IS COMPARED
TO 2019.
WE SEE THIS PARTICULARLY LARGE
AND DIVERSE STUDY.
IMPORTANTLY, WEIGHT GAIN WAS NOT
THE REASON FOR THIS INCREASE IN
HYPERTENSION.
WE NEED TO LOOK AT THIS BECAUSE
HYPERTENSION CAN TRANSLATE INTO
CONSEQUENCES, CARDIOVASCULAR
CONSEQUENCES, STROKE, HEART
FAILURE, ETCETERA, LATER IN LIFE
AND THIS SAY BROAD IMPACT
REPORT.
WE KNOW COVID-19 PANDEMIC HAS
HAD SEX DIFFERENCES IN ITS
IMPACT AND SO WE ARE NOW OUT ON
THE STREET A REQUEST FOR
INFORMATION ON THE INTERSECTION
OF COVID-19 THE PANDEMIC ON LONG
COVID AND ON WOMEN'S HEALTH.
WE'RE LOOKING FOR THE INPUT FROM
THE PUBLIC ON SEX DISPARITIES ON
CLINICAL OUTCOMES, ON THE HEALTH
CONSEQUENCES OF COVID-19 AND
LONG COVID, SEX AND GENDER
DIFFERENCES, REPRODUCTIVE HEALTH
ISSUES, INTIMATE PARTNER
VIOLENCE RELATED CONSEQUENCES,
THE CONTEXT OF DISEASE TREATMENT
AND THAT'S OUT ON THE STREET AND
RESPONSES ARE DUE MAY 6.
HELP US GET THE WORD OUT AND TO
RECEIVE INPUT.
HERE'S ANOTHER IMPORTANT RELATED
PIECE OF INFORMATION ONLY ABOUT
40% OF U.S. WOMEN WHO GAVE BIRTH
IN 2019 HAD GOOD HEART HEALTH
PRIOR TO THEIR PREGNANCY AND
THAT IS A CHANGE IN THE
PROPORTION OF PEOPLE WHO HAD
GOOD HEALTH PRIOR TO BIRTH.
YOUNGER WOMEN WERE MORE LIKELY
TO HAVE GOOD HEART HEALTH AND
THERE WERE GEOGRAPHIC
DIFFERENCES WITH WOMEN LOCATED
IN THE SOUTH AND MIDWEST AS
BEING LESS LIKELY TO HAVE GOOD
HEART HEALTH GOING INTO
PREGNANCY TO RECEIVE STATE-LEVEL
DIFFERENCES AND WE SEE
DIFFERENCES BY MEDICAID
ENROLLMENT AND EDUCATIONAL
ATTAINMENT.
SO THESE ARE DATA THAT AGAIN
ALSO WERE NHLBI FUNDED.
SO YOU'LL HEAR MORE ABOUT THEM
LATER.
THIS RESEARCH WAS FUNDED BY
NHLBI, NIMH AND THE NATIONAL
CANCER INSTITUTE AND LOOKED AT
THE NURSES HEALTH STUDY OVER A
LONG PERIOD, A LARGE NUMBER OF
WOMEN AT THE CONSEQUENCES OF
BOTH SEXUAL ASSAULT AND SEXUAL
HARASSMENT.
WE KNOW EXPERIENCES OF SEXUAL
VIOLENCE WERE COMMON ABOUT 22%
OF WOMEN IN THE STUDY EXPERIENCE
SEXUAL ASSAULT AND 12%
EXPERIENCE WORKPLACE SEXUAL
HARASSMENT AND 6% EXPERIENCE
BOTH.
ABOUT 21% OF THE WOMEN REPORTED
DEVELOPING HYPERTENSION OVER THE
FOLLOW-UP PERIOD OF SEVEN YEARS.
WOMEN WHO EXPERIENCED BOTH
SEXUAL ASSAULT AND HARASSMENT
HAD THE HIGHEST RISK FOLLOWED BY
WOMEN WHO EXPERIENCED WORKPLACE
SEXUAL HARASSMENT AND BY WOMEN
WHO EXPERIENCE SEXUAL ASSAULT.
WE NOW KNOW ASSAULT, HARASSMENT
HAVE DIRECT HEALTH CONSEQUENCES
AND WE HAVE A TARGET WE CAN AIM
AT IN TERMS OF HYPERTENSION AS
AN AREA THAT WE NEED TO FOCUS ON
FOR THE IMPORTANT HEALTH
CONSEQUENCES OF HARASSMENT AND
SEXUAL VIOLENCE.
I WANT TO GIVE YOU A HIGH-LEVEL
UPDATE ON SOME OF THE
ASSESSMENTS THAT WE HAVE ENGAGED
IN TO ADDRESS SABV
IMPLEMENTATION AND WE SEE
SIGNIFICANT EFFORTS TO MOVE SABV
FROM CONCEPT TO POLICY TO
PRACTICE AND WE SEE GROWING
SUPPORT IN THE BIOMEDICAL
RESEARCH COMMUNITY AND REALIZE
THIS WAS A MAJOR CHANGE AND
MAJOR SHIFT.
WE STARTED WITH DEVELOPING THE
POLICY AS YOU KNOW THAT COVERS
DESIGN, ANALYSIS AND REPORTING,
SEX AS A BIOLOGICAL VARIABLE FOR
INVESTIGATORS WORKING WITH
ANIMALS AND HUMANS THAT ARE NIH
FUNDED.
WE DEVELOPED RESOURCES FOR NIH
STAFF, APPLICANTS, PEER
REVIEWERS AND AWARDEES AND SOME
ARE LISTED HERE.
WHETHER IT'S FAQs, ROAD SHOWS WE
HAVE PRESENTED AT, WORK SHOP,
DEVELOPING THE SABV PRIMER AND
INSTRUCTION GUIDES AND GUIDANCE
AND MOVED INTO PRESENTING TO YOU
REVIEWS AND PROGRESS REPORTS SO
WE REVIEWED OUR FIVE-YEAR
PROGRESS AT NIH AND PARTICIPATED
IN PUBLICATION WITH THE
INTEGRATION OF SEX AND GENDER
INTO BIOMEDICAL RESEARCH AND
WE'RE NOW PERFORMING ASSESSMENTS
TO LOOK AT HOW WELL WE'RE DOING
IN TERMS OF APPLICANTS,
PEER-REVIEW, FUNDED
INVESTIGATORS AND STAFF TO A
VARIETY OF MEANS AND LANDSCAPE
ANALYSIS AND CHECKLIST STUDY AND
SRO SURVEY AND I'LL SHARE A
LITTLE BIT ABOUT THE LANDSCAPE
ANALYSIS HERE.
HERE WE LOOKED AT APPLICATIONS
AND SUMMARY STATEMENTS BETWEEN
2011 AND 2021 TO COVER THE TIME
WHERE SABV POLICY WENT INTO
AFFECT AND USED TEXT FINDING AND
LOOK FOR MALE, AND SEX AS A
BIOLOGICAL TEXT AND APPLICATIONS
THAT INCLUDE INVERTEBRATE
ANIMALS AND ONLY.
AND WE LOOKED AT THE PERCENTAGE
OF NIH AWARDS THAT USING THOSE
TERMS.
ON THE LEFT ON THE X AXIS IS
TIME.
IN BLUE IS MALE AND GREEN IS
FEMALE AND RED IS MALE AND
FEMALE AS TEXT WORDS.
YOU CAN SEE WITH THE ONSET OF
THE SABV POLICY WE SEE A
SIGNIFICANT INCREASE IN THE USE
OF THE TERMS MALE AND FEMALES
AND FEMALES THAT WENT FROM BELOW
50% TO ABOVE YEARLY 90% THERE
AND THEN ON THE RIGHT YOU CAN
SEE A CORRESPONDING DECREASE IN
THE USE OF THE TERMS MALES NOT
FEMALE OR FEMALE NOT MALE
CORRESPONDING TO SINGLE-SEX
STUDIES.
WE SEE A PATTERN SHIFTING THE
WAY PEOPLE ARE CONDUCTING
RESEARCH AND CONTINUE TO SUPPORT
A SEMINOLE CHANGE IN RESEARCH
AND MEDICINE.
AND I'LL BE DLAT DELIGHTED TO SHARE MORE
INFORMATION WITH YOU AS WE
COMPLETE OTHER ASSESSMENT.
NOW HAD GLOBAL REACH.
YOU WILL HEAR FROM DR. ELIZABETH
BARR ABOUT OUR EDUCATION PROGRAM
WHETHER IT'S BENCH TO BEDSIDE
COURSE OR PRIMER OR DASHBOARD.
WE HAVE REACHED INDIVIDUALS IN
MANY COUNTRIES AND AT MANY
LEVELS FROM STUDENTS TO
PROFESSORS, FROM RESEARCHERS TO
CLINICIANS.
WE'RE EXCITED ABOUT THAT.
AND WE REACHED 48 COUNTRIES NOW
WITH OUR TOOLS.
THE BENCH TO BEDSIDE COURSE WAS
DEVELOPED IN COLLABORATION WITH
THE FDA OFFICE OF WOMEN'S HEALTH
AND IT PROVIDES A THOROUGH UP TO
DATE UNDERSTANDING OF SEX AND
GENDER INFLUENCES IN HEALTH AND
DISEASE AND HAVE CONTINUING
MEDICAL EDUCATION CREDIT
AVAILABLE AND THE SABV TRAIN THE
TRAINER COURSE WAS THE MOST
RECENT ADDITION TO OUR HEALTH
EDUCATION AND PROVIDES GUIDANCE
FOR VIRTUAL AND ONE-ON-ONE
TRAINING TO HELP ANYONE SUPPORT
SABV EDUCATION IN RESEARCH AND
IN THE PUBLIC.
WE ALSO SEE GROWING GLOBAL
INTEREST IN SEX AND GENDER AND
IT'S MY PRIVILEGE TO DELIVER TM
BEFORE THE U.K. HOUSE OF COMMONS
SCIENCE AND TECHNOLOGY COMMITTEE
LAST YEAR DECEMBER 1.
IT'S A NON-PARTISAN CAUCUS
LOOKING AT REPRODUCIBILITY AND
RIGOR IN SCIENCE.
I HAD THE PRIVILEGE OF JOINING
THE KINGS FUND PODCAST WHEN WE
ADDRESSED WOMEN'S HEALTH
INEQUALITIES AND THE IMPACT ON
THEIR DIAGNOSIS, TREATMENT AND
CARE AND THE U.K. IS PREPARING
TO RELEASE A STRATEGY ON WOMEN'S
HEALTH.
A GOVERNMENT-WIDE STRATEGY ON
WOMEN'S HEALTH.
SUBSEQUENTLY, ONE OF THE U.K.
RESEARCH BODIES ADOPTED IN SABV
POLICY AND MEDICAL RESEARCH
COUNCIL IS PART OF THE U.K.'S
GOVERNMENT UNIT EED KINGDOM AND
INNOVATION WORK AND WILL INVOLVE
TISSUES AND PERMIT SINGLE-SEX
STUDIES WHERE STRONG
JUSTIFICATION IS PROVIDED.
IN THE UPPER RIGHT THERE'S
REQUIREMENTS FOR SEX AND GENDER
INTEGRATION ACROSS A VARIETY OF
TOOLS.
THEY HAVE GENDER EQUALITY PLANS
WITH CRITERIA FOR HORIZON
EUROPE.
THAT'S ANOTHER EXAMPLE OF THE
GLOBAL CONSIDERATION OF SEX AND
GENDER.
MOVING INTO THIS SECTION I'LL
TALK ABOUT SOME OF THE CAREERS
ISSUES AND I'M REALLY EXCITED TO
SHARE WITH YOU ALONG WITH MY
CO-AUTHORS, MARIE BERNARD AND
KELLY KENHAGGEN THE PUBLICATION
ENTITLED COMMUNITY VOICES, NIH
WORKING TOWARDS INCLUSIVE
EXCELLENCE BY PROMOTING WOMEN IN
S.T.E.M.
THE DATA CONTINUES TO SHOCK US
WITH WOMEN RECEIVE HALF LIFE
SCIENCES Ph.D. AND GETTING HALF
THE MEDICAL DEGREES IN THE
UNITED STATES, WOMEN ARE NOT
PROGRESSING INTO LEADERSHIP
POSITIONS AT THE RATE EXPECTED,
THEY'RE PAID LESS IN SCIENCE AND
WOMEN OF COLOR ARE DRAMATICALLY
UNDER REPRESENTED IN ALL CAREER
STAGES.
ALL WOMEN COPE WITH SEXUAL
HARASSMENT AND GENDER
DISCRIMINATION AND IN MEDICINE
THE RATES ARE HIGHER THAN OTHER
FIELD AND THE PANDEMIC HAS OF
COURSE ALSO HAD A
DISPROPORTIONATE IMPACT ON WOMEN
AND THIS IS A REASON TO REDOUBLE
OUR EFFORTS TO SUPPORT AND
PROMOTE WOMEN IN SCIENCE.
WE PUT FORWARD OUR NOTION THE
COMPONENTS OF INCLUSIVE
EXCELLENCE INTERACT TO FOSTER A
DIVERSE SCIENTIFIC ECO SYSTEM IN
THE WORKFORCE.
WE HIGHLIGHT FIVE AREAS AND GIVE
EXAMPLES.
I SEE AT 12:00 THE ENHANCED
FLEXIBILITY OPTIONS WHETHER IT'S
RE-ENTRY AND RE-INTEGRATION
PROGRAMS YOU'LL HEAR ABOUT LATER
TODAY AND STOP THE CLOCK
PROVISIONS OR CHILDCARE
SUPPLEMENTS WE NOW PROVIDE FOR
NSRAs OR AT 3:00 POSITION
CULTURE OF INCLUSION AND COHORT
HIRING AND THE DISTINGUISHED
SCHOLARS PROGRAM, OUR FIRST
PROGRAM AND UNITE INITIATIVE
ACTIVITIES.
DEMONSTRABLE LEADERSHIP SUPPORT
AND THE FORMER NIH DIRECTOR
STATEMENT HE WOULD NOT
PARTICIPATE IN THAT INCLUDED
SO-CALLED MANALES, ALL MALE
PANELS AND HAD A RIPPLE AFFECT
ON OTHER LEADERS AND NIH EQUITY
ASSESSMENTS WE PERFORM
INTRAMURALLY.
THE WORKING GROUP ON WOMEN AND
BIOMEDICAL CAREERS I CONTINUE TO
CO-CHAIR WITH THE NIH DIRECTOR
WITH ACTING DIRECTOR DR. FRANCIS
COLLINS -- EXCUSE ME, ACTING
DIRECTOR LAWRENCE TABAK AND
ACTION-ORIENTED ACCOUNTABILITY
HAS TO DO WITH OUR REPORTING
POLICIES AND INVESTIGATIVE
PROCEDURES ARE LIST HEARD.
EXPECTATIONS FOR CODES OF
CONDUCT AT NIH-SPONSORED
CONFERENCES AND THE SAFE
ENVIRONMENT BEING ESTABLISHED AS
AN EXPLICIT CONDITION OF NIH
AWARDS AND RESEARCH ON
INTERVENTIONS AND BEST PRACTICES
WHETHER IT'S THE CAUSAL FACTORS
IN INTERVENTIONS THAT WE PUT OUT
MANY YEARS AGO AND THE
CONSEQUENT EVIDENCE GENERATED OR
THE PRIZE WE ESTABLISHED AT ORWH
AS A WORKING GROUP ON WOMEN IN
BIOMEDICAL CAREERS WHERE WE
RECOGNIZED INSTITUTIONS AND
EFFORTS THAT ADVANCED GENDER
DIVERSITY.
THE NIH UNITE INITIATIVE IS ALSO
WORKING TO END STRUCTURAL RACISM
AND CONSEQUENCES IN THE RESEARCH
ECO SYSTEM.
I HAD THE PLEASURE TO ADDRESS
HEALTH DISPARITIES AND ADVANCE
HEALTH EQUITY WORKING GROUP AND
THEY PUT OUT TWO FUNDING
ANNOUNCEMENTS AND HAS ONE ON THE
STREET NOW SUPPORTING INNOVATIVE
RESEARCH PROJECTS TO INTENDED TO
HAVE AN IMPACT IN DEVELOPING OR
DISSEMINATING INTERVENTIONS TO
REDUCE OR ELIMINATE HEALTH
DISPARITIES AND ADVANCE HEALTH
EQUITY.
THIS IS FOCUSSED ON
MINORITY-SERVING INSTITUTIONS.
WE PRESENTED A CONCEPT FOR
CAMPUS.
IT STANDS FOR COMMUNITY
PARTNERSHIPS TO ADVANCEMENT FOR
SOCIETY THIS TO DEPLOY
STRUCTURAL INTERVENTIONS THAT
LEVERAGED MULTI-SECTOR
PARTNERSHIPS TO REDUCE HEALTH
DISPARITIES.
STAY TUNED FOR MORE INFORMATION
ON THAT COMING SOON.
ORWH CREATED A DIVERSE VOICES
SEMINAR SERIES AND OUR RECENT
SEMINAR WE HOSTED DR. TODD WHO
AND DR. MUJAHID THAT SPOKE TO
ENVIRONMENTAL JUSTICE.
THAT'S AVAILABLE ON OUR WEBSITE
BUT I WANT TO HIGHLIGHT ONE OF
THE EXAMPLES OF THE WAYS WE ARE
PUTTING OUT DIVERSE PERSPECTIVES
AND ENSURING THE HEALTH AFFECTS
OF THE PANDEMIC AND OTHER HEALTH
CONDITIONS ARE IN UNDER STUDIED
POPULATIONS ARE DISSEMINATE.
COMING TO THE LAST SECTION, I
WANT TO MAKE SURE I SHARE WITH
YOU INFORMATION ABOUT LAST
YEAR'S ORWH RESEARCH PROGRAMS.
IT'S ONE OF MY FAVORITE THINGS
TO DO IS TO SHARE WITH YOU THE
HARD WORK DONE OVER THE LAST
YEAR TO MAKE THESE FUNDS AS HARD
AS POSSIBLE TO ADVANCE THE
HEALTH OF WOMEN.
ON THE LEFT YOU CAN SEE OUR
FUNDING HISTORY SINCE WE WERE
FOUNDED IN 1990.
AND YOU CAN SEE ON THE RIGHT THE
BREAKDOWN OF RESEARCH FUNDING.
YOU CAN SEE A FAIRLY FLAT
FUNDING PATTERN IN THE MIDDLE.
ROUGHLY A THIRD GOES TO A
PROGRAM AND A THIRD TO THE SCORE
PROGRAM AND A THIRD TO OTHER
PROGRAMS AT THE I.C.s WHERE WE
EITHER CO-FUND RESEARCH THEY'RE
LEADING OR THE SEX AND GENDER
RO1 A COLLABORATIVE EFFORT.
YOU CAN TAKE A LOOK THERE AT THE
GRANULAR DATA AND THE THANK YOU
NEWEST SET OF PROGRAMS.
YOU CAN SEE THE BIRCH PROGRAM
AND ORWH SIGNATURE PROGRAM
REPRESENT THE MAJORITY OF THOSE
EXPENDITURES BUT ALSO THE
RE-ENTRY SUPPLEMENT AND SUPPORT
NICHD'S ADMINISTRATIVE
SUPPLEMENTS FOR CONTINUITY FOR
RPGs AND K AWARDEES.
A PROGRAM WAS CREATED BY THE
WORKING GROUP ON WOMEN IN
BIOMEDICAL CAREERS WITH CO-LEADS
WITH THE OFFICE OF EXTRAMURAL
RESEARCH AND WE PROVIDED THE
FIRST SET OF FUNDING FOR THAT
AND HAVE OVER THE LAST TWO YEARS
SUPPORTED THAT.
ALONG WITH THE INSTITUTES AND
CENTERS.
IF YOU WATCH THE IT LOOK AT OUR
OVERALL INVESTMENTS THE BIRCH IS
INDICATED ON THE LEFT WITH
NICHD.
THEY ADMINISTER THE BIRCH
PROGRAM AND COLLABORATES WITH US
ON THE PROGRAM AND YOU CAN SEE
NIA HAS AS THE LEADING I.C.
RECEIVED ORWH CO-FOUNDING
SUPPORT AND NIDDK, NIDA AND NIHM
AND NHLBI.
IF YOU REMOVE THE BIRCWH FUNDING
IT
IT'S EASIER TO SEE.
HERE DIVIDED BY THE SIGNATURE
PROGRAMS STARTING WITH THE
BIRCWH ON TOP AND OTHER CAREER
PROGRAMS AND SCORE PROGRAM AND
OUR COLLABORATORS THERE AND
OURSELF AND GENDER RO1.
YOU'LL HEAR MORE THIS AFTERNOON
AND THE SUPPLEMENT PROGRAM WHICH
WE PRECEDE THE SABV POLICY AND
OUR U3 SUPPLEMENT AND OTHER I.C.
CO-FUNDS ARE EXAMPLES WHERE AN
INSTITUTE COMES TO ORWH TO
REQUEST CO-FUNDING FOR A
RELEVANT ACTIVITY THEY ARE
LEADING.
THIS YEAR SOON IN ABOUT A MONTH
WE WILL HAVE THE SIXTH ANNUAL
SYMPOSIUM.
THIS IS OUR SIGNATURE EVENT
DURING NATIONAL WOMEN'S HEALTH
AND HONORS DR. VIVIAN PINN WE'RE
FOCUSSING ON THE IMPACT OF
COVID-19 AND THE PANDEMIC ON THE
CAREERS OF WOMEN SCIENTISTS AND
WE'RE EXCITED ABOUT THAT.
OTHER UPCOMING EVENTS FOR HIRN
AND WOMEN'S HEALTH, NIEHS IS
HOSTING THEIR 8th ANNUAL WOMEN'S
HEALTH AWARENESS EVENT AND
HAVING A WORKSHOP ON
ENVIRONMENTAL IMPACTS ON HEALTH
DISPARITIES AND REPRODUCTIVE
HEALTH AT THE END OF APRIL.
THE VOICES OF ORWH AND WE HAVE
ONE IN JULY AND SEPTEMBER
FOCUSSED ON COVID IN JULY AND
VIOLENCE IN SEPTEMBER AND AGAIN
MEETING WITH YOU HERE AGAIN AT
THE MEETING IN OCTOBER AT THE
BEGINNING OF THE NEXT FISCAL
YEAR.
IT'S EXCITING TO END WITH YOU IN
SHARING THE MANY WAYS ORWH IS
REACHING OUT AND CONNECTING WITH
MORE STAKEHOLDERS WHETHER
THROUGH OUR MULTIPLE E LEARNING
TOOLS AND RESOURCES LISTED ON
THE RIGHT THROUGH SOCIAL MEDIA
OR EVENTS THROUGH OUR QUARTERLY
PUBLICATION WOMEN'S HEALTH IN
FOCUS AT NIH ARE WE FEATURE
RESEARCH SUPPORTED AND SPOTLIGHT
SCIENTISTS PERFORMING WOMEN'S
HEALTH RESEARCH, FEATURE
INSTITUTIONAL PRACTICES THAT
SUPPORT GENDER, EQUITY, FEATURE
WOMEN SCIENTISTS AND CLINICIANS
OR A MONTHLY PULSE E-MAIL.
YOU CAN SIGN UP TO RECEIVE THIS
INFORMATION AT THE URL LISTED
HERE.
IT'S NOW MY PLEASURE TO TURN THE
VIRTUAL MICROPHONE OVER BACK
OVER TO DR. SAMIA NOURSI.
>> THANK YOU FOR YOUR REPORT.
I'D LIKE TO ACKNOWLEDGE THE
ATTENDANCE OF DOCTORS SIMON AND
SHAW WHO JOINED US.
WELCOME, DR. SIMON AND DR. SHAW.
WE'RE A LITTLE BIT AHEAD OF
SCHEDULE.
IT'S GREAT.
OUR NEXT PRESENTATION WILL BE
REQUESTING CONVENING A WORKING
GROUP TO ADVICE THE ACRHW AND
DIRECTOR ON THE DEVELOPMENT OF
THE 2024 TO 2028 NIH-WIDE
STRATEGIC PLAN ON RESEARCH ON
THE HEALTH OF WOMEN.
I'D LIKE TO PROVIDE YOU WITH A
BACKGROUND AND SUMMARY OF
ACTIVITIES THAT LED TO WHERE WE
ARE RIGHT NOW.
AS YOU ALL MAY RECALL, WE HAVE
DEVELOPED A GUIDE ON THAT
2019-2023 TRANS-NIH STRATEGIC ON
WOMEN'S HEALTH RESEARCH.
SINCE WE STOPPED USING THE WORD
TRANS-NIH AND ARE NOW GOING TO
CALL IT NIH-WIDE STRATEGIC PLAN.
SO AT THAT TIME WE DEVELOPED A
GUIDE AND THIS GUIDE WAS SHARED
WITH ALL THE I.C.s AND DEVELOPED
WITH THE I.C.s AND IT WAS
INTENDED TO ASSIST WITH
IMPLEMENTATION AND EVALUATION OR
OTHER PLAN FOR INCLUSION OF
WOMEN'S HEALTH RESEARCH
ACTIVITIES.
AN ADDITION, WE PUBLISHED A
PAPER IN 2021 HIGHLIGHTING THE
GUIDE DEVELOPMENT PROCESS TITLED
DEVELOPING THE PROCESS AND
TRACKING THE IMPLEMENTATION AND
EVALUATION OF THE NATIONAL
INSTITUTES OF HEALTH STRATEGIC
PLAN FOR WOMEN'S HEALTH
RESEARCH.
TO ASSIST IN THAT EVALUATION OF
THE PLAN, ORWH COLLABORATED WITH
ANOTHER OFFICE.
IT'S THE OFFICE OF EVALUATION
PERFORMANCE AND REPORTING TO
CREATE A DATA CALLED WHAT FORM
ON MODULE IN THE START PLATFORM.
THEY CAN SUPPLEMENT EXISTING
REPORTING DATA.
CALLS HAVE BEEN COMPLETED TO
DATE BY STAFF WHICH ESTABLISHED
A DATABASE FOR FEATURE
EVALUATION.
EVALUATION OF THE 2020, 2019 TO
2023 PLAN WILL CONTRIBUTE TO THE
CREATION OF THE 2024-2028 PLAN.
THE PROCESS TO DEVELOP NEW GOALS
AND THE NEXT ITERATION OF THE
STRATEGIC PLAN IS UNDERWAY.
ONE KEY PIECE IS THE CREATION OF
THE ACRWH WORKING GROUP TO
ASSIST US AND GUIDE US IN THE
PROCESS.
THE WORKING GROUP WILL ADDRESS
THE CURRENT STATE OF SCIENCE ON
THE HEALTH OF WOMEN, RESEARCH
GAPS AND IDENTITY GOALS AND
OBJECTIVES THAT ORWH NEEDS TO
PRIORITIZE FOR THE NEXT FIVE
YEARS.
IN ADDITION, THE WORKING GROUP
WILL REVIEW THE IMPLEMENTATION
OF THE 2019 TO 2023 TRANS-NIH
STRATEGIC PLAN ON RESEARCH ON
THE HEALTH OF WOMEN BY THE NIH
INSTITUTES, CENTERS AND OFFICES
AND THE EVALUATIONS OF THE
IMPLEMENTATIONS THAT THEY
CONDUCTED.
THE RECENTLY COMPLETED I.C.
REPORTS FOR THE BIENNIAL REPORT
WILL HAVE INFORMATION INCLUDING
HOW THE I.C.s HAVE ADDRESSED
STRATEGIC GOALS FROM THE CURRENT
STRATEGIC PLAN AND WILL INFORM
THE DEVELOPMENT OF THE NEXT ONE.
THE EVALUATION OF THE CURRENT
STATE OF SCIENCE AND NIH
PORTFOLIO COMBINED WITH THE
REVIEWS OF THE IMPLEMENTATIONS
AS RECEIVED WILL INFORM THE
UPCOMING 2024-2028.
WE'LL GATHER THE REPORTS AND
REPORTS CREATED AND
IMPLEMENTATION THAT I.C.s SHARED
WITH US TO HELP US MOVE FORWARD
WITH THE NEXT NIH STRATEGIC
PLAN.
THE WORKING GROUP THAT WE WOULD
LIKE TO COMPOSE WILL INCLUDE
MEMBERS OF ACRWH, MEMBERS OF THE
NIH SCIENTIFIC COMMUNITY AS WELL
AS INDIVIDUALS FROM ACROSS HHS
WITH EXPERTISE AND RESEARCH ON
THE HEALTH OF WOMEN.
FOLLOWING THIS MEETING, MEMBERS
OF ACRWH WILL RECEIVE
INFORMATION ON HOW TO VOLUNTEER
FOR THE WORKING GROUP IF THEY
ARE INTERESTED AND HOPE YOU ARE.
AT THIS TIME I'D LIKE TO ASK
YOUR VOTE TO APPROVE THE
CREATION OF AN ACRWH WORKING
GROUP ON THE 2024-2028 NIH WIDE
STRATEGIC PLAN ON RESEARCH ON
BEHALF OF WOMEN.
IS THERE A MOTION ON THE TABLE
TO APPROVE A CREATION OF AN
ACRWH WORKING GROUP ON THE 2024
TO 2028 NIH-WIDE STRATEGIC PLAN
ON RESEARCH ON THE HEALTH OF
WOMEN?
>> SO MOVED.
>> SECOND.
THE MOTION IS SUBMITTED.
DO I HEAR A SECOND?
>> SECOND, DR. LANGER.
>> THANK YOU VERY MUCH.
THE POLL IS OPEN IT RESPOND IF
YOU'RE IN FAVOR, OPPOSED OR
ABSTAIN.
PLEASE ENTER YOUR RESPONSES NOW
AND YOU HAVE 30 SECONDS TO
RESPOND.
SO THE POLL CLOSED.
>> THERE'S 13 IN FAVOR.
>> THANK YOU.
THE CREATION OF THE ACRWH
WORKING GROUP ON THE 2024-2028
NIH STRATEGIC PLAN ON THE
RESEARCH ON HEALTH OF WOMEN.
WE APPRECIATE THAT AND YOU'LL
HEAR FROM US NEXT WEEK HOW TO
VOLUNTEER.
I'D LIKE TO TURN IT BACK TO
DR. CLAYTON TO INTRODUCE OUR
NEXT SPEAKER.
DR. CLAYTON.
>> DR. NOURSI, DO WE HAVE TIME
FOR ONE OR TWO QUESTIONS OR
SHOULD WE MOVE ON?
>> WE DEFINITELY HAVE TIME FOR A
FEW QUESTIONS ACTUALLY.
WE'RE AHEAD OF SCHEDULE.
>> GREAT.
I THINK THERE WAS A HAND UP
EARLIER.
IS THERE NORTHBOUND THAT HAD A
QUESTION EITHER ABOUT THE
WORKING GROUP OR ANY OTHER
QUESTIONS WE CAN ENTERTAIN AT
THIS POINT?
>>
>> YOU CAN UNMUTE YOURSELF AND
ASK A QUESTION.
>> I'D LIKE TO ASK A QUESTION
ABOUT THE PROBLEMS IN THE WOMEN
WORKFORCE.
HAS THERE BEEN RESEARCH TO
IDENTIFY WHERE IN THE CAREER
WOMEN ARE DROPPING OUT AND THE
UNDERLYING CAUSES OF THAT?
>> RESEARCH INDICATES WOMEN DROP
OUT AT KEY TRANSITION POINTS.
SO WHEN IT IS Ph.D. TO POST-DOC,
THAT TRANSITION, WOMEN LEAVE.
FROM POST-DOC TO RR01 AND ONES
WOMEN GET THE FIRST RPG THEY'RE
LESS LIKELY TO APPLY FOR RENEWAL
OR A SECOND.
WE KNOW THE YEARS TEND TO
OVERLAP WITH YEARS FAMILY
RESPONSIBILITIES AS WOMEN HAVING
CHILDREN OR CARING FOR OTHER
FAMILY MEMBERS ARE INCREASED WE
WANTED TO PROVIDED STRATEGIES
FOR WOMEN TO KEEP THEIR RESEARCH
GOING AND THAT'S WHAT THE
CONTINUITY SUPPLEMENTS DO.
AND WE SEE LOWER NUMBERS ACROSS
ALL RACIAL AND ETHNIC UNDER
REPRESENTED MINORITIES AND SEE
FACTORS WHICH ARE FINANCIAL
RESOURCES.
THAT'S ONE OF THE REASONS YOU
ASKED ABOUT REASONS.
WE HAVE CHILD BIRTH, FAMILY
RESPONSIBILITIES, WE HAVE
FINANCIAL RESOURCES.
SO PROGRAMS LIKE OUR LOAN
REPAYMENT PROGRAM ARE DESIGNED
TO SUPPORT INDIVIDUALS GOING
INTO A RESEARCH SUPPORTING FOR
RESEARCH CAREER AND WE EXPANDED
THAT PROGRAM NIH HAS AND SO
THOSE ARE SOME OF THE FACTORS
THAT ARE IN PLAY RIGHT NOW AND
I'LL END WITH THE OTHER FACTOR
THAT REALLY DOES HAVE TO BE SAID
AND THAT IS THE CULTURE AND
CLIMATE OF ACADEMIA.
THE CONSTANT NEED FOR APPLYING
FOR GRANTS.
THE COMPETITIVE ENVIRONMENT IN
TERMS OF THE PUBLISHING SO
CRITICAL TO PROMOTION AND TENURE
AND THE FACT THAT UNFORTUNATELY,
MANY OF OUR PROMOTION AND TENURE
PRACTICES DON'T INCORPORATE IN A
MEANINGFUL WAY MENTORING,
TEACHING THE DIVERSITY-RELATED
ACTIVITIES WHICH ARE SOME OF THE
ACTIVITIES THAT WE SEE WOMEN
ENGAGING IN MORE MEN.
SO THEN THERE'S THE PAY
INEQUITY.
SO YOU HAVE AN ENVIRONMENT THAT
MAY OR MAY NOT BE AS WELCOMING
OR SUPPORTIVE AND BE THE THERE'S
A PAY INEQUITY ISSUE.
WE SEE WOMEN LEAVING THE
SCIENTIFIC WORKFORCE AND GOING
TO OTHER S.T.E.M. JOBS WHICH IS
A REAL CHALLENGE.
THANKS FOR THAT QUESTION.
>> DR. CLAYTON, I JUST WANT TO
ALERT YOU, OUR NEXT SPEAKER JUST
JOINED, DR. GIBBONS IS HERE.
WE HAVE ONE QUESTION FROM
DR. McGREGOR.
MAYBE WE CAN TAKE THAT BEFORE WE
MOVE ON AND I'D LIKE TO
ACKNOWLEDGE DR. AMANDA BRUEGL
JOINED US.
WE'LL TAKE THE LAST QUESTION
FROM DR. IMAGINE GREGOR BEFORE
WE MOVE TO THE NEXT PART OF THE
MEETING.
>> THANK YOU.
IT SHOULDN'T BE -- FIRST, THANK
YOU.
I LOVE THE DIRECTOR'S REPORT.
I FEEL LIKE IT GIVES ME ALL THIS
NEW RESEARCH COMING OUT.
MY QUESTION IS IS THERE WILL THE
OFFICE BE CONSIDERING GENDER AS
A VARIABLE IN THE FUTURE?
>> I THINK GENDER IS INCLUDED
ALREADY IN THE WAY WE THINK
ABOUT HOW BOTH SEX AND GENDER
AFFECT HEALTH AND DISEASE.
ACTUALLY, THAT IS ARTICULATED IN
WHAT I CALL THE HYPER LINK FROM
THE ORIGINAL SABV POLICY AND IT
OUTLINES THE IMPORTANCE OF SEX
AND GENDER.
I THINK WE ALREADY TALKED BIT
AND IS THE FIELD IS ADVANCING SO
THERE'S NOW MORE AVAILABLE
INSTRUMENTS TO BE ABLE TO ASSESS
GENDER.
THAT'S A FAIRLY RECENT LAST YEAR
PUBLICATION AND JUST LIKE ANY
OTHER ADVANCE IN OUR FIELDS AS
MORE INFORMATION BECOMES
AVAILABLE, WE NEED TO SHIFT AND
INCORPORATE THAT INTO WAYS OF
WORKING.
I WOULD ASK IF YOU COULD BRING
THIS UP WHEN DR. BARR PRESENTS
THIS AFTERNOON AND SEE IF THAT
ANSWERS YOUR QUESTIONS IN TERMS
OF THE WAYS WE HOPE TO ADVANCE
SEX AND GENDER CONSIDERATION.
THANKS FOR THE QUESTION.
IT'S NOW MY PLEASURE TO
INTRODUCE DR. GIBBONS.
DR. GIBBONS IS THE DIRECTOR OF
THE NATIONAL HEART, LUNG AND
BLOOD INSTITUTE WHERE WE
OVERSEES THE THIRD LARGEST
INSTITUTE AT NIH WITH AN ANNUAL
BUDGET OF APPROXIMATELY $3
BILLION AND A STAFF OF NEARLY
2100 FEDERAL EMPLOYEES,
CONTRACTORS AND VOLUNTEERS.
NHLBI PROVIDES GLOBAL LEADERSHIP
FOR RESEARCH, TRAINING AND
EDUCATION PROGRAMS TO PROMOTE
THE PREVENTION AND TREATMENT OF
HEART, LUNG AND BLOOD DISEASES
INCLUDING SLEEP AND ENHANCE THE
HEALTH OF ALL INDIVIDUALS SO
THEY CAN LIVE LONGER AND MORE
FULL LIVES.
SINCE BEING NAMED DIRECTOR OF
NHLBI, HE HAS ENHANCED THE
INVESTMENT IN FUNDAMENTAL
DISCOVERY SCIENCE, STEADILY
INCREASING THE PAY LINE AND
NUMBER OF AWARDS FOR ESTABLISHED
AND EARLY STAGE INVESTIGATORS.
HIS COMMITMENT TO NURTURING THE
NEXT GENERATIONS OF SCIENTISTS
IS MANIFESTED IN EXPANDED
FUNDING FOR CAREER DEVELOPMENT
AND LOAN REPAYMENT AWARDS AS
WELL AS INITIATIVES TO
FACILITATE THE TRANSITION TO
INDEPENDENT RESEARCH AWARDS IN
THE OVERALL COMMITMENT TO
DIVERSITY, EQUITY AND INCLUSION.
DR. GIBBONS PROVIDES LEADERSHIP
TO ADVANCE SEVERAL NIH
INITIATIVES AND OFTEN CALLED ON
TO LEAD IMPORTANT ACTIVITIES AND
MADE SCIENTIFIC CONTRIBUTIONS IN
THE FIELD OF VASCULAR BIOLOGY
AND THE PATHOGENESIS OF VASCULAR
DISEASES.
HIS RESEARCH FOCUSES ON
INVESTIGATIVE RELATIONSHIPS
BETWEEN CLINICAL PHENOTYPES,
BEHAVIOR, MOLECULAR INTERACTIONS
AND SOCIAL DETERMINATES ON GENE
EXPRESSION AND THEIR
CONTRIBUTIONS TO CARDIOVASCULAR
DISEASE.
HE HAS RECEIVED SEVERAL PATENTS
FOR HIS REASON IN THE FIELD OF
ASTRO BIOLOGY AND ORIGINALLY
EARNED HIS UNDER GRADUATE DEGREE
FROM PRINCETON AND GRADUATED
MAGNUM CUM LAUDE FROM HARVARD
AND LED THE BRIGHAM AND WOMEN'S
HOSPITAL.
HE WAS A MEMBER OF HARVARD
MEDICAL SCHOOL BEFORE HE SERVED
AS MOREHOUSE MEDICAL SCHOOL
WHERE HE SERVED AS THE
CHAIRPERSON OF THE DEPARTMENT OF
PHYSIOLOGY AND PROFESSOR OF
PHYSIOLOGY AND MEDICINE AT THE
SCHOOL OF MEDICINE.
WHILE AT MOREHOUSE, HE ALSO
SERVED AS THE MEMBER OF THE
NHLBI COUNCIL AND HAS RECEIVED
AWARDS INCLUDING ELECTION TO THE
NATIONAL ACADEMIES, SELECTION TO
FOUNDATIONS AND A PUGH
FOUNDATION BIOMEDICAL SCHOLAR.
IT'S MY PLEASURE TO WELCOME
DR. GIBBONS TO OUR ADVISORY
GROUP TODAY.
>> WOW, DR. CLAYTON.
THANK YOU VERY MUCH FOR THAT
OVERLY GENEROUS VERSION OF MY
BIO.
THINK THERE'S STILL TIME LEFT.
I APPRECIATE THE INVITATION AND
OPPORTUNITY TO PRESENT TO YOUR
BOARD TODAY.
WE HAVE A VERY CLOSE
COLLABORATIVE RELATIONSHIP THE
OFFICE OF RESEARCH FOR WOMEN'S
HEALTH AND WE CHERISH THAT
RELATIONSHIP AND IT'S REALLY AN
OPPORTUNITY MAYBE TO SHARE AND
HOPEFULLY SEE HOW WE CAN FURTHER
ENHANCE THAT COLLABORATION AND
IT'S EMBEDDED IN THE TITLE OF
THE SLIDE, ADVANCING SHARED
PRIORITIES FOR ELIMINATING
HEALTH INEQUITIES AND IMPROVING
WOMEN'S HEALTH.
I ALWAYS START WITH MY TASK IN
THE PRIVILEGED ROLE I PLAY AS A
PUBLISH SERVANT IN LEADING THE
NHLBI AND OUR MISSION TO TURN
DISCOVERY SCIENCE THAT ENHANCES
HUMAN HEALTH.
WE ALWAYS HAD THIS TOUCH STONE
OF THE ENDURING PRINCIPLES TO
DRIVE OUR PORTFOLIO AND AGENDA
THAT ALWAYS BEGINS WITH THOSE
WHO DO THE WORK VALUING
DISCOVERY SCIENCES AS THE
BEDROCK AND MAINTAINS ACROSS THE
PORTFOLIOS THAT SPANS THE
SPECTRUM OF SCIENCE FROM BASIC,
TRANSLATIONAL, CLINICAL,
POPULATION SCIENCE,
COMMUNITY-BASED RESEARCH.
AS WAS MENTIONED A PASSION IS TO
TRAIN A DIVERSE GENERATION OF
LEADERS IN SCIENCE AND ANOTHER
COUPLE OF PASSIONS THAT RELATES
TO SUPPORTING IMPLEMENTATION
SCIENCE THAT EMPOWERS PATIENTS
AND ENABLES PARTNERS TO IMPROVE
HEALTH OF THE NATION BUT FROM
THE LEVEL OF THE COMMUNITY AND
THE REAL WORLD.
AND TO EVENTUALLY INNOVATE
HEALTH INEQUITIES IN THE U.K.
AND AROUND -- U.S. AND AROUND
THE WORLD AND TOUCHES OUR
PORTFOLIO.
TOWARD THAT END I'LL TRY TO
BRIEFLY TOUCH ON A FEW DIFFERENT
THEMES THAT I HOPE IS RELEVANT
AND OF INTEREST TO THIS BODY
THAT FOCUSES ON WOMEN'S HEALTH
AND OUR RESEARCH PORTFOLIO THAT
LOOKS AT THE INTERSECTION WITH
HEALTH EQUITY.
FIRST RELATES TO THE IMPORTANCE
OF EQUITY IN TERMS OF THE
BIOMEDICAL RESEARCH WORKFORCE.
THE IMPORTANCE OF INCLUSIVE
EXCELLENCE IN THAT BIOMEDICAL
WORKFORCE TO DRIVE THE SUCCESS
OF OUR MISSION.
WE ALL RECOGNIZE WE HAVE BOTH
SUCCESSES AND PERSISTENT
CHALLENGES.
SOME OF WHICH HAVE BEEN ALLUDED
TO AND WE RECOGNIZE THOUGH A LOT
OF STRIDES HAVE BEEN MADE THAT
WE STILL HAD SOME CHALLENGES IN
PROMOTING INCLUSIVE EXCELLENCE.
WE KNOW TALENT IS WIDELY
DISPERSED AND COMES FROM EVERY
CORNER OF OUR SOCIETY AND THAT
CLEARLY WE NEED THE BEST AND
BRIGHTEST TO ADDRESS THE
CHALLENGES IMPLICIT IN
FULFILLING OUR MISSION.
CLEARLY WE HAVE SOME CHALLENGES
IN TERMS OF SEX GENDER INCLUSION
WITHIN OUR PORTFOLIO.
AND PART OF THE LAST
CONVERSATION IN PART AND WE
RECOGNIZE AND THERE'S NEWS IN
THE PIPELINE AND AS DR. CLAYTON
MENTIONED THE KEY TRANSITION
POINTS WHERE THERE ARE
DIFFICULTIES WITH THE
CONVERGENCE OF ACTIVITIES THAT
INDIVIDUALS HAVE BALANCING LIFE
CIRCUMSTANCES WITH THE
CHALLENGING CAREER OF BEING AN
ACADEMIC AND A RESEARCHER AND
TRYING TO BE SURE YOU ARE
PURSUING EXCELLENCE IN ALL THE
REALMS.
TO THAT END WE'VE BEEN TRACKING
IN THE PORTFOLIO AND THIS IS THE
NHLBI PERSPECTIVE BUT THIS SHOWS
YOU SOME TRENDS IN OUR AWARD
DATA BY SEX AND GENDER AND YOU
CAN SEE THE TRENDS FOR THE LAST
SEVERAL YEARS FOR ALL RO1s AND
NHLBI AND YOU CAN SEE THE FEMALE
TO MALE DIFFERENCES AND
DISPARITIES AND WHAT GIVES US A
LITTLE HOPE THAT INCLUDES A LOT
OF THE ESTABLISHED INVESTIGATORS
BUT IF YOU BREAK OUT IN THE NEXT
ELEMENT THERE THE RO1s AND EARLY
STAGE INVESTIGATORS, CAN YOU SEE
A SUBSTANTIAL INCREASE IN GOING
TOWARDS PARITY BY SEX GENDER.
AND AS YOU MOVE EARLIER IN THE
PIPELINE WHAT OUR K AWARDS AND
NHLBI YOU CAN SEE WE'RE CLOSER
TO SOMETHING APPROACHING PARITY
AS WELL AS IN THE TRAINING
AWARDS THE Fs, FOR EXAMPLE.
YOU CAN SEE CLOSER TO PARITY.
SIMILARLY, AS DR. CLAYTON
ALLUDED TO, I THINK BOTH THE
CHALLENGES AND OPPORTUNITIES FOR
NIH AS STEWARDS OF THE BIOMARKER
WORKFORCE IS TO SEE WHAT WE CAN
DO TO CONTINUE TO NOT ONLY PRIME
THE PUMP IN THAT DEVELOPMENT
PATHWAY BUT ALSO TO LOOK AT HOW
WE COULD BE MORE EFFECTIVE AND
SUPPORTIVE OF THESE EARLY CAREER
INVESTIGATORS PURSUING THIS
PATHWAY SUCH THAT THEY STAY IN
AND THIS IS THEIR DESIRE OR
PASSION BECAUSE WE ENSURED THE
SYSTEM IS SUPPORTIVE OF THEIR
EFFORTS.
SWITCHING TO OUR RESEARCH
PORTFOLIO OF INCLUSIVE
EXCELLENCE.
NOT ONLY IS IT IMPORTANT WE HAVE
A DIVERSE AND TALENTED
WORKFORCE, BUT DIVERSITY AND IN
INCLUSION IS IMPORTANT IN THE
PARTICIPATION OF THE RESEARCH AS
WELL OF THE SCIENTISTS BUT IN
ACTUALLY CONDUCTING THE SCIENCE
AND TOWARD THAT END I'M PROUD I
HEARD A LEGACY AT THE NHLBI THAT
GOES BACK TO THE FOUNDING IN
WHICH ONE OF THE EARLIEST
RESEARCH PROGRAMS WAS THE ICONIC
FRAMINGHAM HEART STUDY THAT WAS
A RESEARCH NICHD TO ADDRESS THE
PANDEMIC OF THAT TIME WHICH WAS
THE INCREASED INCIDENTS OF
CORONARY HEART DISEASE
SUPPLANTING CORONARY DISEASE OF
WOMEN AND MEN AND FROM THE
BEGINNING FRAMINGHAM WAS
INCLUSIVE OF BOTH MALES AND
FEMALES AS RESEARCH
PARTICIPANTS.
IT WAS AMONG THE FIRST TO SEE
SEX-SPECIFIC DIFFERENCES IN RISK
AND OUTCOMES THAT REALLY STAND
THE TEST OF TIME UP TO TODAY AND
UNDER SCORES THE IMPORTANCE MUCH
INCLUSION AS PART OF
UNDERSTANDING DISCOVERY SCIENCE
AND PUT THE NHLBI ON THE PATHWAY
TO BE GOOD STRATEGIC PARTNERS
WITH THE OFFICE OF RESEARCH AND
WOMEN'S HEALTH AND WE CELEBRATE
THEIR SUCCESS IN WHICH I BELIEVE
WE'VE BEEN GOOD COLLABORATIVE
PARTNERS FROM THE INCEPTION
HOPEFULLY DR. CLAYTON WILL
UPDATE AND THERE'S A WOMEN'S
HEALTH INITIATIVE STARTED IN THE
1990s AND AND THE NHLBI SOON
INHERITED THE WOMEN'S HEALTH
INITIATIVE AND WE HOSTED TO THIS
DAY AND NOT ONLY DID WE HAVE THE
INCREDIBLE RETURN ON INVESTMENT
THE RESEARCH PROGRAM HAS HAD AND
THE TARGETED ISSUES RELEVANT TO
WOMEN'S HEALTH INCLUSIVE OF AL
STUDIES AND CLINICAL TRIALS THAT
HAD IMPLICATIONS ON THE CARE OF
WOMEN AND CONTINUES TO BEARS
FRUIT.
WE CONTINUED TO MIX THE BALANCE
OF OBSERVATIONAL STUDIES COUPLED
TO INTERVENTIONS TO IMPACT
WOMEN'S HEALTH AND THEIR LIVES.
IN THIS REGARD THERE'S THE
ASSOCIATION OF PHYSICAL
ACTIVITIES AND OUTCOMES IN TERMS
OF CARDIOVASCULAR HEALTH.
CLEARLY IT WAS EVIDENT AND SOME
MIGHT SAY TO BE EXPECTED MAY BE
A BENEFIT AS AN ASSOCIATION IN
OBSERVATIONAL STUDY AND THE KEY
TEST IS TO SEE WHETHER WOMEN IN
THEIR LATER YEARS OF LIFE AND
THE LIFE SPAN WHETHER PHYSICAL
ACTIVITY STILL IMPROVES OUTCOMES
AND GIVEN THE POTENTIAL FRAILTY
ISSUES THERE WAS SOME QUESTION
IN CLINICAL EQUIPOISE IN TERMS
OF RELATIVE SAFETY OF EXERCISE
IN THIS CONTEXT AND IT'S AN
ONGOING STUDY THAT WE'RE
CONDUCTING EMBEDDED WITHIN THE
WOMEN'S HEALTH INITIATIVE
TESTING WHETHER PHYSICAL
ACTIVITY INTERVENTION IS STILL
EFFECTIVE IN ENHANCING HEALTH
OUTCOMES AMONGST OLDER WOMEN.
AND WE LOOK FORWARD TO THE
RESULT HELP US GUIDE WOMEN
ACROSS THE LIFE SPAN IN WAYS
THEY CAN CONTINUE TO THRIVE.
AND LIVE HEALTHIER LIVES.
LET ME PIVOT AND REQUEST WE
UPDATE ON SOME OF THE ACTIVITIES
RELATED TO COVID-19 AND THEIR
IMPACT ON WOMEN'S HEALTH.
THOORDZ END, I DON'T NEED TO
TELL THIS AUDIENCE THE
DISRUPTIVE AFFECTS COVID-19 HAS
HAD ON NEARLY EVERY AC SPECT OF
OUR LIVES AND THERE'S A NUMBER
OF FACTORS THAT CONTINUE TO BE
OF CONCERN.
OBVIOUSLY THE VIRUS AND IT'S
IMPACT I WON'T DWELL ON BUT
RELATED TO OUR TOPICS TODAY IN
OUR PORTFOLIO ON HEART, LUNG,
SLEEP DISORDERS YOU SEE THE
COLLABORATIVE AFFECTS OF
COVID-19 ON A NUMBER OF
DIFFERENT ELEMENTS.
IN THIS CASE LOOKING AT BLOOD
PRESSURE AND BLOOD PRESSURE
CONTROLS IN THIS CONTEXT OF THE
PANDEMIC.
AND YOU CAN SEE PARTICULARLY FOR
WOMEN SOME MAJOR CHALLENGES HERE
IN TERMS OF THE DIFFICULTY OF
THE RISK FACTOR MANAGEMENT IN
THIS CONTEXT AND PERHAPS SOME OF
THE STRESSORS THAT COME TO BEAR
IN THE CONTEXT OF A PANDEMIC AND
PERHAPS THE DIFFERENTIAL IMPACT
OF THE PANDEMIC ON WOMEN IN
PARTICULAR AS WE'VE ALL
STRUGGLED WITH WORK LIFE
BALANCE.
LORD KNOWS I HAVE A ADULT
CHILDREN BUT STAFF ATTEMPTING TO
WORK AND DO ALL THE OTHER ARC
ACTIVITIES IT'S CLEARLY BEEN A
STRESSFUL PERIOD AND WILL HAVE A
SUBSTANTIAL IMPACT NOT ONLY
RELATED TO COVID AND THE VIRUS
ITSELF BUT OTHER COLLATERAL
AFFECTS.
TOWARD THAT END NOT ONLY HAVE
THE BROAD IMPLICATIONS BUT WE'RE
ASKED TO ADDRESS SOME OTHER
ELEMENTS OF COVID'S IMPACT.
ONE HAS BEEN ON POTENTIAL OF SEX
DIFFERENCES TO NOT ONLY AFFECT
EXPOSURE AND OUTCOMES OF
COVID-19 BUT SOME OF THE
SEQUELAE AND THE POST-ACUTE
SEQUELAE AND COMPLICATIONS OF
COVID IN WHICH THERE MAY EVEN BE
GREATER SEX SPECIFIC DIFFERENCES
PARTICULARLY AS WE LEARN MORE
ABOUT HOW THE VIRUS NOT ONLY
ATTACKS THE LUNGS AND THE HEART
AS A STANDARD RESPIRATORY
ILLNESS AND INFECTION BUT THE
EFFECT IT'S HAVING IN TERMS OF
MULTIPLE SYSTEMS AND
PARTICULARLY THE IMMUNE SYSTEM
AND THE ACTIVATION AND SOME
SUBSETS TO CONDITIONS THAT
APPEAR TO HAVE ALMOST AN
AUTOIMMUNE BASIS TO THEM AND THE
AUDIENCE IS FAMILIAR WITH A BODY
OF EVIDENCE THAT SHOWS A
DISPROPORTIONATE IMPACT ON
IMMUNE DISEASE ON WOMEN AS SHOWN
ON THE LEFT PANEL.
THIS HAS BEEN A CONSISTENT SORT
OF OBSERVATION.
SO AS WE ANTICIPATE AND ALREADY
SEE EVIDENCE OF AUTOIMMUNE
CLUSTER OF POST-ACUTE SEQUELAE
OF COVID WE'RE BEING VIGILANT IN
ASSESSING SEX-SPECIFIC
DIFFERENCES AS WE LEARN MORE
ABOUT NOT ONLY WHAT HAPPENS
ACUTELY WITH COVID-19 BUT AGAIN
AS WE ADDRESS ISSUES OF LONG
COVID AND THE INTERSECTION WITH
WOMEN'S HEALTH AND SEX AS A
BIOLOGICAL VARIABLE.
MANY ARE AWARE LONG-HAULERS
OVERLAPSED WITH OTHER ORGAN AND
MULTI-SYSTEM SYNDROMES THOUGHT
TO HAVE A MYELITIS AND CHRONIC
FATIGUE SYNDROME AND THERE'S
BEEN EVIDENCE OF IMMUNE SYMPTOMS
AND GREATER PREVALENCE IN WOMEN
AND RAYNAUD'S PHENOMENON AND
MYALGIAS.
TOWARDS THAT END WE RECOGNIZE
THAT NOT ONLY DO SOME OF THOSE
SYMPTOMS OVERLAP WITH POST-ACUTE
SEQUELAE OF COVID PAST OR LONG
COVID BUT SOME SPECIAL CASES OF
PASC AMONG CHILDREN AND MISC.
THIS EMERGED THE FIRST FEW
MONTHS OF THE EPIDEMIC IN WHICH
CHILDREN WHO APPEARED TO HAVE
BEEN EXPOSED TO COVID AND AS A
RESULT OF COV2 WOULD PRESENT
MANY WEEKS LATER, FOUR TO EIGHT
WEEKS LATER WITH A SYMPTOMATIC
COMPLICATIONS.
MANY OF WHICH INVOLVED THE
CARDIOVASCULAR SYSTEM, DECLINES
IN EJECTION FRACTION, HEART
FAILURE, OFTEN REQUIRING
INTENSIVE CARE ADMISSION AND
TREATMENT WITH MEDICATIONS SUCH
AS IBIG TO HOPEFULLY ADDRESS
IMMUNE ACTIVATION AND BE IMMUNE
MODULES AND THAT'S BEEN OBSERVED
AND WE'RE SEEING SEX DIFFERENCES
AND HOW THAT'S PLAYING OUT AS
WE'RE UNDERSTANDING THE IMMUNE
MECHANISMS ACTIVATED AS A RESULT
OF SARS COV2 INFECTION AND WHAT
THAT MAY DO DOWNSTREAM TO
POST-ACUTE SEQUELAE IN TERMS OF
ORGAN DAMAGE AND SYMPTOMS.
SO IN SOME CASES, SOME
SITUATIONS IT'S A SPECIAL CASE
OF LONG COVID, IF YOU WILL.
INDEED, WE'RE STARTING TO GET
EMERGING DATA NOW ABOUT LONG
COVID AND WE'RE CLOSELY
MONITORING FOR SEX-SPECIFIC
DIFFERENCES IN LONG COVID.
I MUST SAY THOUGH WE'D LIKE TO
NAIL THAT DOWN, I THINK IT'S
STILL A BIT EARLY DAYS AS WE
DEVELOP AND SEE MORE SYSTEMATIC
AND EFFECTIVE SAMPLING OF THOSE
AFFECTED TO CHARACTERIZE THIS.
CURRENTLY UNFORTUNATELY, MANY
STUDIES ARE SKEWED TOWARDS
HOSPITALIZED PATIENTS OR NOT.
MAYBE YOU'VE SEEN A SERIES OUT
OF THE V.A. HOSPITAL SYSTEM FOR
EXAMPLE AT GOOD SCALE BUT
EVERYONE ALSO APPRECIATES THAT'S
A SKEWED POPULATION FOR LOOKING
AT SEX DIFFERENCE.
MORE RESEARCH NEEDS TO BE DONE
TO UNDERSTAND ANY PARTICULAR
PATTERNS AMONG WOMEN SUFFERING
FROM LONG COVID RELATIVE TO
OTHER GROUPS.
WE HAVE RECOVER TO ENHANCE
RECOVERY.
THIS INITIATIVE THAT RECEIVES
CONGRESSIONAL APPROPRIATION TO
IMPROVE OUR UNDERSTANDING OF AND
ABILITY TO PREDICT, TREAT AND
PREVENT THE POST-ACUTE SEQUELAE
OF COVID.
WITH THE SAME KEY SCIENTIFIC
AIMS TO UNDERSTAND THE CLINICAL
SPECTRUM AND BIOLOGY AND TO
DEFINE THE RISK FACTORS,
INCIDENTS AND PREVALENCE AND SUB
PHENOTYPES OF LONG COVID AS WELL
AS STUDY PATHOGENESIS OVER TIME
AND RELATIONSHIP TO OTHER ORGAN
DYSFUNCTION AND DISORDER TO
DISSECT OUT THE SYNDROME WHICH
MAY IN FACT BE CLUST ERS --
CLUSTERS OF MANY PROCESSES AND
IDENTIFY INTERVENTIONS THAT CAN
HOPEFULLY PREVENT, PREEMPT OR
TREAT THE CONDITION.
WE'RE TRYING TO DO THIS
INITIATIVE RAPIDLY AND GUIDED BY
CERTAIN PRINCIPLES.
ONE IS TO BE PATIENT-CENTERED IN
WHICH RESEARCH PARTICIPANTS ARE
PARTNERS IN THIS AND HAVE BEEN
FROM THE CONCEPTION OF THE
INITIATIVE WITH PATIENTS FOR
EXAMPLE ENGAGED AND REPRESENTED
IN EVERY LEVEL FROM THE LOCAL
SITES THROUGH THE TASK GROUPS
AND PROTOCOL DEVELOPMENT, TRIAL
DESIGNS, STEERING COMMITTEE, THE
EXECUTIVE COMMITTEE AND EVERY
ELEMENT WITH AGAIN THE DRIVING
PRINCIPLE BEING INCLUSIVE AND
ENGAGING OF THE DIVERSE SET OF
STAKEHOLDERS AND PARTNERS IN
THIS PROGRAM AND TO RECOGNIZE
WE'RE GOING TO HAVE TO BE NIMBLE
AND ADAPTIVE.
AND ALTHOUGH WE'RE MEETING THE
SENSE OF URGENCY OF PATIENTS TO
THEIR SUFFERING, WE KNOW WE HAVE
TO BE DACHT AS WE LEARN WITH THE
VIRUS GOING FORWARD.
MY PRESENTATION CHANGED SO
HOPEFULLY EVERYONE'S SEEING THIS
OKAY.
AND ULTIMATELY TO LEVERAGE EVERY
SOURCE OF RESEARCH RESOURCES
TOWARDS THIS END.
LET ME WRAP UP WITH ONE FINAL
EXAMPLE OF OUR COLLABORATIVE AND
SHARED INTEREST THAT RELATE TO
ADVANCING MATERNAL HEALTH.
AS WE PIVOT FROM COVID, WE CAN'T
PIVOT VERY FAR AND WE'RE HAVING
CHALLENGES WITH BLOOD PRESSURE
CONTROL DURING THE PANDEMIC,
THERE'S ALSO BEEN A RISE IN
MATERNAL MORTALITY AND IT
APPEARS TO BE EXACERBATING
HEALTH DISPARITIES IN THE SPACE
AS SHOWN ON THE LEFT IN WHICH
UNFORTUNATELY THE UNITED STATES
HAS A DISTURBINGLY HIGH MATERNAL
MORBIDITY AND MORTALITY RELATIVE
TO OUR PEER HIGH-INCOME
COUNTRIES IT'S PARTICULARLY
PROBLEMATIC IN COMMUNITIES OF
COLOR, AFRICAN AMERICAN, LATINO,
AMERICAN INDIAN AND CLEARLY IS
ONE OF THE AREAS WE SHARE A HIGH
PRIORITY AND INTEREST WITH ORWH
IN THE SPACE.
MATERNAL HEALTH AND MORBIDITY
AND MORTALITY COME BACK TO OUR
PORTFOLIO.
NOT ONLY ARE THERE HYPERTENSION
BUT BLEEDING DISORDERS AND
MYOPATHY.
ALL THOSE ARE ELEMENTS OF THE
NHLBI MISSION AND THEREFORE
CRITICAL FOR US TO LEAN IN.
WE HAVE TAKEN A LIFE SPAN LENS
TO WOMEN'S HEALTH AND SEE
PREGNANCY DURING THE
REPRODUCTIVE AGE PERIODS AS A
CRITICAL EVENT AND SOMETIMES
SERVES AS A STRESS TEST THAT
IDENTIFIES WOMEN WITH LONG-TERM
RISK TRAJECTORIES FOR
CARDIOVASCULAR DISEASE AND
THAT'S WHAT'S EMERGED FROM THE
EPIDEMIOLOGIC DATA AND LOOKING
AT RISK FACTOR FOR PREGNANCY
OUTCOMES THEY OVERLAP WITH THE
RISK FACTORS FOR HEART DISEASE,
HIGH BLOOD PRESSURE, OBSTRUCTIVE
SLEEP APNEA, DIABETES AND
INSULIN RESISTANCE AND SMOKING
AND DIABETES AND GIVEN THE
SECULAR TRENDS OBSERVED THAT
WOMEN ARE BECOMING PREGNANT
LATER CHRONOLOGICALLY IN AGE AND
THEREFORE MAY TEND TO HAVE AN
INCREASED PREVALENCE OF THE RISK
FACTORS AND CO-MORBID CONDITIONS
SUCH AS OBESITY AND HIGH BLOOD
PRESSURE.
INDEED, UP TO 10% OF PREGNANCIES
ARE COMPLICATE D BY HYPER TENSIVE
DISORDER AND MANY THINGS MAN
TEST IN WOMEN DURING PREGNANCY
SUCH AS PREECLAMPSIA EVEN IF IT
RESOLVES WITHIN THE POSTPARTUM
PERIOD IT IDENTIFIES WOMEN ON A
TRAJECTORY TO EVENTUALLY DEVELOP
PRIMARY HYPERTENSION LATER IN
LIFE MOREOVER IT STARTS TO
IDENTIFY THE CHILD THAT WAS IN
UTERO DURING THE PREGNANCY AND
THAT CHILD IS AT HIGHER RISK TO
DEVELOP HIGH BLOOD PRESSURE
LATER IN LIFE.
THIS IS A CRITICAL WINDOW BOTH
OF UNDERSTANDING THAT
TRAJECTORY, IDENTIFYING THOSE AT
RISK IN THAT TRAJECTORY AND
HOPEFULLY INTERVENING IN A WAY
THAT CAN CHANGE THAT TRAJECTORY
AND ENHANCE THE LIFE AND HEALTH
AND THRIVING OF THE WOMAN AND
CHILD.
TO THAT END WE'RE EXCITED TO BE
CONSIDERED AS A PARTNER IN THE
IMPROVE INITIATIVE AND IMPROVE
EFFORT DR. CLAYTON PLAYS A KEY
LEADERSHIP ROLE MANY OF US
BELIEVE IS A GREAT OPPORTUNITY
TO OPTIMIZE HEALTH OF ALL WOMEN
AND PARTICULARLY WOMEN OF
REPRODUCTIVE AGE BOTH BEFORE,
DURING AND AFTER PREGNANCY.
AND A WHOLISTIC WAY IT'S NOT
LIMITED TO THE LABOR AND
DELIVERY SWEET AND TO PURSUE
IMPLEMENTING A MATERNAL HEALTH
AND PREGNANCY OUTCOME VISION FOR
EVERYONE.
AND HOPEFULLY DEVELOP A
PORTFOLIO OF PROGRAMS TO OBSERVE
AND GET A BETTER UNDERSTANDING
OF THE DRIVERS OF MATERNAL
HEALTH AND MORBIDITY AND
MORTALITY BUT ALSO PROVIDE A
MEANS TO MAKE A DIFFERENCE AND
HAVE AN IMPACT ON THOSE
DISPARITY STATISTICS I SHOWED
BEFORE.
PROGRAMS WE THINK ARE RELEVANT
TO THE UMBRELLA INCLUDE SOME OF
THOSE INDICATED.
WE'RE BUILDING ON ASSETS AND
LOOKING AT OUTCOMES OF WOMEN IN
PREGNANCY AND IDENTIFIED RISK
FACTORS AND SHOULDN'T BE A
SURPRISE AT THIS POINT IN THE
TALK, AGAIN, BLOOD PRESSURE IS
AN IMPORTANT RISK OF OUTCOMES
AND MOREOVER, I'LL NOTE THE
INTERPLAY WITH GESTATIONAL GT AAL
DIABETES, IDENTIFYING A CLUSTER
OR ADVERSE AT-RISK POPULATION
AND IT'S HIGHLY LIKELY
INTERVENTIONS ALONG THE AXIS ARE
LIKELY TO HAVE A MAJOR IMPACT.
TOWARDS THAT END, AGAIN, STUDIES
OBSERVED THE DISTURBING TREND IN
PRE-PREGNANCY HYPERTENSION.
FURTHER YOU MAY BE ABLE TO
DETECT FROM THE BLUE VERSUS THE
RED THE GRADIENT OF RURAL WOMEN
RELATIVE TO THOSE IN URBAN
SETTINGS.
IT'S IMPORTANT TO CONSIDER WOMEN
AND MATERNAL HEALTH
HOLISTICALLY, BEFORE, DURING AND
AFTER PREGNANCY GIVEN THE
TRAJECTORY AND RISK PROFILE AND
TO THAT END THE PREGNANCY TRIAL
AND EVALUATE THE BENEFITS AND
LOOK AT CHRONIC HYPERTENSION
DURING PREGNANCY.
AND THERE'S TREATMENT IN WHICH
IT WAS TO ACHIEVE LESS THAN 140
OVER 90 AND TEST WHETHER THAT
LEAD TO ADVERSE PREGNANCY
OUTCOMES WITHOUT PROMISING FETAL
GROWTH AND THERE'S A STUDY THAT
I BELIEVE IS COMING OUT IN THE
NEW ENGLAND JOURNAL NEXT WEEK OR
NEXT HOT OFF THE PRESSES AND
NOTE THE OBSTETRICIANS HAVE BEEN
CONSIDERED BLOOD PRESSURES ABOVE
140 OVER 90 AS WILD THOUGH FOR
EVERY OTHER ADULT WHO DOESN'T
HAVE TO BE PREGNANT WE'VE KNOWN
FOR YEARS THAT A LOWER BLOOD
PRESSURE GIVES YOU BETTER
OUTCOMES.
THIS IS AN AREA WHERE THERE'S AN
OPPORTUNITY TO ADVANCE THE CARE
OF WOMEN AGAIN BOTH BEFORE,
DURING AND AFTER PREGNANCY IN
WAYS TO REDUCE THEIR RISK OF
PREGNANCY OUTCOMES AS WELL AS
PUT THEM ON A TRAJECTORY TO
BETTER CARDIOVASCULAR HEALTH
OVER TIME.
AND SO WE'RE VERY EXCITED ABOUT
WHAT WE THINK WILL BE A
PRACTICE-CHANGING CLINICAL THAT
HAS MAJOR IMPLICATION FOR
ADVANCING MATERNAL HEALTH.
AS WE PURSUE THE TRIALS TO
ADVANCE WOMEN'S HEALTH, THERE'S
AN OPPORTUNITY TO ENSURE IT GETS
TRANSLATED TO ENSURE THERE'S
ACTUALLY UPTAKE OF THIS EVIDENCE
BASE TO ENSURE IT IS DONE WITH
THE LENS OF HEALTH EQUITY TO
REACH THE POPULATIONS AT
GREATEST RISK AND TOWARDS THAT
END, THE NHLBI IS ALSO ENGAGED
IN PUTTING TOGETHER THE ENRICH
PROGRAM THAT TARGETS A COMMUNITY
EMBEDDED EVIDENCE-BASED
INTERVENTION APPROACH TO
APPROACH HEALTH DISPARITIES.
THIS IS TAKING ADVANTAGE OF WHAT
WE ALREADY KNOW WORKS AND
PLATFORMS WE ALREADY KNOW WORKS.
IN PARTICULAR THE HRSA HOME
VISIT PROGRAM.
IN THIS CASE IS BEING LEVERAGED
TO TEST THIS INTERVENTION WITH
SEVERAL MODALITIES A AT THE
CORE, DIET, SLEEP, STRESS
MANAGEMENT AND THE AMERICAN
HEART ASSOCIATION SIMPLE SEVEN
THAT WILL HELP THESE MOTHERS
ENGAGE IN HEALTHY LIFESTYLE
CHOICES WITH AN APPRECIATION FOR
THE SOCIAL DETERMINATES OF
HEALTH INDICATORS AND ENSURING
IT'S A WRAP-AROUND PROGRAM OF
SUPPORT THAT RECOGNIZES THE HOME
ENVIRONMENT AND RESPONSE TO
PARENTING WITH INDEED A NURSE
VISITING MODEL TO FACILITATE
THAT HOME ENVIRONMENT NOT ONLY
FOR WOMAN BUT FOR CHILDREN AND
THE CHILD AS WELL AND TO ENSURE
ACCESS TO HEALTH CARE COUNSEL,
SUPPORT GROUPS TREATMENT
DELIVERY THAT GOES BEYOND THE
LABOR AND DELIVERY SUITE.
WE'RE DELIGHTED TO HAVE PARTNERS
ACROSS INSTITUTES, CENTERS AND
OFFICE AND APPRECIATE THE
PARTNERSHIP OF OFFICE OF
RESEARCH AND WOMEN'S HEALTH AS
PART OF THE ADVANCEMENT OF
MATERNAL HEALTH.
ANOTHER ASPECT OF ADVANCING
MATERNAL HEALTH APPRECIATES
ANOTHER INTERSECTION WITH SLEEP
AS AN IMPORTANT FACTOR IN WHICH
THERE MAY BE SEX-SPECIFIC
ELEMENTS AS WELL AS THE
INTERSECTION WITH RACE AND
ETHNICITY IN THE SOCIAL
DETERMINATES OF HEALTH.
SHOWN ON THE LEFT YOU CAN SEE
THE PREVALENCE OF SLEEP
DISTURBANCES DURING PREGNANCY BY
RACE ETHNICITY.
AGAIN, IT'S EVIDENT WHERE SHORT
SLEEP IS SHOWING RACIAL ETHNIC
DIFFERENCES AND WE KNOW FROM A
LARGE BODY OF EVIDENCE SLEEP
AFFECTS ALMOST EVERY SYSTEM IN
OUR BODIES AND PLAYS AN
IMPORTANT DRIVER ROLE IN
OBESITY, DIABETES, HIGH BLOOD
PRESSURE, HEART DISEASE AND SO
CLEARLY THIS MAY BE A KEY DRIVER
IN TERMS WHATEVER WE'RE SEEING
IN ADVERSE OUTCOMES IN PREGNANT
WOMEN AND PARTICULARLY PREGNANT
WOMEN OF COLOR.
YOU CAN SEE WOMEN WHO HAD THESE
SLEEP DISORDER ARE IN HIGHER
RISK FOR INCIDENT HIGH BLOOD
PRESSURE AND METABOLIC SYNDROMSYNDROME.
YOU SEE THE CONFLUENCE AND
CONVERGENCE OF RISK AND FACTORS
DRIVING THESE MAJOR
DISPROPORTIONATE IMPACTS.
SIMILARLY IT'S BECOME EVIDENT
SOMETHING MY GENDER DIDN'T
APPRECIATE IN WOMEN DURING
PREGNANCY DEVELOP SLEEP DISORDER
BREATHING PATTERNS AND
OBSTRUCTIVE SLEEP APNEA IN
PREGNANCY.
I SUPPOSE THAT'S SOMETHING WE
SHOULD HAVE INTUITIVELY
CONSIDERED GIVEN BODY CHANGE AND
HOW YOU BREATHE WHILE PREGNANT
AS WELL AS PREDISPOSING FACTORS
SUCH AS OBESITY.
THERE'S A SIGNIFICANT INCIDENTS
AND INDEED WE HAVE GONE FROM
OBSERVATIONAL TO INTERVENTION
AND TOWARD THAT END, CONDUCTED A
TRIAL WITH CPAC TO ADDRESS SLEEP
APNEA IN PREGNANT WOMEN AS A
RANDOMIZED TRIAL AND ADDRESSING
WHETHER BE AN INTERVENTION FOR
OBSTRUCTIVE SLEEP APNEA CAN
IMPROVE HEALTH OUTCOMES AND
WE'RE LOOKING FORWARD TO THE
IMPACT OF THAT WE HOPE IS AS
SIGNIFICANT.
LET ME START TO WRAP UP BY
PIVOTING TOWARD ANOTHER FINAL
EXAMPLE OF OUR MATERNAL HEALTH
PORTFOLIO IN WHICH WE HOPE TO GO
EVEN DEEPER INTO A WHOLISTIC
APPROACH TO WOMEN'S HEALTH AND
PARTICULARLY WOMEN IN
REPRODUCTIVE YEARS TO EMBRACE
THE SOCIAL-ECOLOGICAL FRAME OF
MATERNAL HEALTH.
WE ADDRESS WOMEN NOT ONLY AS
INDIVIDUALS THAT MAY BE ACROSS
THE DESK FROM A CLINICIAN BUT
REALLY SEES WOMEN MORE
HOLISTICALLY AND EMBEDDED IN THE
FAMILY AND LOOK AT SOCIAL
DETERMINATES AND THE BUILT
ENVIRONMENT AND HOW THEY
INTERPLAY TO AFFECT WOMEN'S
HEALTH AND HEALTH TRAJECTORY.
HOW CAN WE BEST ENABLE WOMEN TO
THRIVE AND RELATED TO THE SOCIAL
DETERMINATES OF HEALTH ARE ON A
RISK PROFILE TO HAVE THESE
UNFORTUNATE OUTCOMES AND ARE
THERE WAYS TO TAKE A MORE
HOLISTIC APPROACH THAT SURROUNDS
AND WRAPS AROUND WOMEN IN A
SUPPORTIVE COMMUNITY EMBEDDED
WAY SUCH THAT WOMEN AND CHILD
CAN BOTH THRIVE EVEN IN THE
CONTEXT OF A COMMUNITY THAT HAS
A LOT OF ADVERSITY.
CAN WE BUILD THE RESILIENCE?
CAN WE TAKE AN APPROACH THAT
INCLUDES THE SOCIAL DETERMINATES
OF HEALTH AND TARGETS RESEARCH
TO LOCAL COMMUNITY NEEDS
LEVERAGES COMMUNITY PLATFORMS
AND ASSETS AND PARTNERS TO
PROMOTE INCLUSIVE PARTICIPATION
IN WOMEN'S HEALTH RESEARCH AND
PROMOTES UPTAKE OF KNOWN
INTERVENTIONS THAT HAVE BENEFIT
FOR THAT COMMUNITY.
PARTICULARLY THE COMMUNITIES
MOST ADVERSELY AFFECTS BY THESE
CHALLENGES USING THE
COMMUNITY-ENGAGED RESEARCH AND
PARTNERSHIPS BASED ON TRUST AND
ADDRESSING THE INFORMATION,
INCREASING THE TRUST IN THE
SCIENCE AND PARTICIPATION IN IT
AND THEN ACCELERATING THE UPTAKE
OF BENEFICIAL INTERVENTIONS IN
THE COMMUNITY NEEDS.
I THINK IN MANY WAYS WOMEN'S
HEALTH IS A GREAT OPPORTUNITY TO
BECOME INCREASINGLY COMMUNITY
ENGAGED PARTICULARLY IN
COMMUNITIES OF COLOR.
WE'RE IN THE PROCESS OF
IMPROVING THE HEALTH WITH THE
RECOGNITION THERE'S HOT SPOTS OF
MATERNAL MORBIDITY AND
MORTALITY.
WE KNOW THERE'S MANY HIGH-RISK
COMMUNITIES TODAY AND CAN WE
DEVELOP A COMMUNITY ENGAGED
APPROACH WITH INTERVENTION
STRATEGIES THAT GO BEYOND THE
LABOR AND DELIVERY SUITE WITH
OTHER APPROACHES TO ENSURING
THEY HAVE ACCESS TO HEALTHY
LIFESTYLE AND INFORMATION AND
EDUCATION, NUTRITION AND CAN WE
DO THIS IN A WAY THAT PROVIDES
THE SOCIAL SUPPORT PROBABLY
NECESSARY FOR THAT TO BE
SUSTAINABLE AND SUCCESSFUL.
WE ARE ENGAGED IN THIS WITH FOUR
PROGRAMS SHOWN HERE UNDERWAY
CURRENTLY PURSUING THE
COMMUNITY-ENGAGED APPROACH TO
MATERNAL HEALTH.
I'VE TRIED TO INDICATE TO END ON
A WHAT-IF FORWARD LOOKING NOTE
OF HOW CAN WE CHANGE THESE
HEALTH INEQUITIES STATISTICS
SPECIFICALLY RELATED TO MATERNAL
AND CAN HAVE ANY AGENDA THAT
ADDRESSES DISPARITIES THROUGH A
LIFE COURSE, HOLISTIC APPROACH.
A COMMUNITY-CARE APPROACH.
AND I ENVISION A HYPOTHETICAL
WOMEN, CAMILLA WHO LIVES IN
RURAL LOUISIANA, PREDOMINANTLY
AFRICAN AMERICAN COMMUNITY WITH
LIMITED ACCESS TO HEALTH CARE
AND HEALTHY FOOD.
SHE EXPERIENCES HIGH BLOOD
PRESSURE AND PREECLAMPSIA IN HER
FIRST PREGNANCY AND REQUIRED
PROLONGED HOSPITALIZATION.
CAMILLA WORKS WITH THE COMMUNITY
HEALTH WORKER TO GET ACCESS TO
WIC AND SNAP BENEFITS THROUGH A
LOCAL CLINIC AND IT'S SOCIAL
OUTREACH COMPONENT.
IS GIVEN GUIDANCE TO USE MORE
FRUITS AND VEGETABLE FORWARDS
HER FAMILY AND HAS BEEN ADVISED
AND GIVEN TOOL OF
SELF-MANAGEMENT AND SCHEDULING
OF FEEDINGS WITH HER PARTNER SO
SHE CAN GET A GOOD NIGHT'S SLEEP
AND PRACTICE GOOD SLEEP HYGIENE.
SHE'S ALSO MEASURING AND
MANAGING HER BLOOD PRESSURE WITH
REPORTS BACK TO THE CLINIC.
ALL THESE ARE MEANS BY WHICH WE
CAN CHANGE THE TRAJECTORY OF
CAMILLA'S LIFE AND THE LIFE OF
HER SECOND CHILD AND HER FAMILY.
I THINK THE EVIDENCE BASE WILL
EMERGE FROM THE STUDIES I'VE
INDICATED AND CAN BE TESTED WITH
IMPLEMENTATION IN REAL WORLD IN
COMMUNITIES DISPROPORTIONATELY
AFFECT.
IN SO DOING I THINK WE'LL
FULFILL OUR MISSION TO TURN
DISCOVERY SCIENCE INTO HEALTH
FOR ALL.
THANK YOU FOR YOUR ATTENTION.
>> THANK YOU.
>> THANK YOU, SO MUCH
DR. GIBBONS.
I LOVE THE ECO SYSTEM.
I APPRECIATE YOU COVERING SO
MANY COMPLEX ISSUES THROUGH THE
LENS OF WOMEN BEING CENTERED.
IT LOOKS LIKE DR. KLINE HAS A
QUESTION FOR YOU.
>> NO, I JUST WANTED TO TURN THE
CAMERA ON.
THANK YOU, DR. GIBBONS FOR AN
INCREDIBLE WALK THROUGH WHAT HIS
INSTITUTE DOES.
>> BECAUSE OF YOUR COVID WORK
THAT YOU'RE VERY INTERESTED IN
HEARING ABOUT RECOVER AND WE'RE
EXCITED TO SEE THAT THE ROBUST
INVESTMENT SO DR. RIOS.
YOU HAVE A QUESTION?
SHE'S AN ADVISORY COMMITTEE
MEMBER.
GO AHEAD.
>> THANK YOU FOR THAT.
AND THE 140 OVER 90 WE HAVE TO
BRING IT DOWN FOR THAT
POPULATION OF DOCTORS.
I'VE BEEN INVOLVED WITH CLIMATE
CHANGE AND SEE THAT IS NOT IN
YOUR SLIDES AND LOOK MORE INTO
THIS BUT THEN SPEAK TO THE
NATIONAL ACADEMIES WILL HAVE A
MEETING ON FUTURE RESEARCH
DIRECTION ON ENVIRONMENTAL
HEALTH AND DISPARITIES.
I'D LOVE TO SEE THIS MATERNAL
HEALTH AND FACTORS, BLOOD
PRESSURE, SLEEP, BE A PART OF
THAT FUTURE.
I THINK THE SLIDE ABOUT THE
RURAL COULD CONNECT IT TO
ENVIRONMENTAL.
JUST WONDERING IF YOU'VE HAD
ANY --
>> IT'S A GREAT POINT, DR. RIOS.
I APPRECIATE THAT.
MY TALK WAS ALREADY LONG ENOUGH.
AND THIS IS TOP OF MIND WE'VE
BEEN ENGAGED THINKING ABOUT THE
IMPACT OF ENVIRONMENT ON HEALTH.
AND AS YOU ARE AWARE AND YOU'RE
A PEDIATRICIAN, ASTHMA'S A BIG
PART OF OUR PORTFOLIO.
IT'S ONE THAT HAS THE
INTERSECTION WITH COMMUNITIES OF
COLOR WITH A HIGHER PREVALENCE
AND AS YOU ALSO KNOW ASTHMA'S
AFFECTED BY THE ENVIRONMENTAL
CONDITIONS, AIR POLLUTION,
ALLERGENS, ETCETERA.
AND THAT IS CLEARLY ON THE
PATHWAY TO BEING DRAMATICALLY
AFFECTED BY CLIMATE CHANGE AS A
COMPONENT OF THAT.
AIR QUALITY IS COMPROMISED AND
IT GETS COMPROMISED INCREASINGLY
WITH THE WILDFIRES AND
EVERYTHING ASSOCIATED WITH
CLIMATE CHANGE CLEARLY.
WE ALSO KNOW AND THERE'S DATA
THAT INDICATES THAT
CONCENTRATION OF PARTICULATE
MATTERS IS INCREASED IF YOU DO A
NATIONAL MAP OF COUNTY-LEVEL
RESOLUTION WITHIN CERTAIN
COMMUNITIES.
AND AT THIS POINT IT WOULDN'T
SURPRISE THIS AUDIENCE IT'S
CONCENTRATES IN RACIAL-ETHNIC
COMMUNITIES.
THOSE OF US WHO ARE FAMILIAR
WITH THESE CONTEXT CONTEXTS WE KNOW
WHERE THE PARKING LOTS FOR THE
BUS COMPANIES AND AND THESE ARE
C
CONCENTRATED IN COMMUNITIES OF
COLOR.
WE CAN'T GET INTO BUT WE'RE
CONTEMPLATING INITIATIVES IN THE
SPACE AND WE HAVE BEEN WORKING
WITH LEADERSHIP AND WE'RE
MARSHALLING EFFORTS TO SEE ON
WHAT A TRANS-NIH BASIS WE CAN DO
TO LINK UP LINK UP FACTORS TO
SOCIAL DETERMINATES OF HEALTH
AND HEART AND LUNG DISEASES ARE
VERY MUCH A PART OF THAT AND A
KEY PART OF OUR RESEARCH
AGENDAS.
SOR
SORRY, I CAN'T ELABORATE.
>> THERE'S A WORKSHOP ON THE
ENVIRONMENTAL IMPACT OF WOMEN'S
HEALTH DISPARITIES AND
REPRODUCTIVE HEALTH THROUGH
THROUGH NIEHS.
WE'LL HAVE THAT THE IN THE
MATERIALS.
>> DR. REGENSTEINER DO YOU HAVE
A QUESTION?
>> IN TERMS OF THE WOMEN'S
HEALTH INITIATIVE IT HAD THE
EFFECT OF LESS RESEARCH ON THE
ROLE OF ESTROGEN IN POST-MEN
POST-MENOPAUSAL WOMEN.
WHAT'S GOING ON AT NHLBI WITH
WOMEN AND HEART DISEASE AND
OLDER WOMEN.
IS THERE THOUGHT TO DOING MORE
RESEARCH WITH ESTROGEN WHICH
REMAINS HIGHLY CONTROVERSIAL, AS
YOU KNOW.
>> IT'S A GREAT QUESTION.
IT'S SOMETHING THAT I THINK WE
ALWAYS WANT TO CONTINUAL LY WHAT
WE'RE DOING WITH WOMEN'S HEALTH
AND I ALLUDED TO SOME STUDIES
WE'RE DOING AND WE'RE TRYING TO
ADDRESS WOMEN AT THAT LATER
STAGE OF LIFE AND WHAT IS MOST
EFFECTIVE AND I SPOKE ON THE
EXERCISE INTERVENTION.
WE DON'T HAVE ANYTHING
SPECIFICALLY RELATED TO
IMAGINING POST-MENOPAUSAL ISSUES
BIT I SUSPECT THEY'LL CONTINUE
TO BE INVOLVED.
PART IS APPRECIATING
APPRECIATING THE MECHANISTIC
ELEMENTS OF ADVERSE RISK AND
ADDRESSING SYMPTOMS BUT IN A WAY
THAT CAN BE MORE SAFE AND SO I
THINK THAT'S WHERE HAVING THE
DISCOVERY PHASE AND CYCLE
LOOKING TO DO THINGS MORE
EFFECTIVE THAN 20 YEARS AGO.
HOPEFULLY YOU ALSO CERTAIN WE
THINK IT'S ALSO IMPORTANT NOT
ONLY IN THE MENOPAUSAL,
POST-MENOPAUSAL PERIOD TO MOVE
EARLIER IN THE TRAJECTORY
BECAUSE WE KNOW A LOT OF THAT
ELEMENTS WE STARTED MIDDLE AGED
ON HAVE GENESIS EARLIER AND WHAT
WE'RE HOPING TO PREVENT AND
CHANGE THE TRAJECTORY WELL
BEFORE THE ONSET OF MENOPAUSE
AND CHANGING THAT TRAJECTORY CAN
HAVE THE LIFE LONG BENEFIT IF WE
GET THEM ON THE RIGHT
TRAJECTORY.
WE'RE TRYING TO UNDERSTAND THE
RISK, MOVING EARLIER AND
HOPEFULLY PREEMPTIVELY IN A WAY
THAT CHANGES HOW WE APPROACH
WOMEN IN LATER LIFE.
>> MUSE I AM TO MY EARS.
IT'S SO ALIVE WITH THE LIFE
COURSE PERSPECTIVE ORWH HAS BEEN
PUTTING FORWARD MANY YEARS AND
WE'RE DELIGHTED TO HAVE YOU AND
WE'LL HAVE DR. LANGER HAVE THE
LAST QUESTION FOR DR. GIBBONS
AND THEN MOVE ON TO THE NEXT
AGENDA ITEM.
>> THANK YOU SO MUCH.
THANK YOU FOR A WONDERFUL
PRESENTATION.
I APPRECIATE THE OVERCOLLUSION
IN SCIENCE IN YOUR OVERALL
EFFORT.
I WONDERED IN WHAT WAY YOU ARE
WORKING OR PROMOTING THAT
PREGNANCY IS NOT ONLY GOOD FOR
THE BODY AND MIND AND EVERYTHING
ELSE BUT ALSO AN OPPORTUNITY.
THERE WAS A TIME WHEN MOST WOMEN
HAVE UTILIZED A HEALTH CARE.
THERE'S BIG CHALLENGES LIKE
LIMITED COVERAGE THAT MEDICAID
PROVIDES DURING THE POSTPARTUM
PERIOD AND SCATTERED HEALTH
SYSTEM THAT DON'T ALLOW WOMEN
WHO ARE VULNERABLE TO FOLLOW-UP
IN THE POST-PARTUM PERIOD AND
BEYOND.
>> ANOTHER GREAT POINT.
THAT IS PART OF THE HOPE OR
VISION OF SOME OF THESE PROGRAMS
TO TEST SOME OF THE MODELS AND
PROVIDE AN EVIDENCE BASE TO NOT
ONLY GET EFFICACY IN TRIALS BUT
WE ALSO SHOWED CERTAIN MODELS OF
ENGAGING WOMEN AND CARING FOR
WOMEN OUTSIDE OF THE CLINIC
WALLS IN SUSTAINABLE WAYS THAT
WE BELIEVE LEVERAGES LOCAL
COMMUNITY ASSETS AND REALLY
EMPOWERED AND ENABLES WOMEN
MAYBE AN OPPORTUNITY TO EXTEND
WHAT YOU'RE SAYING RECOGNIZING
THE PRAGMENTATION WHERE THE
HEALTH CARE SYSTEM TENDS TO
OPERATE WHAT WE CALL WRAPPING
AROUND OF COMMUNITY OF EMBEDDED
CARE TO ADDRESS SOME OF THAT AND
EXTEND SOME OF THAT, FILL IN
SOME OF THE GAPS.
INDEED WE'VE HAD SOME
PRELIMINARY DISCUSSIONS WITH NEW
ADMINISTRATOR OF CMS THAT IS
INTERESTED IN LOOKING AT SOME OF
THE MODELS WHEREBY WE CAN CHANGE
THE REIMBURSEMENT TO FOCUS ON
WOMEN AND THEIR OUTCOMES
RELATIVE TO HOW DOCTORS ARE
ARRANGING THEIR VISITS AND
GETTING REIMBURSED.
AGAIN, IF WE LOOK AT THIS
HOLISTICALLY EVEN WITH A
VALUE-BASED CARE LENS WE THINK
IT WILL STILL COME BACK TO
THINGS THAT WORK FOR WOMEN
HOLISTICALLY AND FIT WITHIN A
PREVENTIVE SELF-MANAGEMENT KIND
OF FRAMEWORK.
YOU USE ETCH -- EXTENDERS LIKE
HEALTH WORKERS IN A
COST-EFFECTIVE WAY AND IF WE CAN
DEMONSTRATE THOSE THINGS MAYBE
IT CAN BE A BASIS FOR HRSA AND
CMS TO BE GREAT PARTNERS.
THAT'S OUR ROLE IN TURNING
DISCOVERY SCIENCE AND TO FIGURE
OUT HOW TO MAKE THAT WORK IN THE
REAL WORLD.
THAT'S THE ONLY WAY WE MOVE THE
NEEDLE.
>> THANK YOU SO MUCH, GARY.
OF COURSE I KNEW YOU WOULD NOT
DISAPPOINT AND YOU ACTUALLY CAME
WITH SO MUCH GREATER INFORMATION
THAT IS SO ALIGNED WITH WHERE
WE'RE GOING.
IT'S BEEN A PRIVILEGE TO WORK
WITH YOU AND I STEPPED INTO BIG
SHOES AS I BECAME DIRECTOR AND
IT'S BEEN MY PLEASURE TO GROW
OUR RELATIONSHIP WITH ORWH AND
NHLBI AND I LOOK FORWARD TO
CONTINUING TO WORK TOGETHER TO
IMPROVE THE HEALTH OF ALL WOMEN.
WE'RE SO EXCITED TO HAVE YOU
JOIN US TODAY.
THANK YOU VERY MUCH.
WE APPRECIATE YOU.
>> THANK YOU SO MUCH.
ALWAYS A PLEASURE AND LOOK
FORWARD TO ONGOING
COLLABORATION.
MUCH APPRECIATED.
THANK YOU.
>> THANKS, GARY.
I'LL TURN IT BACK OVER TO
DRDR.
DR. NOURSI THE EXECUTIVE
SECRETARY TO MOVE US TO THE NEXT
SECTION.
>> I APPRECIATE THAT.
I'D LIKE TO HAND THIS ACTUALLY
OFF TO OUR HEALTH POLICY IN THE
TO INTRODUCE OUR NEXT SPEAKER.
>> HELLO, EVERYONE.
I'M PLEASED TO INTRODUCE MS.
CORBETT IN THE OFFICE OF
RESEARCH OER.
SHE PROVIDES OVERSIGHT TO THE
NIH EFFORT TO ENSURE THE
INCLUSION OF WOMEN, MINORITIES
AND INDIVIDUALS ACROSS THEIR
LIFE SPAN IN NIH-DEFINED
CLINICAL RESEARCH.
PRIOR TO JOINING OER, MS.
CORBETT LED EFFORTS TO INCREASE
THE EFFICIENCY AND TRANSPARENCY
OF CLINICAL RESEARCH THROUGH
ENHANCED RECRUITMENT MONITORING
AND INCREASE EFFORTS AS A HEALTH
POLICY ANALYST IN THE NATIONAL
INSTITUTE OF MENTAL HEALTH AT
NIMH OFFICE OF CLINICAL RESEARCH
AND CLINIC TRIALS OPERATIONS AND
BIOSTATISTIC BRANCH.
SHE BEGAN HER CAREER AT OFFICE
FOR DISPARITIES IN GLOBAL MENTAL
HEALTH, FORMERLY THE OFFICE FOR
SPATIAL POPULATIONS WHERE SHE
COORDINATED PROGRAMS RELATED TO
DIVERSITY IN CLINICAL RESEARCH
AND CONDUCTED PORTFOLIO ANALYSES
IN THE AREAS OF MENTAL HEALTH
DISPARITIES.
SHE HAS A MASTER'S DEGREE IN
PUBLIC HEALTH FROM JOHNS HOPKINS
SCHOOL OF PUBLIC HEALTH AND
BACHELOR'S DEGREE IN POLITICAL
SCIENCE FROM THE UNIVERSITY OF
ILLINOIS.
WELCOME, MS. CORBETT.
>> THANK YOU.
>> I WANT TO ACKNOWLEDGE
DR. TEMPLETON JOINED US.
>> I APPRECIATE THE
INTRODUCTION.
IT'S ALWAYS GREAT TO BE BACK AND
LET YOU KNOW WHAT NIH IS DOING
ON INCLUSION.
I'M JUST GOING TO GIVE YOU A
BRIEF OVERVIEW OF NIH INCLUSION
POLICIES.
WE HAVE TWO.
THE FIRST IS ON THE INCLUSION OF
WOMEN AND MINORITIES AND NIH
RESEARCH.
THIS POLICY REQUIRES THAT WOMEN
AND MEMBERS OF RACIAL AND ETHNIC
MINORITY GROUPS BE INCLUDED IN
ALL NIH-FUNDED CLINICAL RESEARCH
STUDIES UNLESS THERE'S A
COMPELLING RATIONALE FOR
EXCLUSION.
THE POLICY HAS BEEN IN PLACE FOR
A LONG TIME SINCE 1994.
WE HAD POLICIES DATING BACK TO
THE 80s ENCOURAGING WOMEN TO BE
INCLUDED IN NIH STUDIES.
IT ALSO REQUIRES ADDITIONAL
ANALYSES FOR PHASED 3 CLINICAL
TRIALS THOSE BROAD BASED
INTERVENTIONAL STUDIES AND
COMPARE AN INTERVENTION AND
OFTEN THE AIM IS TO CHANGE
HEALTH POLICY.
THEY MUST BE DESIGNED TO PERMIT
ANALYSIS BY SEX OR GENDER, RACE
AND ETHNICITY.
AND MORE RECENTLY IN 2017, NIH
IMPLEMENTED SOME ADDITIONAL
REQUIREMENTS FOR NIH-DEFINED
PHASED TRIAL AND MUST REPORT
RESULT OF THE SEES IN
CLINICALTRIALS.gov.
WE HAVE OUR INCLUSION ACROSS THE
LIFE SPAN POLICY.
IT'S MORE RECENT AND REQUIRES
INDIVIDUALS OF ALL AGES MUST BE
INCLUDED IN NIH FUNDED STUDIES.
WE PREVIOUSLY HAD HAD AN
INCLUSION OF CHILDREN POLICY
SINCE 1998 STARTING WITH
APPLICATIONS SUBMITTED FOR DUE
DATES JANUARY 25, 2019 OR LATER.
THOSE APPLICATIONS ARE REQUIRED
TO INCLUDE INDIVIDUALS OF ALL
AGES.
THERE'S AN ADDITIONAL
REQUIREMENT FOR APPLICATIONS
THAT COME UNDER INCLUSION ACROSS
THE LIFE SPAN AND THEY HAVE TO
SUBMIT INDIVIDUAL LEVEL DATA ON
PARTICIPANT SEX OR GENDER, RACE
ETHNICITY AND AGE OF ENROLLMENT
AND PROGRESS REPORTS.
NIH HAS BEEN COLLECTING DATA IN
THE AGGREGATE FOR SOME TIME BUT
THIS WAS A SHIFT TO SUBMITTING
INDIVIDUAL LEVEL DATA AND WE
JUST BEGAN COLLECTING DATA ON
AGE AT ENROLLMENT AND I'LL SHARE
SOME WITH YOU A BIT LATER IN THE
TALK.
IN THE LAST SEVERAL YEARS, NIH
HAS BEEN BUSY IMPLEMENTING
RECOMMENDATIONS THAT CAME OUT OF
GAO REPORT IN 2015.
BACK THEN THEY CONCLUDED BETTER
OVERSIGHT WAS NEEDED TO ENSURE
CONTINUED PROGRESS INCLUDING
RESEARCH AND INCLUDED A NUMBER
OF RECOMMENDATIONS FOR NIH TO
IMPROVE THAT OVERSIGHT.
IN ALL THERE WERE FIVE
RECOMMENDATIONS.
THESE WERE ALLUDED TO
DR. CLAYTON'S TALK EARLIER.
THE FIRST OF THOSE WERE TO MAKE
I.C. LEVEL ENROLLMENT DATA
READILY AVAILABLE THROUGH PUBLIC
MEANS.
NIH DID THAT THROUGH OUR
WEBSITE.
THE DATA ARE NOT AVAILABLE IN
THE NIH REPORT SITE AND
RECOMMENDATIONS CLOSED AND ASKED
US TO EXAMINE APPROACHES FOR
MORE DETAILED ENROLLMENT DATA AT
THE CONDITION LEVEL AND THESE
ARE ALSO AVAILABLE AND THAT
RECOMMENDATION IS CLOSED.
THE THIRD RECOMMENDATION WAS TO
ENSURE THE PROGRAM OFFICERS HAVE
A MEANS OF RECORDING THEIR
MONITORING AWARDEES PLANS FOR
PROGRESS FOR IN PROGRESS IN
CONDUCTING ANALYSIS OF POTENTIAL
SEX DIFFERENCES.
SEVERAL YEARS AGO, NIH
INTRODUCED A CHECKLIST FOR
PROGRAM OFFICERS TO MONITOR
THOSE PLANS IN CONDUCTING
ANALYSES OF POTENTIAL SEX
DIFFERENCES.
THE GAO FURTHER RECOMMEND THE OF
NIH COLLECT AND SUMMARIZE DATA
FOR AWARDEES OF ANALYSES FOR
SPECIAL SEX DIRCHBL --
DIFFERENCES AND WE REPORT THE
DATA IN A REGULAR REPORT TO
CONGRESS AND IF YOU SEE THE
REPORT IN THE MOST RECENT REPORT
YOU'LL SEE DATA ON STUDIES THAT
REQUIRE ANALYSIS ON SEX OR
GENDER.
HI
NIH HAD A WORKSHOP IN SEPTEMBER
2020 INCLUDING A NUMBER OF
STAKEHOLDERS FROM RESEARCHERS,
PROVIDERS, ADVOCACY GROUPS AND
MIM MEMBERS OF ACADEMIA AND
OTHER FEDERAL AGENCIES TO TALK
ABOUT HOW THE POLICY WAS BEING
IMPLEMENTED AND WERE THE BEST
STRATEGIES FOR MOVING FORWARD
FOR DIVERSE CLINICAL TRIALS IN
PARTICULAR.
THERE WERE A NUMBER OF THEMES
THAT CAME FROM THE WORKSHOP AND
I SHARED THESE OFTEN WITH
RESEARCHERS IN THE COMMUNITY AND
WANTED TO SHARE THEM WITH YOU.
AMONG THE THEMES MENTIONED TO
IMPROVE INCLUSION AND NIH TRIALS
INCLUDING SELECTING TRIAL
OUTCOMES THAT REFLECT
PARTICIPANT CONCERNS.
IT WAS MENTIONED AT THE WORKSHOP
WHEN WE'RE DESIGNING A TRIAL ZI
TO REMEMBER TO ASK QUESTIONS
IMPORTANT TO THE PEOPLE WHO WILL
BE PARTICIPATING IN THE TRIAL
AND THAT MEANS CAREFULLY LOOKING
AT TRIAL OUTCOME AND LOOKING AT
PARTICIPANTS AND INCLUSION AND
EXCLUSION CRITERIA.
SO FOR MANY YEARS WE DID SEE
EXPLICIT CRITERIA FOR , GENDER,
RACE, ETHNICITY OR AGE AND WE DO
STILL SEE THOSE SOMETIMES BUT WE
ALSO SEE OTHER INCLUSION
CRITERIA SUCH AS COMORBIDITIES
THAT MAY LIMIT INCLUSION TO
GROUPS DISPROPORTIONATELY.
THIS WAS ADDRESSED AT THE
MEETING.
THE FDA TALKED ABOUT INCLUSION
AND EXCLUSION CRITERIA AND HOW
THAT SHOULD BE ADJUSTED THROUGH
THE PHASES.
ALSO WAS INCLUDING GROUPS WITH
WOMEN AND CHILDREN WITH
PARTICIPATION.
NIH HAS BEEN INVOLVED IN NUMBERS
WITH OHRP AND OTHERS MAKING SURE
RESEARCHERS AND IRBs TAKE INTO
ACCOUNT THE POTENTIAL BENEFITS
OF RESEARCH PARTICIPATION AND
THE KNOWLEDGE TO BE GAINED BY
THE RESEARCH AND WEIGH THOSE
WITH THE RISK OF INCLUSION OF
CERTAIN GROUPS.
MINIMIZING PARTICIPANT AND
CAREGIVER BURDEN AND STUDY
PROCEDURES, HOW MANY TIMES DOES
THE PARTICIPANT HAVE TO GO TO
VISITS.
CAN WE DO THINGS THAT ARE
CONVENIENT FOR PARTICIPANTS AND
CAREGIVERS LIKE TELEHEALTH AND
PROVIDE LANGUAGE SERVICES AND
THOSE THINGS WERE DISCUSSED AT
THE MEETING AS WELL.
ANOTHER POINT WAS CONSIDERING
THE DIVERSITY OF GROUPS.
MOST GROUPS ARE NOT A MONOLITH.
THEY'RE DIVERSE.
WOMEN COME WITH DIFFERENT SIZES
AND COMORBIDITIES AND DIETS AND
COGNITIVE STATUS.
THIS IS AN IMPORTANT
CONSIDERATION AS WE THINK ABOUT
INCLUSION HOLISTICALLY.
AND IT WAS MENTIONED TO ASSESS
RECRUITMENT AND MAKE ASSESSMENTS
AND THESE ARE CONTINUING.
ALSO IF YOU WANT TO READ THE
FULL REPORT THIS IS AVAILABLE ON
OUR WEBSITE.
OER HAS ISSUED COMMUNICATIONS.
WE HAVE TRAINING AVAILABLE FOR
RESEARCHERS AND OTHER STAFF
THERE'S AN OPEN MIC BLOG IN THE
EXTRAMURAL NEXUS.
IT'S A GREAT WAY TO GET UPDATES
ABOUT NOT ONLY NEW NIH POLICIES
AND PROCEDURES BUT ALSO NIH'S
THINKING ON VARIOUS ISSUES,
CLARIFICATION OF ANY POINTS THAT
MAY HAVE BE OF CONFUSION AND
WE'VE HAD SEVERAL ARTICLES ON
INCLUSION-RELATED MATTERS.
I CONDUCT TRAINING EVERY YEAR AT
OUR NIH ENVIRONMENT SEMINAR.
THEY USED TO BE NIH VIRTUAL
SEMINARS WHERE WE USED TO TALK
TO RESEARCHERS, ADMINISTRATORS
AND OTHERS IN THE COMMUNITY
ABOUT SUBMITTING AN NIH GRANT
APPLICATION, POLICIES AND
PROCEDURES AT NIH.
A COUPLE YEARS AGO, WE STARTED A
WORKSHOP ON INCLUSION WHICH IS
NOW A STAND ALONE WORKSHOP AND
HAD PREVIOUSLY COMBINED WITH
HUMAN SUBJECTS RESEARCH.
WE'RE ABLE TO REACH A NUMBER OF
PEOPLE S YOU ARE MOST RECENT HAD
OVER 24,000 REGISTRANT.
WE'VE REACHED LARGE NUMBERS OF
PEOPLE AND HAVE GOTTEN GREAT
FEEDBACK HOW THE SEMINARS ARE
NOW MORE ACCESSIBLE TO
INDIVIDUALS.
WE ALSO HAVE OPPORTUNITIES FOR
ONE-ON-ONE DISCUSSIONS.
WE HAD A POLICY OFFICER SESSION
WHERE PEOPLE CAN ASK ME WHAT'S
ON THEIR MIND.
IT'S BEEN A GREAT WAY TO HAVE
OUTREACH TO THE COMMUNITY.
I NOW WANT TO SHIFT AND TALK A
LITTLE BIT ABOUT WHAT OUR DATA
LOOKS LIKE.
OUR I.C.s HAVE BEEN WORKING ON
THEIR REPORTS.
THE REPORTS COVER FISCAL YEARS
2019 THROUGH 2021.
I WANTED TO SHARE TO GET AN IDEA
HOW NIH IS DOING.
THIS SLIDE SHOWS THE INCLUSION
INCLUSION OF WOMEN HAS INCREASED
A BIT AND INCREASED TO 51% IN 20
AND IS NOW UP TO ALMOST 59% IN
PHYSICAL YEAR 2021.
IF WE LOOK AT OUR NIH DEFINED
PHASE 3 CLINICAL TRIALS, WOMEN
ARE A HIGHER PROPORTION OF
PARTICIPANTS THAN IN OUR
CLINICAL RESEARCH.
IT'S BEEN CONSISTENT FOR A
NUMBER OF YEARS TRIAL.
WE HAVE MORE FEMALE ONLY PHASE 3
TRIALS THAN MALE ONLY.
WE HAD A CONSISTENT TREND ABOUT
61% FROM FISCAL YEARS '19
THROUGH 2021.
THIS SLIDE ENROLLMENT BY RACE
FROM FISCAL YEARS 19 TO 2021.
THE LARGEST RACIAL GROUPS IN ALL
YEARS WERE WHITE.
WHITE PARTICIPANTS MADE UP ABOUT
66% OF PARTICIPANTS IN FISCAL
YEARS 2019.
THAT DECREASED ABOUT 61% IN 2020
AND WENT BACK UP A BIT TO 64% IN
2021.
THE NEXT RACIAL GROUP IS BLACK
OR AFRICAN AMERICAN AND WE SAW A
DECREASE FROM FISCAL YEAR 2019
TO 2021 WHERE IT'S NOW 13% IN
THE GRAY.
THE THIRD LARGEST RACIAL GROUP
IS ASIAN.
WE'VE SEEN AN INCREASE IN ASIAN
PARTICIPANTS IF YOU LOOK THERE
IN THE ORANGE IN FISCAL 2019 WE
HAVE 3% OF PARTICIPANTS
IDENTIFIED TO ASIAN AND THAT
INCREASED IN 2020 TO ABOUT 12
PATIENCE AND NOW UP TO ABOUT 5%.
WE DO HAVE SMALLER BUT STEADY
PERCENTAGE OF AMERICAN INDIAN OR
ALASKAN NATIVE AND THAT IS BEEN
CONSISTENT A BIT OF DECREASE IN
FISCAL 2021 AND NATIVE HAWAIIAN
OR PACIFIC ISLANDERS IT'S .2% TO
.3% AND IT WAS IN 2019 AND 2020
AND NOW UP TO 8.
WE HAVE A HIGH PROPORTION OF
NOT-REPORTED RACE AND HAVE SEEN
AN INCREASE IN RECENT YEARS AS
WE HAVE MORE AND MORE RESEARCH
BEING DONE WITH E.H.R.s AND HAVE
HIGHER NUMBERS OF UNREPORTED
PARTICIPANTS IN THE DATA.
IF WE LOOKED AT NIH DEFINED
PHASE 3 CLINICAL TRIALS WE SEE
SIMILAR TRENDS THEN DATA TEND TO
MORE MORE THAN OUR CLINICAL
RESEARCH DATA GIVEN THE SMALLER
NUMBERS AND STUDIES INCLUDE.
FOR NIH DEFINED PHASE 3 TRIALS
AND HAD A HIGHER PROPORTION OF
WHITE PARTICIPANTS IN OUR
U.S. TRIALS.
ABOUT 73% IN FISCAL 2019.
THAT DROPPED TO 63% IN 2020 UP
TO 75% IN 2021.
AGAIN, BLACK OR AFRICAN AMERICAN
PARTICIPANTS ARE THE NEXT
HIGHEST GROUP AND IT'S NOW DOWN
TO 14%.
AND WE HAD A LOWER PERCENTAGE TO
2.3 IN 2021.
WE SEE SMALLER NUMBERS OF
AMERICAN INDIAN AND ALASKAN
NATIVE AND INCREASE IN NATIVE
HAWAIIAN AND WE HAVE A SMALLER
NUMBER OF UNKNOWN OR UNREPORTED
IN OUR PHASE 3s THAN OTHER
RESEARCH.
AND NOTABLY AN INCREASE IN 1.4%
IN 2019 AND INCREASE IN 2020 AND
WAS AT 3.4% IN 2020.
NOW I'D LIKE TO MOVE TO OUR
CLINICAL RESEARCH ENROLLMENT BY
ETHNICITY.
IN FISCAL YEAR 2019, ABOUT 9% OF
PARTICIPANTS IDENTIFIED AS
HISPANIC OR LATINO.
THAT'S THE AREA IN THE ORANGE ON
THE PIE GRAPH.
IN 2020 THAT INCREASED TO 10.9%
AND THEN WAS FAIRLY CONSISTENT
IN 2021 ABOUT 10.5% IDENTIFIED
AS HISPANIC OR LATINO.
ON THE NEXT SLIDE WE CAN LOOK AT
NIH-DEFINED PHASE 3 CLINICAL
TRIAL.
WE SAW QUITE A BIT OF A JUMP IN
HISPANIC OR LATINO
PARTICIPATION.
IT'S MOSTLY DUE TO ONE STUDY.
IT DOESN'T NECESSARILY MEAN A
HUGE INCREASE ACROSS THE
PORTFOLIO.
ABOUT 8.7% IN FISCAL 2019
INCREASED TO 17% IN 2020 AND A
LARGE JUMP IN 2021.
ALMOST 40% THAT WERE U.S. BASED
PHASE 3 CLINICAL TRIALS.
I'D LIKE TO SHOW YOU NEW DATA ON
AGE AT ENROLLMENT.
THIS IS THE FIRST TIME NIH HAD
DATA AVAILABLE FOR AGE AT
ENROLLMENT AND YOU'RE ONE OF THE
FIRST GROUPS TO SEE IT.
NIH BEGAN COLLECTING THE DATA
WITH OUR INCLUSION ACROSS THE
LIFE SPAN STARTED JANUARY 25,
2019 OR LATER.
WE STARTED RECEIVING PROGRESS
REPORTS FROM THE APPLICATIONS.
THIS IS THE FIRST SNAPSHOT OF
DATA.
IT'S NOT A LARGE NUMBER BUT
GIVES AN IDEA OF ENROLLMENT BY
AGE.
THIS SHOWS PARTICIPANTS UNDER 18
AND 58% WERE ADULTS 18 TO 64 AND
ABOUT 19% WERE OLDER ADULTS, 65
OR OLDER.
3% WERE UNKNOWN OR UNREPORTED I
WON'T THROUGH ALL THE
PERCENTAGES BUT THE AGE GROUPS
WERE DEVELOPED BY NIH ACROSS OUR
FIRST MEETING IN 2017.
MANY PARTICIPANTS EXPRESSED
THEIR IDEAS ABOUT IMPORTANT AGE
GROUPS FOR DEVELOPMENT AND WE
ALSO RECEIVED INPUT THROUGH AN
RFI WE PUT OUT THAT YEAR.
WE DID LISTEN CAREFULLY TO ALL
THE FEEDBACK WE RECEIVED AND
THESE LARGELY REFLECT THE
FEEDBACK RECEIVED.
ONE THING TO NOTE IS THE AGE
GROUPS BECAUSE THEY'RE BASED ON
IMPORTANT DEVELOPMENTAL
MILESTONES.
THEY'RE NOT NECESSARILY UNIFORM
CATEGORIES.
THERE MAY BE A DIFFERENT NUMBER
OF YEARS IN EACH CATEGORY.
BECAUSE ONE LOOKS HIGHER OR
LOWER DOES NOT NECESSARY MEAN
ENROLLMENT FOR THAT GROUP
OVERALL WAS MORE OR LESS THAN
ANOTHER SPECIFIC AGE.
WE HAVE A HEALTHY REPRESENTATION
OF CHILDREN 1-5 AND 6-12 AND
SOME WAS DUE TO THE AGE
GROUPINGS WITH 16 TO
17-YEAR-OLDS AND NOT SURPRISED
MOST PARTICIPANTS ARE MIDDLE AGE
AND WE SEE HIGHER BARS IF WE
LOOK AT THE 55 TO 64 AGE GROUP
THE LARGEST AGE GROUP
REPRESENTED ABOUT 16% OF
PARTICIPANTS IN THE AGE GROUP.
THAT DECREASES AS PARTICIPANTS
ARE OLDER.
ALSO THE CATEGORIES NARROW.
NIS IS -- THIS IS EXCITING AND
HOPE TO LEARN MORE HOW AGE IS
REPRESENTED IN OUR PORTFOLIO.
IF YOU'D LIKE TO LEARN MORE
ABOUT THESE DATA YOU CAN GO TO
OUR REPORT THE NIH REPORT
WEBSITE.
WE DO HAVE A PAGE FOR INCLUSION
OF WOMEN AND MINORITIES AND
THERE YOU CAN LOOK AT OUR NIH
INCLUSION DATA BY RESEARCH
CONDITION AND DISEASE CATEGORY.
THE DATA IS AVAILABLE BY
DIFFERENT CATEGORIES AND IF YOU
ARE INTERESTED IN THE DATA TAKE
A LOOK.
WE RECENTLY UPDATED THE SITE
WITH OUR FISCAL YEAR 2019
THROUGH 2021 DATA.
AS I START TO WRAP UP I WANT TO
TALK WITH THE CURRENT EFFORTS
GOING ON AND HOPEFULLY THEY'LL
INFORM SOME OF OUR NEXT STEPS AT
NIH.
ONE OF EFFORTS THAT IS THE
REPORT BY THE NATIONAL ACADEMIES
OF SCIENCES, ENGINEERING AND
MEDICINE, THEY WILL BE RELEASING
A REPORT ON VERY SOON IN THE
NEXT MONTH OR SO SO KEEP AN EYE
OUT FOR REPRESENTING WOMEN IN
CLINICAL TRIALS AND RESEARCH.
THE COMMITTEE HAS BEEN WORKING
DILIGENTLY IN THE LAST YEAR AND
A HALF AND HELD THREE PUBLIC
MEETINGS NOW ON INCLUSION FOR
WOMEN AND UNDER REPRESENTED
MINORITIES AND THE GROUP HAS
BEEN WORKING HARD ON THIS
REPORT.
NIH VERY MUCH LOOKS FORWARD TO
THE RECOMMENDATIONS WHICH WILL
FOCUS ON INSTITUTIONAL
STRATEGIES TO INCREASE INCLUSION
AS WELL AS LOOKING AT COST AND
HOW INCLUSION MAY AFFECT HEALTH
AND COST ASSOCIATED WITH HEALTH
CARE.
ANOTHER EFFORT ON A DIVERSITY
PROJECT LOOKING AT
ORGANIZATIONAL-LEVEL STRATEGIES
FOR INCLUSION THAT THAT GROUP
HAS STAKEHOLDERS FROM INDUSTRY
AND ACADEMIA AND ADVOCACY AND
MANY OTHER GROUPS AND THEY ARE
WORKING ON CTTI WILL BE PUTTING
OUT RECOMMENDATIONS BASED ON
THAT REPORT.
FINALLY YOU MAY BE FAMILIAR WITH
AN NIH EFFORT.
NHLBI AND NIHD HAVE BEEN LEADING
THE EFFORT TO REACH OUT TO
COMMUNITIES ABOUT COVID-19
RESEARCH AND MUCH EFFORT IS
FOCUSSED ON VACCINE AND
EDUCATION AND EDUCATION ABOUT
BOOSTERS, EDUCATION ABOUT
VACCINES IN CHILDREN.
THIS SITE HAS A NUMBER OF
HELPFUL RESOURCES.
IF YOU HAVEN'T SEEN IT I
ENCOURAGE YOU TO TAKE A LOOK.
I'LL CONCLUDE BY DIRECTING YOU
TO OUR WEBSITE WHERE YOU CAN
NAVIGATE TO MANY THINGS I TALKED
ABOUT TO LEARN MORE ABOUT OUR
POLICIES OR FIND MORE ABOUT OUR
DATA.
WITH THAT, I WANT TO THANK YOU
ALL FOR GIVING ME THE
OPPORTUNITY TO SPEAK AND I'M
HAPPY TO ANSWER ANY QUESTIONS.
>> THANKS, SO MUCH, DAWN.
IT LOOKS LIKE DR. KLEIN HAS A
QUESTION.
>> THANK YOU.
I CAN'T HELP BUT TAKE A MOMENT
TO ACKNOWLEDGE YOU GOT YOUR MPH
HERE WHERE I'M SITTING AT THE
SCHOOL OF PUBLIC HEALTH.
I WANT YOU TO KNOW YOU STARTED
OFF WARMING MY HEART.
I FOUND SO MUCH OF WHAT YOU
PRESENTED TO BE VERY
INTERESTING.
ESPECIALLY THE PHASE 3 TRIALS
AND THE NEED FOR CONSIDERING SEX
AND GENDER AND RACE AND
ETHNICITY AND THOUGH I
UNDERSTAND WHAT'S HAPPENING FOR
NIH-FUNDED TRIALS CAN YOU SPEAK
TO THE IMPACT THIS MIGHT HAVE ON
COMPANIES AND WHERE MY HEAD IS
IS ABOUT THE COVID-19 VACCINES
AND ALL THE COMPANIES AND THEIR
PHASE 3 TRIALS THAT REALLY DID
NOT ADEQUATELY ADDRESS THIS.
>> THEY'VE WORKED ON INCREASING
DATA ON PHASE 3 AND OTHER PHASED
TRIALS.
WHILE NIH DOESN'T HAVE DIRECT
CONTROL OVER NON-NIH TRIALS, ONE
THING THAT'S COME UP QUITE A BIT
IS PERHAPS INDUSTRY AND OTHERS
MAY FOLLOW NIH'S LEAD.
WE'VE BEEN LOOKING AT WHAT'S
BEEN WORKING HERE, WHERE THE
CHALLENGES ARE HERE AND OUTSIDE
NIH AND I THINK WE HOPE WE CAN
LEARN FROM EACH OTHER.
I CAN STAY I'VE BEEN INVOLVED IN
EFFORTS WHERE WE'RE TRYING TO
SHARE BEST PRACTICES SO OUR
ENTIRE CLINICAL TRIAL ENTERPRISE
CAN IMPROVE.
>> I DO.
I HOPE YOU GUYS END UP SETTING
THE STANDARD BY WHICH OTHER
COMPANIES INCLUDING
INTERNATIONALLY MAY PAY
ATTENTION AND FOLLOW.
THANK YOU.
>> THANK YOU FOR HIGHLIGHTING
THE ISSUE BECAUSE SOMETIMES WHEN
PEOPLE EVALUATE INCLUSION
THEY'RE NOT AWARE OF THE VARIOUS
REQUIREMENTS AND HOW THEY DIFFER
AND FROM A RIGOR PERSPECTIVE WE
WANT AS MUCH AS INFORMATION
AVAILABLE FOR AS MANY TYPES OF
PEOPLE AFFECTED BY DISEASE AND
CONDITIONS TO INFORM SEX AND
GENDER AWARE DECISION MAKING.
AND RECOGNIZING RAGE, ETHNICITY,
AGE AND EVEN AS WE MOVE FORWARD
NOT JUST FROM AN INCLUSION
PERSPECTIVE, SOCIAL DETERMINATES
OF HEALTH AND HOW THEY'RE
IMPORTANT FOR OUTCOMES.
AND DON AND I HAVE HAD THESE
CONVERSATIONS MANY TIMES HOW
THIS IS REALLY NOT ABOUT
COUNTING PEOPLE.
AT THE CORE THE ISSUES ARE ABOUT
DOING THE BEST SCIENCE TO
GENERATE THE BEST EVIDENCE TO
INFORM THE BEST CARE.
AND IT'S PART OF THAT AND BUT
NOT ALL OF THAT.
I WANT TO GIVE MS. CORBETT A
SHOUT OUT SHE'S BEEN AN
INCLUSION DIVERSITY OFFICER FOR
SOME YEARS BUT IT'S BEEN OUR
PLEASURE TO WORK CLOSELY WITH
HER OVER THE LAST FEW YEARS AS
I'VE BEEN CO-CHAIRING THE
INCLUSION GOVERNANCE COMMITTEE
FIRST WITH DR. MARIE BERNARD AND
NOW WITH DR. COOPER.
I WANTED TO MENTION TO THE
ADVISORY COMMITTEE WHEN
DR. BERNARD WAS RECENTLY
ACCEPTED THE POSITION OF CHIEF
OFFICER FOR THE DIVERSITY AND
INCLUSION GROUP AND DR. HOOPER
WHO HAS SPOKEN TO THIS ADVISORY
COMMITTEE AND THE DEPUTY
DIRECTOR OF NIMHD NOW MY
CO-CHAIR ON THE INCLUSION
GOVERNANCE COMMITTEE AND PART OF
THE GOVERNANCE STRUCTURE AND
HELPS TO OVERSEE MONITORING
ADHERENCE AND DAWN HAS HAD A
CRITICAL ROLE ALL ALONG.
I WANTED TO SHARE THAT WITH MY
ADVISORY COMMITTEE.
WITHOUT DAWN WE COULD NOT HAVE
THE STATUS IN THE ANNUAL REPORT
SHE REFERENCED.
THANK YOU, DAWN.
WE APPRECIATE I YOU
>> THANK YOU.
>> I'M LOOK FOR HANDS RAISED.
THANK YOU.
DR. GELLAR.
>> THANKS FOR THE PRESENTATION.
I'VE BEEN DOING THE WORK FOR A
WHILE AND INCLUSION IS OBVIOUSLY
CRITICAL AND ABSOLUTELY
NECESSARY BUT NOT SUFFICIENT.
WE NEED TO MAKE SURE AND I DON'T
THINK THE BURDEN FALLS ON NIH
BUT ALL OF US AS LEADERS ON
RESEARCH TO MAKE SURE SHOWS
CONDUCTING THE RESEARCH DO THE
ANALYSIS BY SEX AND GENDER AND
RACE AND ETHNICITY AND THEN
REPORT IT IN THE PUBLICATIONS.
THAT'S WHERE WE FALL DOWN.
>>
>> THANK YOU, DR. GELLAR.
YOUR WORK HAS BEEN HELPFUL AS
WE'VE BEEN THINKING ABOUT THESE
ISSUES AND LOOKING TO SEE
INCLUSION DOES NOT NECESSARILY
LEAD TOE MORE INFORMATION HOW
INTERVENTIONS WORK IN DIFFERENT
POPULATIONS AND SOMETHING NIH IS
TAKING SERIOUSLY.
AND THERE'S TRIALS REGARDING SEX
AND ETHNICITY.
WE DO HAVE THE NEW REQUIREMENT
FOR CLINICAL TRIALS AND THEY
NEED TO PROPOSE THE RESULTS AND
WE'RE SEEING THE FIRST TRIALS
STARTING TO COME UNDER THE
POLICY.
WE'RE HOPING WE'LL SEE MORE AND
MORE AND NOT ONLY HOPING BUT
ACTIVELY TRYING TO TAKE STEPS TO
ENSURE THE INFORMATION IS
DISSEMINATE
DISSEMINATED AND WE HAVE OTHERS
IN OUR DISCUSSIONS TO TRY TO SET
STANDARDS.
WE DID SEE THE NEW ENGLAND
JOURNAL OF MEDICINE HAS NEW
POLICIES SO WE DID APPRECIATE
YOUR EFFORTS AND OTHER'S EFFORTS
TO FRY TO MAKE THIS THE
STANDARD.
YOU'RE RIGHT, IF ALL WE DO IS
COLLECT DATA AND DON'T LOOK AT
IT TO UNDERSTAND HOW
INTERVENTIONS WORK THEN I DON'T
WE'VE ACHIEVED THE GOALS OF THE
POLICY.
>> I SECOND THE ATTESTATION IT'S
BEEN HELPFUL TO HAVE THAT IN THE
PUBLIC DOMAIN AND AT MULTIPLE
TIME POINTS OVER TIME.
I'M PERSONALLY LOOKING FORWARD
TO SEEING THE TRIALS COVERED BY
THE NEW POLICY AND WHAT WE CAN
LEARN FROM CLINICALTRIALS.gov
BUT THAT'S NOT ENOUGH EITHER.
PUBLICATIONS ARE THE POINT OF
THE REALM WE UNDERSTAND THAT AND
CONDITION TO WORK WITH PUBLISHER
AND WONDER IF THE COMMITTEE HAS
OTHER IDEAS FOR PATHWAYS TO
IMPROVE THAT.
WE'D BE HAPPY TO HEAR THOSE AND
DISCUSS STRATEGIES AND ONE IS
THROUGH PROFESSIONAL SOCIETIES
AND ASSOCIATES WHO ARE OFTEN
JOURNAL PUBLISHERS.
YOU SAW I USED THE STUDY I CITED
WITH EQUATOR.
THE WAY YOU'RE ABLE TO MINE MORE
DATA NOW MEANS WE CAN LOOK AT
THIS IN DIFFERENT WAYS.
AND WE LOOK AT HOW CRITICAL IT
IS TO UNDERSTANDING AND HOW IT
WORKS IN WOMEN AND MEN OR HOW
IT'S REQUIRED TO LOOK AT THE
INFORMATION BY SEX AND BASIC
DESCRIPTIVE STATISTICS IS AT
LEAST A START FOR THE PRIMARY
OUTCOME MEASURE.
SO WE HAVE STILL HAVE A WAYS TO
GO BUT WE DO UPTAKE AN
NEUROSCIENCE WHICH IS ONE OF THE
FIELDS THAT HASN'T HAD AS MUCH
AS PROGRESS BUT OTHER SOCIETIES
MAY BE A PATHWAY FOR US?
OTHER QUESTIONS FOR DAWN?
>> THANK YOU, DR. TEMPLETON.
>> JUST RESPONDING TO THE
COMMENT PREVIOUSLY ABOUT
REACHING OUT TO PUBLISHERS WE'RE
WORKING ON THIS AND I APPRECIATE
THE ORGANIZING COMMITTEE.
WE'RE ORGANIZING A MEETING THAT
WILL HAVE REPRESENTATION OF THE
PUBLISHERS AND EDITORIAL BOARDS
OF THE MAJOR MUSCULOSKELETAL
JOURNALS SCHEDULED FOR MARCH OF
NEXT YEAR.
WE'RE STILL IN THE PLANNING
PHASES TO TALK ABOUT WHAT SEX
GENDER AND THE MUSCULOSKELETAL
HEALTH IT'S ABOUT 25% TO 30% AT
BEST TO TALK ABOUT THE RELEVANT
GUIDELINES AND COME UP WITH A
POLICY IN ORTHOPEDICS IN
MUSCULOEXC
MUSCULOSKELETAL HEALTH AND
REACHING OUT EARLY IN THE
PROCESS SO THERE'S NOT A
POST-DOC ANALYSIS BUT
INCORPORATE IT EARLIER ON AND
ARE THERE PLACES WHERE JOURNALS
CAN BE THE SOURCE OF INFORMATION
AND DO MORE OUTREACH TO
RESEARCHERS AND AUTHORS.
>> THANK YOU, I'M EXCITED
DR. TEMPKIN WILL BE PART OF IT.
DISCIPLINE SPECIFIC GROUPS AND
WE GREATLY APPRECIATE THAT AND
TO TOUCH ON COMMENTS MADE BEFORE
A
AND WE'LL DO OUR PHOTO IN A
SECOND IF YOU CAN STAY AROUND.
I THINK YOU MENTIONED INCLUSION
WASN'T ENOUGH.
IT'S REQUIRED AND WE HAVE SEX
AND GENDER CONSIDERATIONS AS
WELL AS RACE, ETHNICITY AND AGE
NORD TO DRIVE INCLUSIVE
EXCELLENCE AND DRIVE INNOVATION
AND TO DRIVE RIGOR AND TO
GENERATE RELEVANT DATA TO
IMPROVE THE HEALTH OF ALL
PEOPLE.
AND WE'RE PART OF A LARGE ECO
SYSTEM.
AS MUCH AS WE DO FUND A LOT OF
WE DON'T FUND ALL AND OTHER
FUNDERS PLAY A SIGNIFICANT ROLE
AND THE PUBLICATION OF THE POINT
OF ENROLLMENT AND THE DATA IS
DISSEMINATED.
UNTIL WE HAVE THAT ALL DONE WE
STILL HAVE LOTS OF WORK TO DO AS
A COLLECTIVE.
THANK YOU SO MUCH FOR JOINING US
FOR UPDATES AND I DO BELIEVE AND
I WANT TO ACKNOWLEDGE THE
AMAZING PRESENTATION AND I
BELIEVE WE WANT TO TAKE OUR
VIRTUAL GROUP PHOTO NOW.
IS THAT RIGHT, SARAH?
>> THANK YOU FOR EVERYONE TO
JOIN US.
I'D LIKE TO ASK THAT ACRWH
MEMBERS TO STAY ON AND PUT YOUR
CAMERA ON TO TAKE YOUR PICTURE.
THANK YOU VERY MUCH.
>> THANK YOU VERY MUCH.
DR. SIMON.
>> I HAVE MEMBERS WITHOUT THEIR
CAMERA ON.
PLEASE, DR. SIMON, DR. SHAW,
DR. RIOS, IF YOU ARE ON, CAN YOU
PLEASE PUT YOUR CAMERA ON.
>> IF YOU ARE ABLE TO DO SO,
WE'D GREATLY APPRECIATE IT.
>> THANK YOU.
IT LOOKS LIKE WE GOT MOST FOLKS.
I'LL GO AHEAD AND TAKE THE PHOTO
IF EVERYBODY CAN GIVE ME THEIR
BEST SMILES, THREE, TWO, ONE.
I'VE GOT YOU.
THANK YOU, EVERYONE.
DR. NOURSI IS IT OKAY TO ADJOURN
FOR LUNCH.
>> YES.
COME BACK AT 1:00.
WE WILL HAVE A ROTATOR SLIDES
DURING THE TIME ENJOY IT.
IT INCLUDES HIGHLIGHTS FROM
EVENTS AND PUBLICATIONS,
ETCETERA.
WITH HOPE YOU'LL LOOK AT IT IN
THE MEANTIME WE'LL SEE YOU ALL
AT 1:00.
THANK YOU, ALL.
>> WELCOME BACK.
I HOPE YOU ENJOYED YOUR LUNCHES
AND THE SLIDE SHOW OF EVENTS AND
PUBLICATIONS ORWH HAS BEEN
INVOLVED WITH.
ALSO I'D LIKE TO CALL THE
MEETING BACK TO ORDER AND
INTRODUCE DR. SARAH TEMKIN AND
JUDY REGENSTEINER JOINING ME FOR
THE NEXT PRESENTATION.
DR. TEMKIN M.D. IS THE ASSOCIATE
DIRECTOR FOR CLINICAL RESEARCH
AT THE ORWH.
SHE PROVIDES CLINIC EXPERT IN
CANCER CONTROL, SUPPORTIVE
CONTROL AND THERAPEUTICS FOR
FEMALE SPECIFIC MALIGNANCIES AND
THEIR TEAM OVERSEE THE
SUPPLEMENT DR. CLAYTON MENTIONED
EARLIER AS WELL AS THE OFFICE'S
INTERPROFESSIONAL DEVELOPMENT
PROGRAM.
DR. TEMKIN HAS THOUGHTFULLY
CONTRIBUTED TO NATIONAL
CONVERSATIONS ABOUT CANCER
PREVENTION AND EQUITY IN CANCER
CARE.
SHE HAS PROVIDED A VOICE FOR
EQUITY IN THE PHYSICIAN WORK
WORKFORCE AND ATTUNED TO
SURGEONS AND GYNECOLOGIST WHO'S
ARE WOMEN.
DR. REGENSTEINER'S EXPERTISE IS
IN THE CARDIOVASCULAR AFFECTS OF
DIABETES WITH A SPECIFIC FOCUS
ON WOMEN WITH TYPE II DIABETES.
HER LAB HAS BEEN FUNDED FOR OVER
20 YEARS AND HAS 120 RESEARCH
PUBLICATIONS AND KNOWN FOR HER
RESEARCH ON PERIPHERAL ARTERIAL
DISEASE.
SHE IS CURRENTLY PRINCIPLE
INVESTIGATOR FOR THE UNIVERSITY
OF COLORADO SCHOOL OF MEDICINE
PROGRAM OF NIH BIRCWH GRANT AND
PROGRAM DIRECTOR OF THE DORIS
DUKE CHARITABLE FOUNDATION FUND
TO RETAIN CLINICAL SCIENTISTS.
AT THE LOUDEN FAMILY CENTER FOR
RESEARCH SHE LEADS AN
INTERDISCIPLINARY TEAM OF
RESEARCHERS FOCUSSED ON WOMEN'S
HEALTH AND SEX DIFFERENCE
RESEARCH.
WELCOME.
I PARTS PA-- PARTICIPATED IN
PUTTING THE MEETING TOGETHER AND
WE HAVE FUTURE PLANS WITH THE
MEETING AND NEXT STEPS.
IN FISCAL YEARS 2021 REPORT THE
HOUSE AND SENATE APPROPRIATIONS
COMMITTEE NIH CONVENE RESEARCH
IN RISING RATES OF MATERNAL AND
MORTALITY, SECOND, RISING RATES
OF CERVICAL CANCER IN WOMEN AND
SURVIVAL RATES.
ORWH DEVELOPED A STRATEGY TO
COLLECT INPUT ON THE THREE AREAS
FROM EXPERTS IN WOMEN'S HEALTH
MEMBERS OF THE PUBLIC AND
INSTITUTE CENTERS AND OFFICES
AND MEMBERS OF THE COMMITTEE.
THE WOMEN'S HEALTH CONFERENCE
WORKING GROUP WHC WAS FORMED TO
REVIEW AND DISCUSS ACTIVITIES
AND PLAN A REPORT.
OCTOBER LAST YEAR, THERE WAS A
CO-HOSTING OF THE CONFERENCE
WHICH WE TITLED ADVANCING NIH
RESEARCH ON THE HEALTH OF WOMEN
IN 2021 CONFERENCE.
IN CONJUNCTION WITH THE ACRWH
MEETING AND WE VOTED ON
OPPORTUNITIES FOR FUTURE
RESEARCH ON WOMEN'S HEALTH,
MATERNITY MORBIDITY AND
MORTALITY AND CERVICAL CANCER
AND RISING RATES OF CHRONIC
DEBILITATING CONDITIONS.
AS WE STARTED THE PROCESS WE
FORMED A COMMITTEE AND
HARMONIZED THE DATA COMING FROM
THE THREE CLUSTERS.
EACH WAS CO-LED WITH SUBJECT
MATTER EXPERTS FROM NIH AND
SCIENTISTS AND SUBJECT MATTER
EXPERTS FROM ACROSS NIH AND
OTHER AGENCIES FROM WITHIN NIH
AND HHS AND HRSA AND CENTER FOR
MEDICARE AND MEDICAID AND THE
DEPARTMENT OF VETERANS AFFAIRS.
EACH CLUSTER HAS RELEVANT
RESEARCH PORTFOLIOS, HELD
DISCUSSIONS ON ITS RESPECTIVE
TOPIC AREAS AND PRESENTED
ANALYSIS FINDING AND
RECOMMENDATION TO THE ACRWH
WOMEN'S HEALTH WORKING GROUP.
WHERE POSSIBLE THE RECORDS FOR
NIH FUNDING ON SPECIFIC RESEARCH
TOPICS WHICH WE CALL OUR CTC IS
RESEARCH CONDITIONS AND DISEASE
CATEGORIZATION WAS USED AS
METRIC FOR FUNDING.
AND WE ARE PLEASED TO SAY ON
BEHALF OF DR. REGENSTEINER AND
TEMKIN OUR EXECUTIVE SUMMARY WAS
CLEARED YESTERDAY FOR
PUBLICATION.
IT'S THERE AS A LINK.
IT'S POSTED ON THE WEBSITE.
I'D LIKE TO TURN IT TO
DR. KEMKIN FOR THE NEXT SLIDES.
>> THANK YOU.
I'LL REVIEW SOME OF THE
ACTIVITI
ACTIVITIES MAINLY FOR THE
CLUSTERS AND DESCRIBE THE
OPPORTUNITIES DISCUSSED.
AS PART OF FULFILLING THE
REQUEST THE ACTIVITIES WERE
REVIEWED FISCAL YEAR 2020 WAS
THE MOST RECENT YEAR WE HAD DATA
AND IN THAT YEAR 10.8% OF THE
OVERALL NIH BUDGET SUPPORTED
RESEARCH ON WOMEN'S HEALTH THE
INSTITUTE CENTERS AND OFFICES
WITH THE LARGEST ABSOLUTE
FUNDING AMOUNTS WERE THE ONES
WITH THE LARGEST AMOUNTS OF
FUNDING TO WOMEN'S HEALTH
RESEARCH THE NHLBI AND NCI.
WHEN EVALUATED BY PERCENTAGE,
NICHD, NIAMS AND NIMHD HAD THE
LARGEST FRACTION OF THEIR BUDGET
TO WOMEN'S HEALTH AND THESE WERE
29%, 28%, 25% RESPECTIVE.
MATERNAL MORBIDITY WERE TOPIC
THAT OUR GROUP FOCUSSED ON
ACCORDING TO RECENTLY RELEASED
FIGURES THE MATERNAL MORBIDITY
AND MORTALITY CRISIS HAS
CONTINUED TO WORSEN IN THE
UNITED STATES.
MATERNAL MORTALITY
DISPROPORTIONATELY AFFECTS BLACK
AND HISPANIC AND ALASKAN NATIVE
PATIENTS COMPARED TO
NON-HISPANIC WHITE PATIENTS.
BLACK AND AMERICAN INDIAN AND
ALASKAN NATIVE BEAR THE HIGHEST
SHORT AND LONG-TERM CONSEQUENCES
ASSOCIATED WITH NEAR-MISS EVENTS
AND UNEXPECTED COMPLICATIONS
WITH PREGNANCY AND POSTPARTUM
PERIOD.
THE NIH IS INVESTING RESEARCH IN
RESPONSE TO THIS PUBLIC HEALTH
CRISIS.
A CATEGORY THAT DESCRIBES
MATERNAL HEALTH SPENDING ON
RESEARCH WAS CREATED IN 2013 TO
CAPTURE PROJECTS THAT FOCUS ON
PRE-PREGNANCY THROUGH THE END OF
THE FIRST YEAR POSTPARTUM AND IN
2020 AN ADDITIONAL CATEGORY FOR
MATERNAL MORBIDITY AND MORTALITY
WAS CREATED TO CAPTURE THE
UNIQUE SET OF MATERNAL HEALTH
TOPICS AND RESEARCH PROJECTS
THAT ARE SPECIFICALLY RELATED TO
PREGNANCY COMPLICATIONS AND
DEATHS ASSOCIATED WITH
PREGNANCY.
YOU CAN SEE THE DOLLAR AMOUNTS
ON THE SLIDE.
IN FY2020 MULTIPLE INSTITUTES
AND CENTERS INCLUDING NICHD,
NHLBI, NIDDK SUPPORTED LARGE
PROJECTS SPECIFIC TO MMM.
WE HEARD FROM DR. GIBBONS ABOUT
THE EFFORTS WITHIN NHLBI TO
ADDRESS MATERNAL MORBIDITY AND
MORTALITY THERE WASIMENT
IMPLEMENTATION OF THE IMPROVE
INITIATIVE AND SUPPORT RESEARCH
AIMED AT PREVENTING MATERNAL
DEATH AND IMPROVING THE HEALTH
OF WOMEN BEFORE, DURING AND
AFTER PREGNANCY.
THE INSTITUTIONAL DEVELOPMENT
AWARD OR IDEA PROGRAM IS A
CONGRESSIONALLY MANDATED PROGRAM
WITH THE GOAL OF BUILDING
RESEARCH CAPACITY IN STATES AND
GEOGRAPHIC REGIONS THAT HAVE
HISTORICALLY HAD LOW LEVELS OF
NIH FUNDING.
THESE INCLUDE 23 STATES IN
PUERTO RICO AND IN FY20, 13
AWARDS ON MATERNAL MORBIDITY AND
MORTALITY WERE SUPPORTED.
OUR SECOND TOPIC WAS CHRONIC
DEBILITATING CONDITIONS IN
WOMEN.
WE'VE NOT ONLY SEEN RISING RATES
OF WOMEN AND WOMEN ARE MORE
LIKELY TO HAVE CHRONIC
CONDITIONS THAN MEN.
WOMEN ARE AFFECTED BY DIFFERENT
CHRONIC DISEASES THAN MEN AND
MORE LIKELY TO HAVE MULTIPLE
CHRONIC CONDITIONS COMPARED TO
MEN.
SEVERAL CHALLENGES AROSE ON THE
TOP
TOPIC INCLUDING THE DEFINITION
SPECIFIC TO WOMEN AND THE
UNAVAILABILITY OF THE RCDC
CATEGORY TO ASSESS SUPPORT THERE
ARE THE VARIOUS CONDITIONS WHICH
FALL UNDER THE BROAD TOPIC.
CMS HAS DATA TO CREATE A
FRAMEWORK ON CHRONIC
DEBILITATING CONDITIONS IN WOMEN
AND IN 2010 HHS DEFINED CHRONIC
ILLNESSES AS CONDITIONS THAT
LAST A YEAR OR MO AND REQUIRE
ONGOING MEDICAL ATTENTION AND/OR
LIMIT ACTIVITIES OF DAILY LIVING
AND ULTIMATELY THIS WAS THE
DEFINITION WE USED TO DESCRIBE
NIH ACTIVITIES IN THIS REALM.
WE CREATED A FRAMEWORK FOR
FEMALE SPECIFIC CONDITIONS.
CONDITIONS MORE COMMON IN WOMEN
AND/OR HAVE HIGHER MORBIDITY IN
WOMEN THOSE CONDITIONS TYPICALLY
NEGLECTED IN WOMEN AND HAVE HIGH
MORBIDITY IN WOMEN.
BECAUSE OF QUANTITATIVE REVIEW
OF THE TOPIC WAS NOT FELT TO BE
FEASIBLE WE PERFORMED A SURVEY
OF THE INSTITUTES AND CENTERS
THAT PARTICIPATED IN OUR CLUSTER
WORKING GROUPS RELATED TO WOMEN
THE WOMEN'S HEALTH CONFERENCE.
THIS INFORMAL SURVEY
DEMONSTRATED NEARLY HALF OF
WOMEN'S HEALTH RESEARCH ON
CHRONIC CONDITIONS FOCUSSED ON
CONDITIONS MORE COMMON ON WOMEN.
A QUARTER ON THOSE POTENTIALLY
NEGLECTED IN WOMEN.
15% ON HIGH MORBIDITY CONDITIONS
AND 11% ON FEMALE SPECIFIC
CONDITIONS.
THERE WERE A FEW PROJECTS
IDENTIFIED THAT FOCUSSED ON
MULTI-MORBIDITY OR OVERLAPPING
AND INTERSECTING CONDITIONS AND
AS MEASURED BY DISABILITY
ADJUSTED LIFE YEARS OR DAILY
AMONG THE U.S. FEMALE POPULATION
WHICH WE USED AS A PROXY FOR THE
BURDEN OF DISEASES AMONG WOMEN
IT VARIED FROM $17 FOR LOWER
BACK PAIN TO ALMOST $26,000 PER
DAILY FOR HIV.
ANOTHER TOPIC OF FOCUS WAS
CERVICAL CANCER SURVIVAL DESPITE
THE AVAILABILITY OF SCREENING
AND PREVENTION WITH AN HPV
VACCINE SINCE 2006.
THE AGE ADJUSTED DEATH RATE FELL
SLIGHTLY FROM 2009 AND 2018 BY
.7% ANNUALLY.
LESS IS A LESS IMPROVEMENT THAN
BREAST AND OTHER CANCERS AND
BLACK PATIENTS ARE 30% MORE
LIKELY TO BE DIAGNOSED WITH
CERVICAL CANCER AT 75% MORE LIKE
TO DIE OF ZEEDZ.
-- DISEASE.
PROGRESS HAS BEEN UNEVEN ACROSS
THE UNITED STATES AND ON THE
LEFT SIDE IS THE RECENT REPORT
THAT DEMONSTRATED MY
DISAGGREGATE INCOME LOWER INCOME
AREAS HAD HAD A SLIGHT DECREASE
IN INCIDENTS SINCE 2010.
THE NIH SUPPORTS MULTIPLE
PROJECTS RELATED TO CERVICAL
CANCER ON PROJECTS CATEGORIZED
WITHIN THE CERVICAL CANCER RCDC
THE NCI FUNDS OVER 80% OF THE
TOTAL PROJECTS RELATED TO
CERVICAL CANCER AND NICHD HAVE
PROJECTS RELATED TO SCREENING
AND PREVENTION OF HPV RELATED
DISEASE.
THE RCDC INCLUDES A WIDE VARIETY
OF TOPICS INCLUDES BASIC
SCIENCES AND TRANSLATIONAL AND
CLINICAL AND HEALTH SERVICES
RESEARCH RELATED TO
PRE-MALIGNANT DISEASE AS WELL AS
INVASIVE DISEASE AND RESEARCH ON
SCREENING PREVENTION AND
TREATMENT.
AND IN JULY OF 2021 A REQUEST
FOR INFORMATION FROM THE PUBLIC
WAS PUBLISHED IN THE FEDERAL
REGISTER 247 COMMENTS WERE ED.
THEY WERE SUBMITTED BY' VARIETY
OF OF A VARIETY OF INDIVIDUALS
FROM RESEARCHERS, MEMBERS OF THE
PUBLIC, PATIENTS, AWARENESS AND
ADVOCACY GROUP AND PROFESSIONAL
SOCIETIES AND HEALTH CARE
PROFESSIONAL ORGANIZATIONS.
THE 10 MOST FREQUENTLY
IDENTIFIED KEY WORDS WERE
MATERNAL MORBIDITY, MORTALITY,
RACIAL DISPARITIES, ACCESS TO
CARE, HEALTH CARE PROFESSIONAL
TRAINING, MENTAL HEALTH, LACK OR
AFRICAN AMERICAN WOMEN AND
SCREENING AND QUALITY OF CARE
AND TIME TO DIAGNOSIS AND SOCIAL
DETERMINATES OF HEALTH.
OF THE 247 COMMENTS RECEIVED
THERE CHRONIC DEBILITATING
CONDITIONS AND AMONG THE
COMMENTS WERE FOCUSSED ON FEMALE
SPECIFIC CONDITIONS.
CONDITIONS POTENTIALLY UNDER
STUDIED AMONG WOMEN AND THOSE
WITH GREATER MORBIDITY AND
FOCUSSED ON HEART DISEASE OR
DIABETES THAT CAUSE HIGH
MORBIDITY AMONG WOMEN.
THE NEXT SLIDE AND THEN I'LL
TURN IT OVER TO
DR. REGENSTEINER.
THE RESULTS OF THIS CONFERENCE
WERE BOTH STUNNING AND
EDUCATIONAL.
STUNNING IN THE SENSE THAT
RESEARCH IS URGENTLY NEEDED AS
DETERMINED FROM LOOKING AT THE
DATA.
THE FIRST IDEA WE NEED TO DO AS
A THEME IS IMPLEMENTING BEST
PRACTICES THAT ARE EVIDENCE
BASED AND MORE HOLISTIC AND
PATIENT-CENTERED CARE NODE TO BE
A FOCUS OF WHAT WE DO.
EXAMPLES INCLUDE SAFETY BUNDLES
IN MATERNAL MORTALITY AND
MORTALITY AND SAFETY BUNDLES ARE
A CLUSTER OF EVIDENCE-BASED
PRACTICES THAT CAN IMPROVE AN
OUTCOME.
WE USE DATA FOR SEX-SPECIFIC
GUIDELINES BECAUSE THEY'RE NOW
HIGHLY INADEQUATE AND THERE'S
FEW SEX-SPECIFIC GUIDELINES FOR
CARE FOR EXAMPLE IN
CARDIOVASCULAR DISEASE OR MOST
OTHER CONDITIONS.
IN TERMS OF CERVICAL CANCER
SURVIVAL VACCINES HAVE BEEN
AVAILABLE SINCE 2006 YET HALF
ADOLESCENTS HAVE COMPLETE THE
VACCINE SERIES.
CLEARLY A LOT OF WORK TO DO IN
THE AREA.
IN ADDITION TO IMPLEMENTING BEST
PRACTICES WE ALSO CLEARLY NEED
TO ADDRESS CARE INEQUITIES.
EXAMPLES INCLUDE FOR INSTANCE
PREGNANCY RELATES DEATHS OCCUR
HIGHER THAN NATIVE AMERICAN AND
ALASKA NATIVE AMERICANS AND
THERE'S RISKS FOR
MULTI-MORBIDITY WHICH IS COMMON.
BLACK CERVICAL CANCER PATIENTS
ARE LIKELY TO BE DIAGNOSED WITH
ADVANCED OR METASTATIC DISEASE.
THERE'S AN URGENT NEED TO BETTER
UNDERSTAND AND TREAT AND PREVENT
INEQUITIES.
THIRD OF ALL, INTENTIONAL
RESEARCH IS NEED.
WE IDENTIFIED TWO COMPONENT.
THERE'S AN OVER RELIANCE ON MALE
CLINICAL RESEARCH SUBJECTS AND
LEFT GAPS IN DISORDERS AND
DISEASES THAT OCCUR IN WOMEN.
WHILE THIS STILL PERSISTS, STILL
MUCH OF THE TREATMENT IN THE
BASED ON STUDIES DONE IN MEN.
MANY CHRONIC AND DEBILITATING
CONDITIONS INCLUDING MENOPAUSE
AND ENDOMETRIOSIS AND FIBROIDS
HAVE FEWER STUDIES.
THERE NEEDS TO BE CLINICAL
OUTCOMES DATA TIED TO MENOPAUSE
AND OTHERS FROM A DIVERSE
POPULATION OF WOMEN.
A CONTINUED NEED FOR RESEARCH
THAT INCLUDES WOMEN IN
REASONABLE NUMBERS TO DRAW
CONCLUSIONS.
IN ADDITION, DESPITE SEX AS A
BIOLOGICAL VARIABLE, THE SABV
POLICY, GAPS REMAIN IN
UNDERSTANDING OF SEX
DIFFERENCES.
WE ALSO REALLY NEED TO THINK AS
SOMEBODY POINTED OUT MORE AND
MORE ABOUT GENDER.
THE MANY ROLES AND ISSUES WE
HAVE TO TAKE TO UNDERSTAND
GENDER BUT WE HAVE TO DO THAT.
CONTINUED APPLICATION AND
ENFORCEMENT OF SABV POLICY AND
UPTAKE OF GENDER CONCEPTS WILL
ALLOW FURTHER UNDERSTANDING OF
HOW SEX INFLUENCES
PATHOPHYSIOLOGY.
THIS WILL PAVE FOR IMPROVED
PREVENTION AND TREATMENT
STRATEGY IN WHAT PRESENTS AND
REQUIRES DIFFERENT THERAPIES
THAN WOMEN THAN MEN.
WE'RE NOW TO THE QUESTIONS
PORTION.
I WANT TO THANK NIH.
THIS WAS AN AMAZING OPPORTUNITY
I WAS HONORED TO PARTICIPATE IN
AND COLEAD IN THE CONFERENCE AND
THANKS TO MY COLLEAGUES I DON'T
KNOW WHO'S MODERATING QUESTIONS.
>> I WILL MODERATE DR. CLAYTON
UNLESS YOU WANT TO DO THAT.
>> THAT WOULD BE GREAT.
THANK YOU, I APPRECIATE IT.
>> WE HAVE TIME FOR QUESTIONS
>> THANK YOU.
JUDY, THIS IS AN INCREDIBLE BODY
OF WORK.
WHEN I LOOK AT THE OFFICE OF
WOMEN'S HEALTH WHEN THEY DISCUSS
MATERNAL MORTALITY INCLUDING
ETHNIC AND RACIAL DISPARITIES,
I'M NEVER SEEING INFECTIOUS
DISEASES BROUGHT INTO THIS
THOUGH WE KNOW THAT FOR EXAMPLE,
EVERY YEAR WITH SEASONAL FLU
PREGNANT WOMEN ARE MORE LIKELY
TO HAVE COMPLICATIONS AND IT'S A
MISSED OPPORTUNITY TO LOOK
THROUGH THAT RACIAL AND ETHNIC
LENS TO SEE IF ACCESS TO CARE OR
OTHER SOCIAL DETERMINATES HEALTH
AFFECT THAT AND WE SEE INCREASED
MORTALITY DURING THE COVID-19
PANDEMIC WE CAN RAISE AWARENESS
AROUND LOTS THAT INCREASE THIS.
>> INFECTIOUS DISEASE IN
PREGNANCY IS SUCH AN IMPORTANT
ISSUE AND THE SARS COV2 PANDEMIC
MADE IT MORE PARENT TO THE
GENERAL PUBLIC.
I DON'T KNOW IT WAS AS WISELY
RECOGNIZED BUT I'LL SHARE THE
FIRST NOESI FOR IMPROVED
INCLUDED THREE MAJOR FOCUS
AREAS.
THEY WERE CARDIOVASCULAR
DISEASE, INFECTION AND IMMUNITY
ABDOMEN TAL HEALTH WAS A THIRD
ONE.
INFECTION AND IMMUNITY WAS
PROMINENTLY PLACED IN THAT
PARTICULAR NOSI.
THAT'S A NARROW FUNDING
OPPORTUNITY.
I WILL RECOGNIZE THAT.
IT WAS AN ADMINISTRATIVE
SUPPLEMENT THOUGH FAIRLY LARGE
BUDGETS WERE ALLOWED FOR THAT.
BUT I DID WANT TOO REASSURE YOU
THAT HAS BEEN RECOGNIZED BUT I
DO WANT TO SEE IF OTHERS HAVE
THOUGHTS ON OPPORTUNITIES TO
INCORPORATE INFECTION AND I
DON'T KNOW HOW YOU FEEL ABOUT
INFECTION AND INFLAMMATION.
WE PUT INFECTION AND IMMUNITY
BECAUSE WE FEEL LIKE THEY'RE TWO
SIDES OF THE SAME COIN.
I'M GETTING A DOUBLE THUMBS UP
AS A WAY TO BRING MORE EXPERTISE
AND CONVERSATION TO MATERNAL
HEALTH FROM OUR MICROBIOLOGY
COLLEAGUES AND RHEUMATOLOGY AND
IMMUNOLOGY COLLEAGUES.
I'M GETTING LOTS OF SMILES SO I
THINK I'M MUST BE --
>> IT'S PARTLY THE FOCUS ON
CONGRESS WE FOCUSSED ON IN THIS
PARTICULAR CONVERSATION WHICH
WAS MORBIDITY, MORTALITY AND
CHRONIC CONDITIONS IN WOMEN.
YOUR WORK IS INCREDIBLY
IMPORTANT AND THE FIELD IS
INCREDIBLY IMPORTANT.
I THINK THE WORK OF CONGRESS
DICTATED THE CONFERENCE.
>> THANK YOU FOR CLARIFYING
THAT.
>> YOU GET INTO MATERNAL
MORBIDITY DESCRIBED BECAUSE
THEY'RE THE NEAR MISS LEAD TO
MORTALITY AND THAT DOESN'T MEAN
THAT ALTHOUGH ISSUES ARE NOT
IMPORTANT.
TYPICALLY I USUALLY USE AN
ICEBERG SLIDE TO SHOW ALL THE
OTHER THINGS BENEATH THAT.
I HEARD DR. GIBBONS TALK ABOUT
THE WORK OF THIS AND WE WORKED
ON VACCINATION AND IMMUNIZATION
IS THE ONLY WAY TO PREEMPT POOR
OUTCOMES.
>> THERE WAS DISCUSSION ABOUT
EXTENDING HPV VACCINATION
THROUGH LESSONS LEARNED FROM
COVID VACCINATION AND ALSO
ALTERNATE DELIVERY AND
SURVEILLANCE METHODS FOR
SCREENING.
I WANT TO THANK YOU FOR THE
LESSONED LEARNED FROM COVID
BECAUSE THAT SHOULD INFUSE ALL
THREE TOPICS.
>> SO I MENTIONED INFECTION AND
IMMUNITY WAS IMPROVED BUT I WANT
TO MAKE SURE YOU'RE ALSO AWARE
INFECTION IMMUNITY IS INCLUDED
IN THE CHALLENGES AND OTHER
MATERNAL HEALTH OPPORTUNITIES.
WE'LL PUT THAT INFORMATION IN
THE CHAT SO EVERYBODY CAN ACCESS
THAT.
AND SO FOR POINT OF CARE
DIAGNOSTICS AND TECHNOLOGY
DEVELOPMENT AS WELL.
THANK YOU.
I'LL TURN IT BACK TO SAMIA.
>> THANK YOU, DR. CLAYTON.
I WAS GOING TO LET EVERYBODY
KNOW DR. THOMAS POSTED
INFORMATION.
WE HAVE ONE MINUTE LEFT
DR. SIMON.
I SEE YOUR HANDS ARE UP SO WE
CAN TAKE YOUR QUESTION AND THAT
WOULD BE LAST BEFORE WE MOVE IT
ON THE NEXT SESSION.
>> THANK YOU.
THIS IS A GREAT PRESENTATION.
I HAVE A QUESTION AND I
APOLOGIZE IF I DIDN'T HEAR IT,
BUT THE LOGISTICS OF THE REPORT
FROM THE CONFERENCE, HOW IS IT
GOING TO BE DISTRIBUTED?
I KNOW THERE'S AN EXECUTIVE
SUMMARY AND THEN A FULL REPORT.
ARE BOTH OF THOSE THINGS THE
FULL REPORT AND EXEC SUMMARY
GOING TO CONGRESS?
IS THAT PART OF THE REPORTING
PROCESS?
>> THERE'S SO MUCH RICHNESS IN
ALL OF THAT.
THERE'S IMPORTANT CONTEXT AND
INFORMATION THAT COMPLIMENTS THE
EXECUTIVE SUMMARY'S GOOD BUT
IT'S NOT GOOD ENOUGH TO GIVE THE
INFORMATION I BELIEVE THAT
CONGRESS NEEDS.
>> "WAS GOING TO LET YOU ANSWER.
>> SARA.
>> I WORK ON TOPICS RELATED TO
VACCINE.
RIGHT NOW THE EXECUTIVE SUMMARY
IS GOING TO CONGRESS.
THE REPORT IS BEING VETTED
THROUGH ORWH LEADERSHIP AND THEN
SHARED WITH YOU AND THEN GOING
TO THE LEGISLATIVE OFFICE.
WE TRY TO BE DIRECT AND ELOQUENT
IN THE REPORTS AND TRY TO SEND
THE MESSAGE TO CONGRESS WHAT IS
LEFT TO BE DONE WITH REGARD TO
RESEARCH ON WOMEN HEALTH WITH
THE ROLE OF THE OFFICE OF
LEGISLATION IS TO MAKE SURE IT'S
WORDED IN A WAY THAT ARTICULATES
WHAT WE ARE DOING TO IMPROVE THE
HEALTH OF WOMEN AND THAT IS OUR
ROLE.
EVENTUALLY AFTER A PERIOD OF
TIME WHERE THE CLEARANCES ARE
OBTAINED, IT WILL BE SHARED WITH
CONGRESS AND WE HOPE THAT THE
LANGUAGE THERE WILL BE REALLY
ALLUDE TO THE IMPORTANCE OF THE
WORK WE NEED TO DO IN THOSE
SPECIFIC AREAS.
>> THANK YOU BUT I'M STILL
CONFUSED.
SO THE FULL REPORT CANNOT GO TO
CONGRESS -- IT WILL GO, YEAH.
THE FULL REPORT WILL GO AS WELL.
THE PLAN IS TO SHARE IT WITH OUR
LEGISLATIVE OFFICE WITHIN A
MONTH OR SO BECAUSE WARE WORKING
ON IT INTERNALLY AND IT DEPENDS
ON WHAT CHANGES AND REVISIONS WE
NEED TO MAKE.
IT'S A MATTER OF HOW LONG IT
TAKES TO REFLECT WHAT'S GOING ON
AND BE ABLE TO SHARE WITH THE
PUBLIC DOES THAT ANSWER THE
QUESTION?
>> YEAH, I ALSO WANT TO SAY FROM
AN ADVISORY COMMITTEE
PERSPECTIVE I PERSONALLY THINK
THAT REPORT'S SO RICH AND
DESERVES TO BE CONNECTED
IMMEDIATELY TO THE EXECUTIVE
SUMMARY BECAUSE IT'S IMPORTANT
TO HAVE EVERYBODY ON THE SAME
PAGE WHILE READING IT EACH
MEMBER OF CONGRESS AND THEIR
TEAMS.
THERE'S ANYTHING WE CAN DO TO
SUPPORT THE PROCESS AND
ENCOURAGE THINGS GO TOGETHER AS
A FAMILY UNIT I'D BE HAPPY TO
HELP.
LET US KNOW.
WE ARE RELYING ON YOU TO HELP US
AND IT'S A REPORT AND
RECOMMENDATION OF OUR ADVISORY
COMMITTEE BECAUSE WE'LL BE
LEANING ON YOU TO MAKE SURE
THEY'RE SHARED WITH THE STAKE
HOLDERS.
THANK YOU FOR OFFERING.
WE'RE AS COMMITTED TO HAVING A
REPORT PUBLISHED WE WANT ALL THE
WORK DONE TO PUT THE VIM
TOGETHER TO BE AVAILABLE TO THE
PUBLIC.
>> THANK YOU, EVERYBODY.
>> I'LL TURN IT BACK TO
DR. CLAYTON FOR THE NEXT
SESSION.
OKAY.
SEE WHERE WE ARE.
WE ARE AT DR. TIGNO'S
PRESENTATION.
THANK YOU FOR THE ROBUST
DISCUSSION AND THANK YOU FOR THE
WOMEN'S HEALTH CONFERENCE UPDATE
AND WE'RE THRILLED THE EXECUTIVE
SUMMARY IS AVAILABLE NOW ON THE
WEBSITE.
IF YOU HAVEN'T READ THAT TAKE A
LOOK.
DR. TIGNO IS THE ASSOCIATE
DIRECTOR FOR CAREERS AT ORWH.
PRIOR TO HER CURRENT POSITION
SHE WAS A PROGRAM OFFICER AT THE
NHLBI AND AT THE NATIONAL
INSTITUTE FOR NURSING RESEARCH.
SHE HAS PUBLISHED WIDELY IN THE
AREAS OF BIO PHYSICS AND
OBESITY, DIABETES AND
MICROCIRCULATION AND AGING AND
COMMUNITY-BASED EPIDEMIOLOGY AND
ANALYSIS AND HERBAL MEDICINE AND
WOMEN'S HEALTH.
HER CURRENT EFFORTS ARE DIRECTED
TOWARDS SUPPORTING THE
ADVANCEMENT OF WOMEN IN
BIOMEDICAL CAREERS AND PROMOTING
DIVERSITY AND INCLUSION IN
ACADEMIA AND WILL PRESENT A
CONCEPT CLEARANCE FOR US.
WELCOME.
>> THANK YOU AND GOOD AFTERNOON.
MY NAME IS DR. TIGNO THE
ASSOCIATE FOR CAREERS AND IT'S
MY PLEASURE TO PRESENT OUR
PROPOSAL TOWARDS THE RE-ISSUANCE
OF TWO IMPORTANT FUNDING
OPPORTUNITIES WHICH WERE
MENTIONED EARLIER THIS MORNING.
THEY'RE THE ADMINISTRATIVE
SUPPLEMENTS TO PROMOTE RESEARCH
CONTINUITY AND RETENTION FOR
MENTORED CAREER ACADEMIC AWARD
RECIPIENTS AND THE CONTINUITY OF
RESEARCH PROJECT GRANTS.
THE OVER ARCHING GOAL OF NOT
O.D.024 AND 55 IS FOR THE
BIOMEDICAL RESEARCH WORKFORCE BY
SUPPORTING THE TRANSITION AND
RETENTION OF INVESTIGATORS AT
TWO CRITICAL JUNCTURES IN THEIR
BIOMEDICAL CAREERS.
ONE BEING THE TRANSITION FROM A
MENTORED CAREER DEVELOPMENT
KNOWN AS THE K AWARD TO AN
INDEPENDENT RESEARCH PROJECT
AWARD.
AND THE OTHER IS THE STAGE AT
WHICH THE INVESTIGATOR ATTEMPTS
TO SECURE A SUSTAINED RESEARCH
SUPPORT IN THE FORM OF THE
RENEWAL OF THE FIRST RPG OR BY
OBTAINING A SECOND RO1 OR RO1
EQUIVALENT AWARD.
THE STAGES WERE IDENTIFIED FROM
DATA-DRIVEN STUDIES THAT FOLLOW
THE CAREERS OF MORE THAN 6,000
SCIENTISTS FROM THE
POST-DOCTORAL FELLOWSHIP STAGE
TO BECOMING A PRINCIPLE
INVESTIGATOR.
AN IMPORTANT STAGE IN THE CAREER
LIFE IN LIFE SCIENCES.
WHAT EMERGED FROM THE STUDY WAS
THE GENDER GAP IN THE LIFE
SCIENCES OCCURS DURING THE TWO
TRANSITION PERIODS FROM K TO R
OR THE RENEWAL OF THE FIRST R.
AND BECOMING P.I.s AT A LOWER
RATE THAN MEN.
WHILE THE CONTINUITY PROGRAMS
ARE OPEN ELIGIBILITY IS TIED TO
QUALIFYING LIFE EVENTS DURING
THE PROJECT PERIOD OF THE GRANT
AND THESE INCLUDE CHILD BIRTH,
ADOPTION, PRIMARY CARE GIVING
RESPONSIBILITIES FOR AN AILING
SPOUSE, CHILD, PARTNER OR MEMBER
OF THE IMMEDIATE FAMILY.
BY DEFINING THESE EVENTS, THESE
SUPPLEMENTS WERE INTENDED TO BE
OF GREATER BENEFIT TO WOMEN
SINCE WOMEN ARE MORE LIKELY THAN
MEN TO SITE FAMILY
RESPONSIBILITIES AS A REASON FOR
LEAVING THE WORKFORCE.
THIS PROGRAM IS DESIGNED TO
SUSTAIN ONGOING NIH FUNDED
RESEARCH AS WELL AS TO IMPROVE
GENDER EQUITY AT CAREER STAGES
WHEN MORE WOMEN THAN MEN LEAVE
THEIR RESEARCH CAREERS OR CHANGE
THEIR CAREER TRAJECTORIES.
THESE TWO CONCEPTS AS MENTIONED
EARLIER BY DR. CLAYTON WERE
DEVELOPED BY THE WOMEN IN
BIOMEDICAL CAREERS AND ARE
PARTLY RESPONSIVE TO THE NASEM
PROMISING PRACTICES REPORT.
AND THE BUDGET REQUEST FOR THESE
SUPPLEMENTS WOULD NOT EXCEED
$50,000 BUT THE APPROPRIATE
INDIRECTS.
THE QUALIFYING LIFE EVENT WAS
DURING THE PARENT AWARD WHEN THE
QUALIFYING LIFE EVENT IS PENDING
BUT EXPECTED TO INCUR IN THE
PROJECT PERIOD, THE APPLICATION
MAY BE SUBMITTED IN ADVANCE ON
EVENT.
FOR PARENT AWARDS THAT HAVE
MULTIPLE P.I.s THAT IS WHERE THE
R AWARDS, ANY OF THE P.I.s
MEETING THE ELIGIBILITY CRITERIA
IS ALLOWED TO APPLY.
AND THERE'S A TOLL OF 192
SUPPLEMENTS ISSUED.
THIS PROGRAM WAS ANTICIPATED TO
HAVE BROAD IMPACT BECAUSE THERE
ARE SO MANY DIFFERENT TYPES OF
RESEARCH PROJECT GRANTS AS WELL
AS K AWARDS THAT WERE ELIGIBLE
TO APPLY.
HERE'S THE LIST OF THE K AND RPG
AWARDS ELIGIBLE MAYBE SOME OF
THE MECHANISMS MAY NOT BE
ENTIRELY FAMILIAR.
FOR INSTANCE, WE HAVE THE K38
WHICH IS A NEWER K AWARD WHICH
IS EMPLOYED BY THE NHLBI AND NCI
AND NIA AND NIDA.
THE K43 IS CALLED THE GLOBAL
EMERGING LEADER AWARD AND ISSUED
BY THE FOGARTY INSTITUTE AND
DESIGNED FOR CLINICALLY TRAINED
HEALTH PROFESSIONALS WHO ARE
ESIs.
AND THERE'S INVESTIGATORS WITHIN
THEIR DEGREE AND OPT TO FORGO
POST-DOCTORAL TRAINING.
AND NIH SPENDING DURING THE TWO
YEARS THAT THIS PROGRAM HAS BEEN
AROUND TOTALLED $10.5 MILLION
AND THIS IS BASED ON THE
CATEGORY OF THE PARENT GRANT.
THIS CAN BE OBSERVED MORE K
AWARDEES WERE AWARDED THAN R
AWARDEES.
THIS REFLECTS A NUMBER OF
APPLICATIONS SUBMITTED FOR EACH
CATEGORY.
AND WHEN THE ELIGIBILITY FOR THE
PROGRAM WAS DRAFTED AND FOR THE
TWO YEARS COMBINED AND MEN WERE
ALSO ELIGIBLE.
APPLICATIONS ARE TO BE REVIEWED
BY THE INSTITUTE OR CENTER OF
THE PARENT AWARD AND DIFFERENT
I.C.s MAY HAVE DIFFERENT
FREQUENCIES OF ACCEPTING
APPLICATIONS AND DIFFERENT
DEADLINES DURING THE YEAR AND A
REQUIRED PERIOD ON THE REMAINING
AWARD AND THERE'S VARIABILITY IN
THE ISSUANCE OF AWARDS BY
DIFFERENT I.C.s.
BUT IN GENERAL PROJECTS WITH
NO-COST EXTENSIONS ARE NOT
ELIGIBLE TO APPLY.
DESPITE THE RESTRICTIONS AND THE
CRITERIA FOR QUALIFYING LIFE
EVENT SUCCESS RATES WERE 64% FOR
OUR LEVEL AND 57% FOR K
AWARDEES.
AND OF THE APPLICANTS WHO ED
SUPPLEMENTS THE MAJORITY HAD K23
AWARD INTENDED FOR CLINICIANS
FOR RESEARCH.
THEY WERE FOLLOWED BY K1
AWARDEES AND K08s.
THE TWO FUNDING OPPORTUNITIES
ENJOYED WIDE UTILIZATION AND
EMPLOYED BY I.C.s.
15 OF THE 150 WERE FUND ORWH AND
CAN BE SEEN OF ALL THE
INSTITUTES AND NIDDK AWARDED THE
MOST K-LEVEL SUPPLEMENTS
FOLLOWED BY NHLBI AND NIMH.
THERE WERE 42R LEVEL RESIPIENTS,
14 OF WHOM WERE FUNDED BY ORWH.
AMONG THE R AWARDS, NIGMS ISSUED
THE MOST FOLLOWED BY NIDA AND AS
MENTIONED THE AWARD DECISIONS
ARE MADE BY THE I.C.s AND
SEVERAL FACTORS DICTATE THE
ISSUANCE INCLUDING THE
PRIORITIES, BUDGETS, DEFINITIONS
OF ELIGIBILITIES AND TIMING AND
ISSUANCE AS WELL AS THE VETTING
PROCESS.
BASED ON RACE AMONG RECIPIENTS
MOST WERE WHITES FOLLOWED BY
ASIANS AND THEN BLACKS.
THIS IS SIMILAR TO THE
DISTRIBUTION OF NIH PRINCIPLE
INVESTIGATORS BY RACE AS
REPORTED BY THE DATA BOOK WHERE
MOST GRANTS ISSUED FORCH
RESEARCH AND TRAINING GRANTS.
IN THE LANGUAGE IN THE FUNDING
OPPORTUNITY ANNOUNCEMENT, THE
SUGGESTED USE OF THE FUNDS WERE
FOR COMPUTATIONAL SERVICES,
SUPPLIES, EQUIPMENT AND SUPPORT
OF ADDITIONAL SCIENTIFIC STAFF
TO SUSTAIN THE P.D.s OR P.I.s
RESEARCH DURING THE CRITICAL
LIFE EVENT.
BASED ON THE NARRATIVE OF THE
APPLICATIONS, MOST THE FUNDS
WERE USED TO HIRE ADDITIONAL
PERSONNEL.
THIS INCLUDED RESEARCH
ASSISTANCE, TECHNICIANS,
RESEARCH COORDINATORS AND POST
DOCS AND INFORMATICIAN AND THERE
WERE CARE GIVING FOR SPOUSE AND
MEMBERS OF THE FAMILY.
LITERATURE SHOWS PREGNANCY AND
CHILD BIRTH IN PARTICULAR IS A
SIGNIFICANT CONTRIBUTOR TO THE
UNDER EMPLOYMENT OF WOMEN
SCIENTISTS AND ENGINEERS.
THE DEMANDS OF CHILD BIRTH AND
SUBSEQUENT CARE GIVING
RESPONSIBILITIES TRIGGER CHANGES
TO CAREER GOALS AND ALTER
RESEARCH CAREER TRAJECTORIES.
THEREFORE RETAINING
INVESTIGATORS DURING THE LIFE
EVENT IS CRUCIAL TO PROTECTING
GROWTH AND THE RESEARCH
INVESTMENT AND RETAINING HIGHLY
TRAINED CAREER SCIENTISTS IN THE
INVESTIGATOR POOL.
REPORTS COMING FROM THE
DIFFERENT PARTICIPATING I.C.s
CONFIRM 73% OF APPLICANTS SITE
CHILD BIRTH AS A JUSTIFICATION
FOR REQUESTING SUPPLEMENTS.
FOR CARE GIVING IN THE VARIOUS
FORMS IS CITED NEXT AND THE
PROGRAM US AN IMPORTANT
MECHANISM BY WHICH TO ASSIST
EARLY CAREER SCIENTIST WHO'S HAD
TO ASSURE CARE GIVING
RESPONSIBILITIES DURING THE
PANDEMIC.
OTHER CITATIONS WERE STAYING
HOME FOR THE SAFETY OF THE
CHILDREN DURING THE COVID-19 AND
BEING THE SOLE CAREGIVER FOR THE
CHILDREN WHEN THE SPOUSE
ACCEPTED A POSITION AT A
DIFFERENT LOCATION, PTSD IN FACT
WAS THERE AND STEM FROM WORK OF
THE ORDs AND ADOPTION WAS CITED
AND CARE GIVING THAT RESULT FROM
THE COVID-RELATED SCHOOL
CLOSURES.
SPOUSE CARE GIVING FOR CHILDREN
DIAGNOSED WITH MENTAL ILLNESS.
BASED ON OUR ONGOING EVALUATION
THE PROGRAM GARNERED WIDE
ACCEPTANCE AND THEY CAN BE
ISSUED FROM THE TIME OF
SUBMISSION OF THE APPLICATION
AND AS SHOWN BY THE DATA, THESE
SUPPLEMENTS SUPPORT
INVESTIGATORS INSENSITIVE
PERIODS IN THEIR LIFE WHEN THEIR
RESEARCH PRODUCTIVITY AND
CAREERS ARE AT RISK.
WE THEREFORE REQUEST THE ORWH
AND NIH BE ALLOWED TO CONTINUE
THE ISSUANCE OF THESE NOTICES
WHICH ARE POUND TO EXPIRE IN THE
COMING YEAR.
THE MECHANISM WILL ADD ELIGIBLE
GRANTS AND CONSIDERING OTHER
QUALIFYING LIFE EVENTS.
WE REGULARLY MEET WITH OUR
PARTICIPATING I.C.s FOR
FEEDBACK.
THE NEGATIVE AND LONG-TERM
IMPACT OF COVID FURTHER PROVIDES
A COMPELLING NEED TO RE-ISSUE
THE FUNDING OPPORTUNITY.
THERE'S THE TRANS-NIH STRATEGIC
PLAN FOR WOMEN'S HEALTH RESEARCH
AND THE FOURTH GOAL WHICH IS TO
PROMOTE TRAINING AND CAREERS TO
DEVELOP A WELL-TRAINED ROBUST
WORKFORCE AND ADVANCE THE
SCIENCE OF WOMEN'S HEALTH AND
SUPPORT NIH BY STRATEGIC PLAN TO
DEVELOP AND PLAIN TAIN
SCIENTIFIC RESEARCH CAPACITY AS
WELL AS ENHANCE THE BEHAVIORAL
RESEARCH WORKFORCE AND ENHANCING
WOMEN'S HEALTH.
AND LAST BUT NOT LEAST ADDRESSES
THE NATIONAL STRATEGY ON GENDER
EQUITY RELEASED BY THE WHITE
HOUSE IN OCTOBER LAST YEAR AND
INCLUDES CLOSING GENDER GAPS IN
SCIENCE, TECHNOLOGY, ENGINEERING
AND MATHEMATICS.
WITH THAT I'D LIKE TO OPEN IT UP
FOR QUESTIONS.
THANK YOU FOR THE OPPORTUNITY TO
PRESENT.
>> SHE IS TAKING QUESTIONS NOW
AND YOU CAN PUT THEM IN THE CHAT
BOX AND WE'LL GO THROUGH THEM.
>> I WANT TO MAKE SURE
DR. ANDERSON GOT HER QUESTION
ANSWERED.
I SUPPORT THE PROGRAM.
I'M WONDERING ABOUT THE
FOLLOW-UP OF THE RECIPIENTS.
ARE YOU PLANNING TO DETERMINE
HOW IT'S EFFECTIVE IN KEEPING
THE WORKFORCE LONG-TERM.
WE HAVE AN ONGOING EVALUATION OF
THE PROGRAM.
PRIOR TO REISS-ISSUANCE.
>> IT'S TOO EARLY TO DO
EXTENSIVE FOLLOW-UP MAYBE AFTER
A NUMBER OF YEARS WE'LL BE IN A
BETTER PLACE TO ASSESS THE
IMPACT BUT THANK YOU FOR YOUR
QUESTION.
>> DR. ROBINSON, YOU HAVE A
QUESTION.
>> MY QUESTION WAS SIMILAR TO
DR. ANDERSON'S.
I'M GOING TO ASK IT ON THE OTHER
END THE, T GRANTS IS SOMETIMES A
MECHANISM USED BY WOMEN AS A
PRE-K AWARD.
IS THERE DATA BEING GATHERED ON
THAT END TO LOOK AT WHAT THE
STATISTICS ARE FOR THE TRAINING
GRANTS AND HOW THAT MIGHT FEED
INTO THE K AWARDS?
>> MY FORMER I.C. HAD TRAINING
GRANTS AND A HANDLED MANY BUT
IT'S DIFFICULT TO DO THAT
ASSESSMENT.
I THINK IT HAS TO BE I.C.
DIRECTED BECAUSE THEY HAVE THE
DATA ON THE ACTUAL GRANTEES, THE
TRAINEES OF THE PROGRAMS.
WEIR GOING FEEDBACK FROM THE
I.C.s AND TRYING TO TRACK THE
TRAINEES WHICH IS EASIER THAN
THE GRANTEES OF THE T32s BECAUSE
THEY'RE IN THE NAME OF THE
TRAINEES THEMSELVES.
>> THERE'S A QUESTION ABOUT THE
IMPORTANCE IN DIVERSITY AND
MENTORING FOR FUTURE WORKFORCE
AND THE QUESTION IS MINORITY
SUPPLEMENTS AND ABOUT THE
PERSONS AS FACULTY.
>> I WAS RELATING TO THESE
PARTICULAR PEOPLE BEING SUPPORT
NIH TO DO INCREASE THE RESEARCH
OF WOMEN IN THEIR CAREERS.
ARE YOU CONSIDERING OTHER WAYS
TO HELP CHANGE THE SYSTEM?
>> DEFINITELY AND IT'S THE GOAL
OF THE ORWH WHERE WE SEEK
REPRESENTATION FROM OUR
DIFFERENT COMMUNITIES ESPECIALLY
THOSE UNDER SERVED WHICH INCLUDE
WOMEN ESPECIALLY WOMEN OF COLOR.
WHENEVER WE DO ANY KIND OF
ASSESSMENT, WE ALWAYS INCLUDE
THE DIVERSITY PERSPECTIVE AS
PART OF THE ASSESSMENT AND WE
ARE WORKING TO IMPROVE THE
REPRESENTATION OF OTHERS GROUPS.
THAT'S A MAJOR CONSIDERATION FOR
US.
>>
>> NEXT.
>> THANK YOU SO MUCH FOR LEADING
THIS INCREDIBLY IMPORTANT
INITIATIVE TO TARGET THE
TRANSITION POINTS WE KNOW PEOPLE
ARE VULNERABLE AND THE LIFE
EVENTS EVERYONE NEEDS TO LIVE
THROUGH SO WE CAN HARNESS THE
TALENT OF EVERYBODY IN THE
POPULATION.
HATS OFF TO YOU.
MY QUESTION IS NIH IS CREATE
BEING AN INCREDIBLY IMPORTANT
PART OF THE ECO SYSTEM OF
ACADEMIC MEDICINE AS A FUNDER.
I WONDER IF THERE ARE OTHER
THINGS THAT OTHERS CAN AND
SHOULD ALSO BE DOING I LOVE THAT
YOU LOOKED AT THE NARRATIVES TO
LOOK AT THE DISRUPTIONS IN THE
AWARDS.
DO YOU HAVE DATA OR INTENTION
OFF GATHERING DATA TO
UNDERSTANDING THE EXPERIENCE OF
THESE INDIVIDUALS AND OTHER
THINGS THAT MAY BE HELPFUL TO
THEM IN ADDITION TO THE
PERSONNEL SUPPORT AND WHAT
THEY'RE ABLE TO FUND THROUGH THE
IMPORTANT SUPPLEMENTS?
IS THERE OTHER STUFF IN THE
STRUCTURES OF THEIR INSTITUTIONS
OR SOCIETY TO LEARN FROM PEOPLE
WHO SELF-IDENTIFIED AS BEING IN
THIS SITUATION?
>> I'M SURE THAT'S A TOPIC WE'D
LOVE TO INVESTIGATE IN THE
FUTURE.
NIH CAN'T DO IT ON ITS OWN.
WE NEED BUY IN FROM EXTRAMURAL
PARTNERS AND THE DIFFERENT
UNIVERSITY
UNIVERSITIES AND ACROSS THE
COUNTRY AND THE SOCIAL
STRUCTURE, SHALL WE SAY, WHERE
THERE IS A MORE WELCOMING AND
SUPPORTIVE ENVIRONMENT ACROSS
THE ECO SYSTEMS.
IT INCLUDES SECTORS OUTSIDE OF
ACADEMIA.
>> DOES THAT ANSWER YOUR
QUESTION?
>> IT DOES.
WHEN NIH ACT LIKE THIS IT MAKES
THE INSTITUTIONS TAKE HEED AND
GETS ALL OF SOCIETY TO ACT.
>> THANK YOU.
WE'LL MOVE ON.
DR. ANDERSON YOU HAD YOUR HAND
UP?
>> THE RECENT AWARDEES COULD
BECOME A COHORT WHERE YOU
COLLECT SUCH DATA AND WOULD BE
INTERESTED IN THINGS LIKE LOCAL
INSTITUTIONS PROVIDING ON-SITE
DAYCARE AND THINGS THAT CAN
FACILITATE A YOUNG MOTHER
CONTINUING HER EFFORTS.
AND KNOWING WHY SECTORS OF OUR
WORKFORCE ARE IMPACTED.
I HEARD ABOUT THE CLINICAL
RESEARCHERS.
I'M ALSO INTERESTED IN THE BENCH
SCIENTISTS VERSUS THE POPULATION
SCIENCE TESTS BECAUSE I THINK
THERE'S DIFFERENT CULTURES IN
THOSE AND IT WOULD BE
INTERESTING TO KNOW WHETHER ONE
IS WORSE OR BETTER IN PROMOTING
ENVIRONMENTS.
>> I CAN ONLY SPEAK FOR THE
FIRST TWO YEARS OF THE AWARD
BECAUSE AS YOU HAVE SEEN FROM
THE BAR GRAPHS, MOST OF THOSE
WHO APPLIED WERE K23 AWARDEE
WHICH IS MEANS THEY WERE
CLINICIANS AND THEY WERE
INVOLVED IN PATIENT-ORIENTED
RESEARCH.
NEXT IN LINE WERE THE K01s DOING
BASIC RESEARCH.
MOSTLY Ph.D.s AND CLINICIANS
DOING BASIC RESEARCH.
SO I THINK IMPACTS EVERYBODY AND
CERTAINLY THAT IS ONE OF OUR
INTERESTS IN THE COMING YEARS TO
DATE THEY'VE ONLY HAD 192 AWARDS
FOR BOTH MECHANISMS.
WE DO NOT HAVE THE SAMPLE SIZE I
THINK TO BE ABLE TO DO SUCH AN
EM TENSIVE EVALUATION AT THIS
POINT.
THAT'S ON THE HORIZON.
THANK YOU FOR COMMENT.
>> DR. CLAYTON, DO YOU WANT TO
SAY ANYTHING BEFORE WE LOAD THE
CONCEPT?
>> NO, THANK YOU AND TO
EVERYBODY FOR A ROBUST
DISCUSSION.
>> WE'LL VOTE TO APPROVE THE
RE-ISSUANCE FOR THE SUPPLEMENT
TO PROMOTE RESEARCH RETENTION
FOR K AWARD RECIPIENTS AND
CONTINUITY OF BIOMEDICAL
RESEARCH AMONG FIRST-TIME
RECIPIENTS OF NIH RPGs.
IS THERE A MOTION ON THE TABLE
TO APPROVE THE CONCEPT CLEARANCE
FOR THE RE-ISSUANCE OF
ADMINISTRATIVE SUPPLEMENT TO
PROMOTE RESEARCH CONTINUITY FOR
MENTORED CAREER DEVELOPMENT, K
AWARD RECIPIENTS AMONG FIRST
TIME RECIPIENTS OF NIH RPGs.
>> SO MOVED.
>> THANK YOU, DR. ANDQUANERSON.
DO I HEAR A SECOND.
THANK YOU.
A POLL IS OPEN FOR TO YOU VOTE.
ENCE TER YOUR RESPONSE AND
YOU'LL HAVE 30 SECONDS TO
RESPOND.
>> THE RE-ISSUANCE CONCEPT
CLEARANCE HAS BEEN ACCEPTED WITH
12 IN FAVOR.
THANK YOU, EVERYONE AND I WOULD
LIKE TO TURN IT BACK TO
DR. CLAYTON.
>> THANK YOU.
AT THIS TIME I'D LIKE TO
INTRODUCE DR. SHARON HUNTER
ASSOCIATE DIRECTOR FOR BASIC AND
TRANSLATIONAL RESEARCH AT ORWH.
SO IT LOOKS LIKE HER SLIDES ARE
COMING UP.
SHE LEADS A TEAM OF
ADMINISTRATOR IN THE DEVELOPMENT
AND ADMINISTRATION AND
MANAGEMENT OF THE ORWH SCORE
PROGRAMS ON SEX DIFFERENCES AND
ADMINISTRATIVE OR SEX AND GENDER
ADMINISTRATIVE SUPPLEMENT
PROGRAM AND NIH'S FIRST EVER RO1
ON SEX AND GENDER CALLED THE
INTERSECTION OF SEX AND GENER
INFLUENCES ON HEALTH AND
DISEASE.
SHE'S BEEN A POINT OF CONTACT
FOR MANY EFFORTS TO ENHANCE SEX
AS A BIOLOGICAL VARIABLE AND
SHE'LL PRESENT A CONCEPT ON THE
RE-ISSUANCE ON HEALTH AND
DISEASE RESEARCH.
WELCOME.
>> THANK YOU, DR. CLAYTON AND
COUNCIL.
I'D LIKE TO SEEK YOUR INPUT ON
THE RE-ISSUANCE OF THE RO1 THE
INTERSECTION OF SEX AND GENDER
INFLUENCES ON THE HEALTH AND
DISEASE RESEARCH.
DR. DELCARMEN WIGGINS WAS THE
LEAD AND THE TIRELESS ADVOCATE
FOR THIS NIH INITIATIVE AND THIS
UNIQUE FUNDING OPPORTUNITY HAS
NOT ONLY STIMULATED CUTTING EDGE
RESEARCH BUT PROVIDED UNEXPECTED
DIVIDENDS TO THE COMMUNITY AT
LARGE THE TOPIC ARE THREE.
FIRST, THE ORIGINAL RATIONALE
AND GOALS FOR SUPPORTING
RESEARCH AT THE INTERSECTION OF
SEX AND GENDER INFLUENCES ON
HEALTH AND DISEASE, AND SECOND
I'D LIKE TO DISCUSS THIS REQUEST
FOR APPLICATION PUBLISHED IN
SEPTEMBER OF 2019 FOLLOWING THE
FIRST CONCEPT CLEARANCE.
THAT WAS ENTITLED RO1OD-19-029
AND SEX AND GENDER INFLUENCES ON
HEALTH AND DISEASE.
I'D LIKE TO PROVIDE A REPORT AND
LESSONS LEARN AND DISCUSS
CONSIDERATION FOR RE-ISSUANCE OF
THE RO1.
WHEN WE FIRST BROUGHT THIS
FORWARD WE FOCUSSED ON THE
HEALTH OF WOMEN.
OTHER REASONS REASONS TO SPONSOR
A PROGRAM BASED ON THE UNIQUE
NICHE IT WOULD FIRST ENCOURAGE
NEW RESEARCH ON THE DIFFERENTIAL
AFFECTS OF SEX AND GENDER AND
THE INTERSECTION OF WOMEN'S
HEALTH AND INCREASE AND SUPPORT
DISEASE AGNOSTIC TOPICS TO
ADVANCE WOMEN'S HEALTH AND
PROVIDE AN OPPORTUNITY TO
CONDUCT TRANS-DISCIPLINARY
RESEARCH ORDINARILY BEYOND THE
SCOPE OF ANY ONE NIH INSTITUTE
OR CENTER.
AND LAST BUT NOT LEAST AWARE
THIS INITIATIVE HAD THE CAPACITY
TO SATISFY MANDATES IN THE 21st
CENTURIES CURES ACT AND THE
STRATEGIC PLAN OF WOMEN'S HEALTH
RESEARCH.
IN ADDITION, THIS NEW INITIATIVE
WAS TO BUILD ON CURRENT PROGRAMS
LIKE THE SPECIALIZED CENTER ON
SEX DIFFERENCES AND OUR ORWH
SUPPLEMENT PROGRAM SUPPORTING
SEX AND GENDER RESEARCH AND THE
RESEARCH OF UNDER REPRESENTED
AND UNDER STUDIED POPULATIONS TO
ADVANCE BUT NOT ONLY SEX AND
GENDER BUT IMPORTANT THE
INTEGRATION OF SEX AND GENDER
CONSIDERATIONS INTO RESEARCH.
THIS NEW INITIATIVE WAS
PUBLISHED AS RFA-OD-19-029 AND
THIS FOA IS DESIGNED TO
STIMULATE RESEARCH TO
INCORPORATE OR ENHANCE OUR
INFORMATION OF THE INFLUENCE OF
SEX AND GENDER AND THEIR
INTERSECTIONALITY ACROSS THE
BROAD ARRAY OF SCIENTIFIC
DISCIPLINES.
APPLICATIONS MUST ADDRESS THE
INTERSECTION OF SEX AND GENDER
IN HEALTH AND DISEASE RELATED
VARIABLES AND VARIABLES AS WELL
AS THE INTERSECTION OF SEX AND
GENDER RELATED VARIABLES AND
ALSO HAD TO ADDRESS THE 2019,
2023, TRANS-NIH STRATEGIC PLAN
FOR WOMEN'S HEALTH RESEARCH.
THE GOA
ON THE RIGHT YOU SEE THE GOALS
AND OBJECTIVES OF THE PLAN.
ON THE RIGHT, WE SEE IN ADDITION
TO ADDRESSING GOAL 1 OBJECTIVES
THE APPLICATIONS SUBMITTED IN
RESPONSE TO THE FUNDING
OPPORTUNITY WERE TO ENCOURAGE
CONSIDERATION HEALTH DISPARITY
POPULATIONS BECAUSE WOMEN ARE
DISPROPORTIONATELY AFFECT SOME
CONDITIONS AND DISEASES IN TERMS
OF INCIDENTS, DIAGNOSES AND
COURSE AND RESPONSE TO
TREATMENT.
IN ADDITION, APPLICANTS WERE
ALSO ENCOURAGED TO CONSIDER THE
LIFE SPAN.
AS WE KNOW THE HEALTH OF GIRLS
AND WOMEN IS AFFECT THE
DEVELOPMENT AND PSYCHOLOGICAL
AGE.
IN ADDITION THERE'S LOOKING AT
LIFE IN THE ELDERLY YEARS AND
REPRODUCTIVE LIFE AND THE
MENOPAUSAL TRANSITION AND THE
ELDERLY AND FRAIL ELDERLY.
DISCUSS OF LIFE COURSE, LIFE
SPAN IS AN IMPORTANT ELEMENT FOR
THIS INITIATIVE.
ALSO, THE INITIATIVE INCORPORATE
INCORPORATES OR ENHANCING OUR
UNDERSTANDING OF THE INFLUENCE
OF SEX AND GENDER AND THE
INTERSECTIONALITY ACROSS A BROAD
ARRAY OF SCIENTIFIC DISCIPLINES.
THIS IS REFLECTED IN THE
INSTITUTES AND CENTERS AT NIH.
LASTLY, WE WERE FORTUNATE EXPAND
THE INITIATIVE TO INCLUDE
INVESTIGATIONS TO ADDRESS
CUTTING-EDGE STUDIES ON THE
UNDERSTANDING ON THE DEVELOPMENT
AND ADMINISTRATION OF
THERAPEUTIC VACCINES AND THE
INVESTIGATIONS WITH SEX AND
GENDER DIFFERENCES AND ACCESS TO
CARE THAT IS DIAGNOSIS,
TREATMENT AND HOSPITAL ADMISSION
OF COVID-19 AFFECTED INDIVIDUALS
AND WE HOPE IT WOULD ENCOURAGE
THE INVESTIGATION OF SEX AND
GENDER INFLUENCES ON THE OUTCOME
OF PATIENT INTERACTIONS WITH
HEALTH CARE PROVIDERS.
WITH THE PUBLICATION WE HAVE
THREE RECEIVE DATES.
GIVEN IT WAS PUBLISHED AND HAD A
SHORT TIME BEFORE THE FIRST
RECEIPT DATE WE HAD A ROBUST
RESPONSE FOR EACH OF THE DISEASE
STATES.
YOU SEE FOR THE FIRST DATE IN
FISCAL 2020 WE RECEIVED
APPLICATIONS FOR AND FOR FUNDED
AND A 2021 WE RECEIVED 46
APPLICATIONS AND NINE WERE
FUNDED AND THIS YEAR WE RECEIVED
ANOTHER 46 APPLICATIONS AND THEY
WERE SUBMITTED AS PART OF THE
THIRD AND FINAL CYCLE WERE JUST
REVIEWED LATE LAST WEEK SO CAN'T
UPDATE YOU ON THAT JUST YET.
TO DATE FOR 2002 AND 2021 AND
THE INVESTMENT HAS BEEN $9
MILLION WITH AN OVERALL SUCCESS
RATE.
THANK YOU TO THE PARTNERS THAT
CONTRIBUTE AND FUNDING OF THE
INVESTIGATORS.
THIS SHOWS A NUMBER OF
APPLICATIONS SUBMITTED BY
INSTITUTE PARTNERS.
THE BIG WINNER IS NHLBI WITH
OVER 24% AFTER APPLICATIONS
SUBMITTED FOR THE THREE RECEIPT
DATES.
WHAT'S REMARKABLE IS NHLBI
JOINED THE INITIATIVE NOT IN THE
FIRST ROUND BUT BEGINNING WITH
THE SECOND RECEIPT DATE.
VERY REMARKABLE.
THE EXPANSION OF THE INITIATIVE
BETWEEN INCLUDE COVID ARE IN THE
SECOND ROUND OF APPLICATIONS.
THE SEX AND GENDER MINORITY
RESEARCH OFFICE ALSO SIGNED ON
TO THIS INITIATIVE AND EXPRESSED
THEIR INTEREST IN CO-FUNDING
APPLICATION.
ONE THING TO NOTE THAT SPEAKS TO
THE IMPORT OF THIS IS NIA SIGNED
ALL THREE ROUNDS BUT IN THE
SECOND ROUND THE LIMITED
APPLICATIONS TO THOSE RELEVANT
TO ALZHEIMER'S DISEASE ONLY IN
THE SECOND ROUND.
I THINK DUE IN PART TO THAT THE
NUMBER OF APPLICATIONS SUBMITTED
IN THE SECOND ROUND TO THE
MISSION WERE REDUCED BY OVER
HALF.
I THINK THIS DEVELOPMENT AND THE
FACT THAT NHLBI HAD SO MANY
APPLICATIONS WITH ONLY TWO
RECEIPT DATES SPEAKS TO THE
IMPORTANCE OF THE INITIATIVE AND
INTEREST IN THIS SCIENTIFIC
RESEARCH TOPIC IN THE BIOMEDICAL
COMMUNITY.
AT THE BOTTOM WE SEE THE OVERALL
NUMBER OF APPLICATIONS HAVE
REMAINED STABLE OVER THE THREE
RECEIPT DATES.
WHEN YOU CONSIDER THE NUMBER OF
NEW AND EARLY STAGE APPLICANTS,
THEY REPRESENT AN INCREASING
PERCENTAGE OF THE APPLICANT
POOL.
YOU CAN SEE THAT HERE GOING TO
24 NEW OR EARLY STAGE
INVESTIGATORS OVER THE THREE
YEARS OF THE RFA.
THE BOTTOM LINE IS WE HAVE TO
DATE AN OVERALL SUCCESS RATE OF
APPLICANTS OF 17% BUT THE
SUCCESS RATE OF NEW AND EARLY
STAGE INVESTIGATORS IS 30% WHICH
TOPS THE NEW INVESTIGATOR
SUCCESS RATE.
AND MOREOVER, NEW AND EARLY
STAGE INVESTIGATORS REPRESENTED
ALMOST HALF OF THE AWARDEES FOR
THE PROGRAM WHICH I THINK AGAIN
SPEAKS TO THE COMPETITIVENESS OF
THE NEW INVESTIGATORS AND THE
IMPORT OF THIS FIELD OF
RESEARCH.
IN THE NEXT TWO SLIDES I
HIGHLIGHT THE TITLES OF THE
FUNDED AWARDS YOU CAN SEE SO THE
TITLES AND TOPIC AND THE
INSTITUTES THAT SUPPORTED THE
APPLICATIO
APPLICATIONS.
DR. CLAYTON, I KNOW HERE THAT IN
THE CLASS OF 2020 IS A NEW
INVESTIGATOR, DR. IS A MARD WHO
DR. CLAYTON HIGHLIGHTED IN HER
DIRECTOR'S REPORT.
THESE ARE THE INVESTIGATORS
FUNDED AND YOU CAN SEE HERE VERY
DIVERSE TOPICS FUNDED BY SEVERAL
NIH INSTITUTES.
AGAIN, HERE WE SAW 50% OF THE
AWARDEES WERE NEW INVESTIGATORS.
I'D ALSO LIKE TO SAY A NUMBER OF
THESE INVESTIGATORS HAVE BEEN
TAPPED TO SERVE ON NIH STUDY
SECTIONS.
WITH THIS I'D LIKE TO HIGHLIGHT
THE WORK OF ANOTHER NEW
INVESTIGATOR, DR. SILVERIA.
SHE IS AN ASSOCIATE PROFESSOR AT
INDIANA UNIVERSITY IN
BLOOMINGTON.
HER OBSERVATION WAS ASTHMA
IMPACTS SEX DIFFERENTLY THROUGH
THE DEVELOP AND PRE AND POST
PUBERTY AS WELL AS THE MENSTRUAL
CYCLE.
STARTING AROUND PUBERTY AND
PEAKING DURING MIDLIFE, WOMEN
HAVE HIGHER RATES OF ASTHMA
ASKA
AS -- EXACERBATIONS AND
MECHANISMS CONTROLLED BY
HORMONES CONTRIBUTE TO
DIFFERENCES IN AIRWAY ACTIVITY
IN RESPONSE TO ENVIRONMENTAL
STIMULI.
HER STUDY ENTITLED GONADAL
HORMONES OF SEX MEDIATORS IN
ASTHMA IS CO-FUNDED BY THE
NATIONAL HEART, LUNG AND BLOOD
INSTITUTE AND THIS IS THE FIRST
STUDY TO LOOK AT THIS IN ASTHMA
PHENOTYPES IN MALE AND FEMALE
LUNG CONTRIBUTING TO THE
CHARACTERIZATION OF SEX AND
GENDER SPECIFIC FACTORS FOR
FEMINIZING THIS IN MICROBIOLOGY
AND THERE'S THE USE OF THE MOUSE
MODEL AS WELL AS HUMAN CELLS
THAT WEREEXPOSED IN AN ASTHMA
PARADIGM IN A MOUSE MODEL AND TO
IMPROVE CLINICAL PRACTICALS FOR
CISGENDER AND TRANSGENDER
COHORT.
IN THE SHORT THREE RECEIPT DATES
THE SEX AND GENDER RO1 HAS
SUCCESSFULLY MET ITS OBJECTIVES.
TO SIMULATE RESEARCH TO
UNDERSTAND THE INFLUENCE OF SEX
AND GENDER AND INTERSECTIONALITY
IN HEALTH OUTCOMES ACROSS A
BROAD ARRAY OF SCIENTIFIC DIN
DISCIPLINES TO LOOK AT SEX-BASED
VARIABLES INCLUDING THE
EVALUATION OF SEX AS A VARIABLE
AND SEX-BASED COMPARISONS OR
CONDITIONS IN MALES AND AND
BIOLOGY DIFFERENCES LIKE
HORMONES OR ANATOMY OR
BIOMARKERS.
ASSESSMENT OF PSYCHOSOCIAL
VARIABLES RELEVANT TO HEALTH
CONDITIONS, MEASURES OF SOCIALLY
CONSTRUCTIVE ROLES, EXPERIENCES,
IDENTITIES OR BEHAVIOR OF GIRLS
AND WOMEN BOYS, MEN OR GENDER
DIVERSE PEOPLE.
IN ADDITION THE RFA HAS HAD
UNEXPECTED BUT POSITIVE
DEVELOPMENTS TO ADVANCE WOMEN'S
HEALTH.
IT HAS IDENTIFIED A CADRE OF
REVIEWERS IN EXPERTISE IN SEX
AND GENDER AND THE INTERSECTION
OF SEX AND GENDER IN RESEARCH.
IT STIMULATED RESEARCH IN UNDER
STUDIED POPULATIONS AND WITH
EXPANSION TO INCLUDE COVID, THE
SEX GENDER RO1 ADVANCES RESEARCH
ON THE CONSIDERATION OF SEX AND
GENDER RESEARCH AND
INTERSECTIONALITY IN SARS COV2.
THIS HAS REACHED A DIVIDEND FOR
THE SCIENTIFIC COMMUNITY AT
LARGE.
FOR FUTURE DIRECTIONS WE
RECOMMEND RE-ISSUANCE OF SEX AND
GENDER INFLUENCES ON HEALTH AND
DISEASE RESEARCH AS AN RO1
MECHANISM AND WITH THAT WE WOULD
ENCOURAGE ADDITIONAL INSTITUTES
AND CENTERS TO PARTNER WHICH I
THINK IS QUITE POSSIBLE.
AS PART OF THE FUTURE INITIATIVE
WE RECOMMEND EXPANDING THE
SCIENTIFIC AREAS OF INTEREST TO
NOW INCLUDE COVID-19 AND TO
HIGHLIGHT THE FACT THAT WE HAVE
AN OPPORTUNITY HERE TO LEVERAGE
AND CURATE LARGE SEX AND GENDER
DATA SET AND WOULD LIKE TO
FACILITATE NA IN A FUTURE
INITIATIVE.
WE HAVE A WEALTH OF CUTTING EDGE
TOPICS AND WE'D LIKE TO
HIGHLIGHT THAT WITH OUR NEW
INVESTIGATORS IN A NEW
INVESTIGATORS FORUM.
WE'D LIKE TO THANK OUR BE
SCIENTIFIC PARTNERS AND WE'RE
LOOKING FOR MORE WITH YOUR
CONCURRENCE FOR THE NEW
INITIATIVE AND WITH THAT I WILL
STOP AND TAKE QUESTIONS.
THANK YOU VERY MUCH.
>> FEEL FREE TO L UTILIZE THE
CHAT AND WE HAVE A FEW MINUTES
FOR QUESTIONS.
DR. ANDERSON.
>> THANK YOU.
GREAT TO SEE THIS.
I'M VERY SUPPORTIVE.
I HAVE A QUESTION FOR
CLARIFICATION.
FOR CONDITIONS THAT OCCUR IN
BOTH MEN AND WOMEN, ARE THE
PROPOSALS REQUIRED TO ADDRESS
BOTH SEXES OR CAN THERE BE
SEX-SPECIFIC PROPOSALS?
>> AS LONG AS THEY ADDRESS SEX
AND GENDER.
THEY HAVE TO ADDRESS BOTH SEX
AND GENDER AND ADDRESS THE
GENDER VARIABLE.
>> THANK YOU.
>> ALL RIGHT.
DR. CLAYTON, IS IT OKAY IF WE
MOVE ON TO TAKE THE VOTE?
I DON'T SEE OTHER QUESTIONS.
>> THANK YOU DR. ANDAND
DR. HUNTER.
WE'LL MOVE TON VOTE AND APPROVE
THE CONCEPT CLEARANCE FOR SEX
AND GENDER INFLUENCES ON HEALTH
AND DISEASE RO1 RE-ISSUANCE.
IS THERE A MOTION ON THE TABLE
TO APPROVE THE CONCEPT CLEARANCE
NOR THE INTEROCEPTION ON HEALTH
AND DISEASE RO1 RE-ISSUANCE.
>> I MOVE.
>> DR. REGENSTEINER HAS
SUBMITTED THE MOTION.
DO I HEAR A SECOND?
>> I SECOND.
>> THANK YOU.
A POLL HAS BEENTO RESPOND.
ENTER NOW AS YOU'LL HAVE ONLY 30
SECONDS TO RESPOND.
ALL RIGHT.
DO WE HAVE A RECORD OF THE
VOTES?
THE RE-ISSUANCE HAS BEEN
ACCEPTED WITH 13 IN FAVOR.
THANKS, AGAIN, EVERYONE.
IT'S MY PLEASURE TO WELCOME
DR. BARR.
SHE'S A SOCIAL AND BEHAVIORAL
SCIENTIST ADMINISTRATOR AT ORWH.
SHE COORDINATES ORWH
INTERPROFESSIONAL EDUCATION
EFFORTS, CO-LEADS THE DIVERSE
VOICES SPEAKER SERIES AND
SUPPORTS EFFORTS TO GENDER
VARIABLES IN HEALTH RESEARCH.
HER BACKGROUND IS IN
COMMUNITY-CENTERED RESEARCH, HIV
TREATMENT AND REPRODUCTIVE
JUSTICE AND GENDER-BASED
VIOLENCE.
WELCOME.
>> THANK YOU.
I'M TO SEEK INPUT ON A NEW
PROGRAM GALVANIZING HEALTH
EQUITY THROUGH DIVERSE AND
EDUCATIONAL RESOURCE OR GENDER.
THIS SHOWS THE STRATEGIC GOALS
OUTLINED IN THE TRANS-NIH
STRATEGIC PLAN FOR WOMEN'S
HEALTH RESEARCH.
GOAL FOUR TO PROMOTE TRAINING
AND CAREER TO ADVANCE SCIENCE
FOR THE HEALTH OF WOMEN IS OF
PARTICULAR RELEVANCE FOR THIS
PRESENTATION.
KNOWLEDGE OF SEX AND GENDER
INFLUENCES SHOULD BE INTEGRATED
WITH THE SKILLS THAT NURTURE
EFFECTIVE RESEARCHERS AND
DEVELOPMENT AND IMPLEMENTATION
OF EDUCATIONAL TRAINING PROGRAMS
WILL BE NEEDED TO UPDATE THE
KNOWLEDGE AND SKILL OF CURRENT
BIOMEDICAL RESEARCHERS AS WELL
AS THOSE RETURNING TO OR
ENTERING THE WORKFORCE.
IT HAS BEEN WELL DOCUMENTED THAT
TRAINING ON SEX AND GENDER IN
HEALTH IS LACKING.
EXISTING DATA SUGGESTS THE
CONCEPTS OF SEX AND GENDER IN
HEALTH ARE UNDER EXPLORED ACROSS
HEALTH RELATED FIELD INCLUDING
MEDICAL EDUCATION, PHARMACY
CURRICULA AND EMERGENCY MEDICINE
RESIDENCY PROGRAMS RECENT
STUDIES FOUND LESS THAN HALF OF
PHARMACY FACULTY TAUGHT ON
GENDERER OR SEX-RELATED
DIFFERENCE.
A STUDY FOUND THAT MEDICAL
STUDENTS HAVE A STRONG DESIRE
FOR SEX AND GENDER-SPECIFIC
TRAINING HOWEVER, LESS THAN HALF
FEEL PREPARED TO APPLY KNOWLEDGE
CLINICALLY.
THE IMPLICATIONS OF THIS DEARTH
OF TRAINING ARE WIDE RANGING.
COORDINATED EFFORTS HAVE BEEN
IDENTIFIED AS CRUCIAL TO MOVING
THE NEEDLE ON SEX AND GENDER
SPECIFIC TRAINING FOR
INDIVIDUALS AT ALL CAREER STAGES
IN HEALTH-RELATED FIELD.
I WOULD LIKE TO TURN TO
INTERPROFESSIONAL EDUCATION
EFFORTS.
OUR PROGRAM IS CURRENTLY PRICED
OF FIVE OFFERINGS.
FIRST IS BENCH TO BEDSIDE
INTEGRATING SEX AND GENDER TO
IMPROVE HUMAN HEALTH DEVELOPED
IN PARTNERSHIP WITH THE FDA
OFFICE OF WOMEN'S HEALTH AND
COURSE EXAMPLES FROM BASIC
SCIENCE THROUGH CLINICAL TRIALS
AND TRANSLATION INTO SCIENCE TO
PROVIDE AN UNDERSTANDING OF THE
IMPORTANCE OF CONSIDERING THE
INFLUENCE OF SEX AND GENDER
ACROSS THE RESEARCH SPECTRUM AND
BEYOND.
THROUGH THE MODULE THE COURSE
FOCUSES ON KEY HEALTH CONDITIONS
ON WHICH SEX AND GENDER HAVE AN
IMPACT.
THE MODULES ARE SHOWN HERE AND
IMMUNOLOGY, CARDIOVASCULAR
DISEASE AND PULMONARY DISEASE
AND MENTAL HEALTH.
AS DR. CLAYTON ANNOUNCED
EARLIER, WE ARE THRILLED TO
SHARE WITH YOU THE NEWS THAT
THROUGH THE JOINT PROVIDERSHIP
OF JOHNS HOPKINS SCHOOL OF
MEDICINE AND NIH THEY DESIGNATED
BENCH TO BEDSIDE FOR CREDITS AND
OTHERS ARE THE NATIONAL
CERTIFICATION PROGRAM AND THE
NATIONAL COMMISSION ON VERT
FICTION OF PHYSICIAN ASSISTANTS
SO WE'RE EXCITED ABOUT THAT
DEVELOPMENT.
WHEN THE CME LAUNCHED LAST MONTH
WE BUILT SURVEYS BUILT IN THE
AND THEY'LL TRACK LEARNERS'
ATTITUDES AND KNOWLEDGE ABOUT
SEX AND GENDER AND USED FOR
ONGOING PROGRAM EVALUATION.
AND THE SECOND IS THE NATIONAL
INSTITUTE OF SCIENCES AND THE
PRIMER INCLUDES FOUR INTERACTIVE
MODULE WALK USERS HOW TO
CONSIDER SEX AS A BIOLOGICAL
VARIABLE IN THE SPECTRUM.
THE FOUR MODULES OF THE COURSE
CLARIFY THE REQUIREMENT OF THE
NIH, SABV POLICY AS WELL AS
ADDRESSING MONTHS AND PERCEIVED
CHALLENGES TO IMPLEMENTATION.
WE HAD A COURSE DESIGNED FOR THE
RESEARCH COMMUNED AND
RESEARCHERS AND GRANT APPLICANTS
AND TRAINING TO ACCOUNT FOR AND
TEACH THE SABV POLICY.
THE COURSE HAS SIX MODULES THAT
COVER A RANGE OF TRAINING
SETTINGS INCLUDING IN PERSON
TRAINING AND ENVIRONMENT
TRAINING AND ONE-ON-ONE
TRAINING.
AND SEX AND GENDER RELATED
DIFFERENCES IN HEALTH A TRAINING
THAT'S A POWER POINT WITH AN
ACCOMPANYING FACILITATOR'S GUIDE
FOR INDIVIDUAL OR GROUP
TRAININGS AND THE MATERIALS
PRESENT CONCEPTS INCLUDING THE
PERSPECTIVES OF GENDER AND
CONSISTENT AND ACCURATE
TERMINOLOGY AND REQUIREMENTS
RELATED TO SEX AND GENDER.
I'LL SPEAK ABOUT UPDATES IN
PROGRESS FOR THIS TRAINING ON
THE NEXT SLIDE.
WE ALSO CURATE AND MAINTAIN A
LIST OF RESOURCES FROM ACROSS
NIH AND HHS AND NON-FEDERAL
RESOURCES.
THE INTRODUCTORY TRAINING IS
CURRENT LLY UNDERGOING A REVISION
AND ADDING CONTENT THAT
ELABORATES ON THE MULTIPLE
DOMAINS OF GENDER INCLUDING
GENDER IDENTITY AND NORMS AND
ROLES, GENDER RELATIONS AND
GENDER INEQUITY.
WE'RE ALSO EXPANDING THE
TRAINING DISCUSSION OF
INTERSECTIONALITY AND SOCIAL
DETERMINATES OF HEALTH AND
ADDING CONTENT ON FEMALE
SPECIFIC CONDITION AND RECENT
ADVANCES AND NOTABLE
PUBLICATIONS ON SEX DIFFERENCES
AND HEALTH.
WE EXPECT TO COMPLETE THE
CONTENT REVISION THIS SUMMER AND
WILL SHARE THOSE AS THEY'RE
AVAILABLE.
I'M PLEAD TO REPORT OUR CURRENT
EFFORTS HAVE WIDE APPEAL AND
BROAD REACH.
AS OF MARCH 1, OVER 1600
INDIVIDUALS HAVE REGISTERED FOR
A COURSE VIA THE ORWH COURSE
DASHBOARD.
NEARLY 600 LEARNERS HAVE STARTED
OR COMPLETED A MODULE OF THE
SABV PRIMER AND SOME HAVE TARTED
THE MODULE OF BENCH TO BEDSIDE.
LEARNERS HAVE AFFILIATION IN 48
COUNTRIES.
WE'RE EXCITED TO SEE THE HIGH
LEVEL OF INTEREST IN OUR E
LEARNING EFFORTS AND A WANT TO
EXPRESS OUR GRATITUDE TO THE
AUTHORIZE AND THE STAFF THAT
CONTRIBUTED TO THIS PROGRAM.
OPPORTUNITIES TO EXPAND OUR
PROGRAM REMAIN.
WE RECEIVED NEARLY 250 COMMENTS
IN RESPONSE TO THE REQUEST FOR
INFORMATION PUBLISHED PRIOR TO
ADVANCING NIH RESEARCH ON THE
HEALTH OF WOMEN, A 2021
CONFERENCE.
ONE IN FIVE COMMENTERS
IDENTIFIED PROVIDER TRAINING AS
AN PRIORITY FOR ADVANCING THE
HEALTH OF WOMEN.
A PATIENT TESTIMONY INCLUDED
THAT DOCTORS NEED TO BE TRAINED
IN LISTENING TO AND CARING FOR
WOMEN WITH CHRONIC ISSUES.
A PROVIDER GROUP COMMENTED,
QUOTE, WHILE I AM PROVING THE
CARE DELIVERED TO ALL PATIENTS
WHO PRESENT TO THE EMERGENCY
DEPARTMENT WILL IMPROVE CARE FOR
WOMEN, SPECIAL ATTENTION SHOULD
BE PAID TO SEX AND GENDER
DIFFERENCES IN HEALTH AND
DISEASE BETWEEN INDIVIDUALS AND
ACROSS POPULATIONS THROUGHOUT
THE HEALTH EDUCATION CONTINUUM.
FINALLY, IN ORDER TO CREATE A
SUSTAINABLE PIPELINE FOR WOMEN'S
HEALTH RESEARCH DEDICATED
RESOURCES AND TRAINING
MECHANISMS SHOULD BE DEVELOPED
TO ENGAGE THE NEXT GENERATION OF
LEADERS IN SCIENCE AND MEDICINE
COGNIZANT OF THE BIOLOGICAL AND
SOCIAL DETERMINATES OF HEALTH
IMPARTED BY SEX AND GENDER.
AS ONE EFFORT TO ADDRESS THE
IDENTIFIED GAPS I'LL INTRODUCE
GALVANIZING HEALTH EQUITY
THROUGH NOVEL AND DIVERSE
EDUCATIONAL RESOURCES OR GENDER.
THE OBJECTIVE IS TO SUPPORT THE
DEVELOPMENT OF COURSES FOR
SKILLS DEVELOPMENT AND CURRICULA
AND METHOD RELATED TO SEX AND/OR
GENDER.
THE TARGET AUDIENCE FOR COURSES,
CURRICULA AND METHOD IS
INTENTIONALLY BROAD AND INCLUDES
INDIVIDUALS AT ANY AND EVERY
CAREER STAGE.
SOME POTENTIAL AUDIENCES ARE
LISTED HERE AND INCLUDE
RESEARCHERS, CLINICIANS AND
HEALTH CARE PROVIDERS,
UNDERGRADUATE STUDENTS, GRADUATE
STUDENTS AND MEDICAL, DENTAL,
VETERINARY, NURSING, PUBLIC
HEALTH AND OTHER ALLIED STUDENTS
AND POST-DOCTORAL FELLOWS AND
MORE.
IN MATERIALS OF DISSEMINATION,
COURSES AND CURRICULA WILL BE
MADE PUBLIC AVAILABLE THROUGH
THE ORWH INTERPROFESSIONAL
EDUCATION PORTAL.
METHOD ARE LISTED HERE AND
INCLUDE MULTI-DIMENSIONAL AND
LIFE-COURSE APPROACHES.
INNOVATIVE METHODOLOGIES AND
ADVOCACY AND COMMUNITY-BASED
EDUCATION AS WELL AS OTHER
TOPICS RELEVANT TO THE TRANS-HIP
TRAFFIC PLAN FOR WOMEN'S HEALTH
RESEARCH.
WE ENGAGED IN DISCUSSION WITH
OUR ICO PARTNERS AND PRESENTED
THIS CONCEPT FOR DISCUSSION AT
THE COORDINATING COMMITTEE ON
RESEARCH ON WOMEN'S HEALTH.
AND FINALLY, BEFORE I CLOSE, I
WANTED TO KALE YOUR ATTENTION TO
A WORKSHOP ORWH WILL BE HOSTING
IN COLLABORATION WITH MANY OF
OUR OCIO PARTNERS OCTOBER 26
THIS YEAR.
THE VIRTUAL SCIENTIFIC WORKSHOP
WILL CONVENE THE COMMUNITY AND
NIH PROGRAM STAFF AND OTHER
STAKEHOLDERS TO DISCUSS METHODS
AND BEST PRACTICES FOR BIOMARKER
AND SOCIO BEHAVIORAL RESEARCH ON
GENDER ROLES AND NORMS AND
GENDER INEQUITY.
THE WORKSHOP EMERGED OUT OF A
SERIES OF NIH ROUNDTABLE
DISCUSSIONS AND THE PLANNING
COMMITTEE INCLUDES ORWH AS WELL
AS REPRESENTATIVES FROM 10
INSTITUTES.
WE LOOK FORWARD TO SHARING
ADDITIONAL DETAILS AS THEY'RE
AVAILABLE.
WITH THAT THANK YOU AND I'M
HAPPY TO ANSWER QUESTIONS AS I
AM ABLE.
>> THANK YOU, DR. BARR.
DR. McGREGOR, DID YOU HAVE
QUESTIONS?
>> THANK YOU FOR THAT.
I FEEL AS SOON AS WE START TO
CATCH UP SEX AS A BIOLOGICAL
VARIABLE IS TANGIBLE AND SO WE
CREATE ALL THE STRUCTURES AND
NOW YOUR WORK IS TRYING TO
INCLUDE GENDER INTO THAT.
I RECENTLY DID A RESEARCH
PROJECT WHERE AS THE BEGINNING
PART OF THE DEMOGRAPHICS I
COLLECT THE DEMOGRAPHICS OF
FACULTY AND STUDENTS IN THE
MEDICAL SCHOOL AND I OFFERED AS
MANY OPTIONS AS POSSIBLE SO IF
SOMEONE IDENTIFIES IN A SPECIFIC
WAY THEY WOULD RECOGNIZE AND SEE
THEIR BOX AND CHECK IT.
WHAT I DISCOVERED WAS THAT THE
STUDENTS AND THAT GENERATION ARE
INCREASINGLY LOOKING AT
THEMSELVES ON THE ENTIRE
SPECTRUM AND MORE VARIABLE.
IT'S NOT JUST MAN WOMEN AND
PEOPLE ARE SAYING THEY SHOULD BE
REFERRING TO BIRTHING PEOPLE TO
UNDERSTAND IT'S EVOLVING BEYOND
BINARY AND THE IT'S ALSO VERY
CHALLENGING TO LOOK AT LOOK AT
REASON WHEN THE TERMS ARE USED
INTERCHANGEABLY.
I THINK THERE NEEDS TO BE A LOT
OF CLARITY AROUND THOSE TERMS
AND FUTURE ORIENTED AND HOW
WE'LL COLLECT DATA IF THERE'S A
SPECTRUM.
I'D LOVE ANY THOUGHTS.
>> THANKS FOR THAT QUESTION.
THOSE ARE REALLY IMPORTANT
ISSUES.
IN TERMS OF THE SEX ORIENTATION
AND GENDER QUESTION OUR
COLLEAGUES ARE DOING EXCELLENT
WORK IN TERMS OF ADVANCING BEST
PRACTICES AROUND DATA COLLECTION
IN THAT REGARD AND WHAT HAS BEEN
SOMETIMES NOT AS PRESENT THOSE
DISCUSSIONS ARE THE OTHER
DOMAINS OF GENDER WITH STRONG
AND PROFOUND IMPACTS ON HEALTH.
THE WAYS CULTURAL AND POLITICAL
FORCES CAN INFLUENCE GENDER
BEHAVIORS AND OPPORTUNITIES AND
THOSE ARE REAL INFLUENCES ON
HEALTH.
THAT WHEN GENDER IS ONLY
UNDERSTAND AS GENDER IDENTITY WE
MISS THE NUANCES OF GENDER NORMS
AND INEQUITIES.
OUR HOPE IS TO CALL ATTENTION TO
THE IMPORTANCE WORK BEING DONE
AND DEVELOP AND IMPLEMENT
PRECISE LANGUAGE BECAUSE IF YOU
THINK ABOUT SEX AS A BIOLOGICAL
VARIABLE WE THINK IT'S NEATER OR
MORE BINARY BUT SEX AS A
BIOLOGICAL BARRIERS INCLUDE
HORMONES ETCETERA DEPENDS ON
GENDER ROLES OR POWER RELATIONS
ARE RELEVANT TO THE STUDY MAY
BUBBLE TO THE SURFACE.
WE'RE HOPEFUL WE CAN SUPPORT A
BROAD RANGE OF EFFORTS TO
ADVANCE GENDER-RELATED RESEARCH.
>> THANK YOU.
THE DIRECTOR OF THE OFFICE IS
WITH US.
DR. PARKER AND I WANTED TO SEE
IF SHE WANTS TO ADD ANYTHING.
>> A COMPLICATED ISSUE AND WE
SAY THAT WORD IN OUR OFFICE
MULTIPLE TIMES A DAY.
WE ALSO KNOW HOW IMPORTANT IT IS
TO ACCURATELY CAPTURE FOLKS IN
OUR STUDIES.
FOR THOSE WHO HAVEN'T HEARD,
SGMRO WITH 18 OF OUR OTHER
COLLEAGUES AT NIH INCLUDING THE
OFFICE OF RESEARCH ON WOMEN'S
HEALTH FUNDED IN 2021 A REPORT
OUT OF THE NATIONAL ACADEMIES OF
SCIENCE, ENGINEERING AND
MEDICINE AND LOOK HOW TO BEST
MEASURE GENDER IDENTITY AND
SEXUAL ORIENTATION.
THAT REPORT CAME OUT EARLIER IN
THE MONTH AND I'LL PUT THAT
REPORT IN THE CHAT.
THE EVIDENCE WAS REVIEWED AND
ONE MAIN CONCERN AS THEY WORK
WORKING ON THE REPORT WAS
THINKING ABOUT OUR NEEDS HAVING
TO DO WITH CLINICAL SPACES NOT
JUST AT NIH BUT HOPING IT WILL
INFORM OTHER FEDERAL AGENCY.
ONE MAIN CONCERN WAS ADDRESSING
THE QUESTIONS BEING RECOMMENDED
ARE QUESTIONS THAT CAN BE
UNDERSTOOD BY THE GENERAL
POPULATION.
WE KNOW THERE'S HUGE SHIFTS.
A RECENT GALLUP POLL SHOWED GEN
Z I THINK FOLKS BORN AFTER '96
OR '99 MOST IDENTIFIED AS A
SEXUAL OR GENDER MINORITY.
BECAUSE WE'RE SEEING THE HUGE
DEMOGRAPHIC SHIFT WE KNOW THERE
ARE REAL CHALLENGES BUT WHEN YOU
ASK THE QUESTIONS ON SURVEYS IF
THE GENERAL POPULATION OF
CISGENDER AND STRAIGHT FOLKS
DON'T UNDERSTAND THE QUESTION, A
LITTLE BIT OF ERROR CAN CAUSE
SERIOUS PROBLEMS IN DATA
ANALYSIS AND WE'RE WORKING WITH
OTHER DEPARTMENTS TO THINK HOW
BEST TO IMPLEMENT THE
RECOMMENDATIONS COMING OUT OF
THE ACADEMIES BUT IN PARTICULAR
WE'RE INTERESTED IN THE FURTHER
NEEDS TO HAPPEN AND LAYS OUTS
OPPORTUNITIES HOW TO DO THIS
BEST.
I HOPE FOLKS CHECK OUT THE
REPORT.
IF YOU HAVE QUESTIONS WE'RE
ALWAYS HAPPY TO CHAT WITH FOLKS.
>> THANK YOU.
I HOPE THIS ANSWERS YOUR
QUESTION.
ARE THERE ANY OTHER QUESTIONS
FOR DR. BARR REGARDING THE
CONCEPT THAT SHE SHARED WITH US?
DR. ROBINSON, DID YOU HAVE A
QUESTION FOR DR. BARR?
>> YES, THANK YOU FOR SHOWING US
SO MANY RESOURCES.
IT LOOKED VERY COMPREHENSIVE AND
THANK YOU DR. BARR.
MY QUESTION ABOUT THE RESOURCES.
ARE THEY MEANT TO BE CUMULATIVE
IN NATURE?
DID THE KNOWLEDGE BUILD ON EACH
OTHER OR MORE MEANT FOR DISCREET
KNOWLEDGE AND CONTENT.
I'LL GO TO THIS MODULE OR CAN
YOU BUILD ON YOUR KNOWLEDGE AND
BE CERTIFIED AFTER YOU'VE GONE
THROUGH A CERTAIN NUMBER OF
MODULES?
>> THERE'S A BEAUTIFUL VISION TO
HAVE A WOMEN'S HEALTH
CERTIFICATION.
PRESENT
PRESENTLY IT'S A SLIGHTLY
DIFFERENT AUDIENCE.
IF YOU'RE INTERESTED IN
IMMUNOLOGY, THAT MAY BE THE ONLY
MODULE YOU COMPLETE AND WOULDN'T
HAVE REASON TO REVIEW THE MENTAL
HEALTH MODULE, FOR EXAMPLE.
SIMILARLY EACH MODULE IS
INDEPENDENT WITH THE TRAIN THE
TRAINERS THOUGH THAT RESEARCH IS
RELEVANT FOR TEACHING THE SABV
POLICY BUT GENERALLY IN THE
COVID-19 ERA AS MANY FOLKS HAVE
HAD TO REFRESH THEIR ONLINE
TEACHING SKILLS THERE'S BEST
PRACTICES THAT COULD BE DRAWN ON
SO EACH COURSE HAS A SLIGHTLY
DIFFERENT AUDIENCE BUT WE TRY TO
WEAVE THROUGH WITH THE
FOUNDATIONAL PRINCIPLES THAT GID
OUR WORK.
>> THANK YOU.
>> THANK YOU, DR. BARR AND
ROBINSON.
WE HAVE A FEW MORE MINUTES FOR
ADDITIONAL QUESTIONS IF THERE
ARE ANY.
>> I HAVE A COMMENT.
>> SURE, DR. GELLAR.
>> I THINK ALL OF US THINK ABOUT
THIS A LOT THESE DAYS AND I
THINK ACKNOWLEDGING THIS WHEN
WRITING PAPERS OR DOING TALKS OR
ANY KIND OF PUBLICATION THAT
ACKNOWLEDGING IT IN SOME WAY AND
NOT SURE ANY OF US KNOW THE
RIGHT ANSWER BUT THE AWARENESS
AND COMPLEXITY IS IMPORTANT.
IF I'M DOING -- I DO WORK IN
MATERNAL HEALTH AS MANY OF YOU
KNOW.
IF I'M DOING SOMETHING THAT'S
STAND ALONE SO AS NOT TO INCLUDE
I SAY PREGNANT PERSONS.
IF I'M DOING A TALK, I MAY TALK
ABOUT IT DIFFERENTLY BUT I CAN
ACKNOWLEDGE IT IN THE TALK AND
HAVE A CONVERSATION I WE'RE ALL
TRYING TO FIGURE THIS OUT BUT
I'M GLAD WE'RE TALKING ABOUT IT
SO THANKS.
>> DID YOU WANT TO SAY ANYTHING
IN RESPONSE?
>> THANK YOU FOR THAT COMMENT.
I AGREE THAT LANGUAGE AS
SCIENTIFIC CHANGES CONTINUE AND
GENDER PARTICULARLY AS A SOCIAL
CONSTRUCT CAN VARY ACROSS
CULTURES, CONTEXT AND TIMES.
WE LIVE AN CULTURE CONTEXT TO
TIME SO THERE CAN BE VARIATION
WITHIN OUR OWN LIVES IN THE WAYS
WE TALK ABOUT GENDER.
AND SO I AGREE THAT
ACKNOWLEDGING AND DOING THE BEST
THAT WE CAN TO USE PRECISE
WELL-CONTEXTUALIZED LANGUAGE AS
APPROPRIATE.
>> THANK YOU, ELIZABETH.
I SEE DR. REGENSTEINER WANTS TO
SAY SOMETHING.
>> I HAVE A QUESTION AND I
ALWAYS WANT TO BE INCLUSIVE BUT
ACCORDING TO SEX AS A BIOLOGICAL
VARIABLE THERE'S WOMEN AND MEN
WHO ARE VERY DIFFERENT GENDERS.
I'M STRUGGLING A BIT AND WANT TO
BE INCLUSIVE BUT SEX IS A
BIOLOGY AND WITH GENDER THERE
ARE MANY DIFFERENT GENDERS
POTENTIALLY SO HOW DO WE TALK
ABOUT THAT AND WE MAIN INCLUSIVE
BUT CORRECT IN OUR USE OF SEX
AND GENDER?
>> THAT YOU.
THAT'S AN ISSUE WE COVER IN THE
INTRODUCTORY TRAINING AS TO THE
RESOURCES LINKED FOR EXAMPLE,
THERE'S A NICE JOB EXPLAINING
WHEN TO USE WHICH TERMS SO
GENERALLY IF YOU'RE TALKING
ABOUT A SOCIAL OR CULTURAL
VARIABLE, YOU WOULD WANT TO USE
GENDER TERMS AND THE CANADIAN
RESEARCH FACILITY HAS FANTASTIC
TRAININGS.
IN TERMS OF GENDER IDENTITY OF
WIDELY AFFECTED BEST PRACTICES
TO USE THE LANGUAGE THE PATIENT
USES IF THAT'S THE LANGUAGE USED
TO DESCRIBE THEM.
IN TERMS OF THE OTHER GENDER
VARIABLES LIKE GENDER NORMS OR
GENDER POWER RELATIONS, THERE
ARE AS DR. CLAYTON NOTED, NEWLY
EMERGED WELL-VALIDATED MEASURES
TO EVALUATE SOME OF THOSE
STRUCTURAL SEXISM OR THE IMPACT
PARTICULARLY ON A GLOBAL HEALTH
SETTING OF GENDER INEQUITIES ON
HEALTH.
AS THOSE CAN BE ADOPTED AND
ADAPTED FOR OTHER CONTEXT THEY
CAN GIVE LANGUAGE TO GENDER
BEYOND GENDER IDENTITY.
>> THANK YOU.
THERE ARE 12 COMMENTS IN THE
CHAT.
>> I CAN ASK DR. TEMPLETON WHAT
SHE HAS TO SAY.
>> THIS IS A CRITICALLY
IMPORTANT ISSUE.
EVEN IN AREAS WE SEE MORE AND
MORE SUCH AS HEALTH CARE
PROFESSIONAL BURNOUT.
A LOT OF THE DRIVERS OF BURNOUT
AS THOUGH PROFESSIONALS DON'T
FEEL THEY LOCK IN THE WORKPLACE
AND FACE MICROAGGRESSION AS WE
LOOK AT STUDIES OF HEALTH CARE
OR PHYSICIAN BURNOUT YOU HAVE TO
INCLUDE WHEN YOU'RE ASKING ABOUT
THEIR GENDER, YOU HAVE TO
INCLUDE THE SPECTRUM BECAUSE IF
YOU DON'T YOU'LL BE MISSING A
LOT AND MANY PRIOR STUDIES OF
BURNOUT DIDN'T LOOK AT
DIFFERENCES BETWEEN A MAN AND A
WOMAN AND WE GOT BEYOND THE
POINT OF ASKING BEYOND THAT BUT
BE MORE INCLUSIVE.
>> THANK YOU VERY MUCH.
KAREN, DID YOU WANT TO ADD
ANYTHING?
DR. PARKER?
DO YOU WANT TO ADD ANYTHING TO
THAT?
>> SEX ISN'T ALWAYS AS NEAT AS
WE WANT IT TO BE AND IT'S NOT
ALWAYS A BINARY CONSTRUCT.
>> THANK YOU.
UNLESS WE HAVE ANY OTHER
COMMENTS OR QUESTIONS, I'D LIKE
TO MOVE ON TO VOTE ON THE
CONCEPT.
ANY COMMENTS, QUESTIONS?
ALL RIGHT.
AT THIS TIME WE'LL MOVE ON TO
VOTE APPROVE THE CONCEPT
CLEARANCE FOR THE GALVANIZING
HEALTH REQUEST THROUGH NOVEL AND
DIVERSE EDUCATIONAL RESOURCES
GENDER.
IS THERE A MOTION TO APPROVE THE
CONCEPT CLEARANCE?
>> SO MOVED.
MICHELLE ROBINSON.
>> SECOND.
>> DR. TEMPLETON SECONDED THE
MOTION.
WE'RE OPENING A POLL.
INDICATE IF YOU'RE IN FAVOR,
OPPOSED OR ABSTAIN AND HAVE YOU
30 SECONDS.
>> YOU HAVE 13 IN FAVOR.
>> IT'S BEEN ACCEPTED WITH 13 IN
FAVOR.
THANK YOU EVERYONE AND DR. BARR.
NOW I'D LIKE TO WELCOME BACK
DR. TEMKIN FOR THE FINAL
CLEARANCE CONCEPT CLEARANCE
PRESENTATION THIS AFTERNOON.
>> THANK YOU.
I'M GOING TALK ABOUT THE U3
RESEARCH PROGRAM EXPANSION TO
EMPHASIZE UNDER STUDIED
CONDITIONS RELEVANT TO THE
HEALTH OF WOMEN.
THE U3 SUPPLEMENT PROGRAM HAS
BEEN AN ORWH SIGNATURE PROGRAM
SINCE 2017 AND IT'S PURPOSE IS
TO SUPPORT RESEARCH THAT'S
FOCUSSED ON POPULATIONS OF WOMEN
WHO ARE UNDER STUDIED AND UNDER
REPRESENTED AND UNDER REPORTED.
THE PURPOSE OF THIS CONCEPT I'M
GOING DISCUSS NIS AFTERNOON IS
TO EXPAND ORWH PROGRAMMING FOR
SUPPORT FOR WOMEN IN CONDITIONS
UNDER STUDIED AND THIS ALIGNS
WITH THE STRATEGIC PLAN GOAL
NUMBER 1 TO ADVANCE RIGOROUS
RESEARCH RELEVANT TO THE HEALTH
OF WOMEN AND OBJECTIVE 1.5.
TO EXPAND THE RESEARCH ON FEMALE
SPECIFIC CONDITIONS AND DISEASES
INCLUDING REPRODUCTIVE STAGES
AND MATERNAL AND GYNECOLOGIC
HEALTH.
THE U3 FRAMEWORK IN WHICH THE
SUPPLEMENT PROGRAM WAS DESIGNED
WAS DEVELOPED TO DRAW ATTENTION
TO THE LACK OF RESEARCH ON
PERSISTENT DISPARITIES IN
WOMEN'S HEALTH AND HEALTH CARE
AND TO SUPPORT RESEARCH AND
EVIDENCE-BASED PROGRAMS AND
EXPLOSION THE WAYS IN WHICH
SOCIAL DETERMINATE DETERMINATIONS AFFECT
COMMUNITY.
THIS PROGRAM OVER THE LAST FOUR
YEARS HAS SUPPORTED RESEARCH ON
MANY UNDER STUDIED CONDITIONS.
THE NUMBER OF PROGRAMS THAT HAVE
BEEN SUPPORTED BETWEEN FY17 AND
FY21 IS 71 AND AS YOU CAN SEE
FROM THE MAP THE PROGRAMS HAVE
BEEN SUPPORTED IN GEOGRAPHICALLY
DIVERSE LOCATIONS AND WITH A
DIVERSE SET OF INVESTIGATORS.
THE PROJECTS THAT HAVE BEEN
FUNDED HAVE BEEN FUNDED WITH
SUPPORT FROM 16 I.C.s AND IN
FY21 THERE WERE 12 APPLICATIONS
FUNDED WITH SUPPORT FROM NINE
INSTITUTES AND CENTERS.
AN ADDITION TO BUILDING ON THE
U3 FRAMEWORK THE GOAL WAS TO
BUILD ON LAST YEAR'S WOMEN'S
HEALTH CONFERENCE.
RISING RATES OF CHRONIC
DEBILITATING CONDITIONS WAS
IDENTIFIED BY CONGRESS WAS
ADDRESSED BY WOMEN'S HEALTH
RESEARCH.
ONE IDENTITY IDENTIFIED WAS
INTENTIONAL RESEARCH THAT IS
CENTERED ON THE NEEDS OF WOMEN.
THIS SLIDE SHOWS IN MORE DETAIL
BY THE CMS CENTERS FOR MEDICARE
SERVICES DEFINITION, THERE ARE
SEVERAL CONDITIONS THAT COMMON
AMONGST WOMEN THAN MEN INCLUDING
ARTHRITIS, DEMENTIA AND
OSTEOPOROSIS AND ASTHMA AND THE
RED ARROWS INDICATE THE HIGHER
PREVALENCE AMONG FEMALES.
WE SPENT A FAIR AMOUNT OF TIME
TALKING ABOUT MULTI-MORBIDITY OR
THE CO-OCCURRENCE OF TWO OR MORE
CHRONIC DISEASES IN ONE
INDIVIDUAL WHICH IS ALSO MORE
COMMON IN WOMEN.
WOMEN ARE LIKELY TO ONE CHRONIC
CONDITION AND PARTLY THIS MAY BE
EXPLAINED BY INCREASED LONGEVITY
FOR WOMEN AND WOMEN'S SYMPTOMS
ARE OFTEN DESCRIBED AS ATYPICAL
WHICH MAY RESULT IN DIAGNOSTIC
DELAYS AND ULTIMATELY POORER
RESPONSES TO FIRST-LINE
TREATMENTS.
AND INTERACTIONS BETWEEN
CONDITIONS AND THE DEVELOPMENT
OF MULTI-MORBIDITY ARE POORLY
UNDERSTOOD IN WOMEN AND WE KNOW
THAT THE NETWORKS OF MORBIDITIES
AND DIAGNOSES ARE DIFFERENT IN
WOMEN THAN IN MEN.
IN CONSIDERING THE U-3
POPULATIONS AND DEBILITATING
CONDITIONS THERE'S MULTIPLE
INTERSECTIONS.
RACE INFLUENCES THE INCIDENTS OF
MORBIDITY AND BLACK WOMEN HAVE
SIGNIFICANTLY HIGHER RATES OF
CARRYING A DIAGNOSIS OF THREE OR
MORE CHRONIC CONDITIONS COMPARED
TO ANY OTHER RACIAL GROUP THAT
WAS LOOKED AT IN THIS
PUBLICATION.
THIS IS ONE OF THE ONLY
PUBLICATION THAT DISAGGREGATES
BY RACE AND PREVALENCY OF
DISEASE AND IN OUR SNAPSHOT OF
NIH ACTIVITIES OF CHRONIC
CONDITIONS WE DID SEE ACTIVITY
SUPPORTING RESEARCH IN WOMEN.
HOWEVER, SUPPORT FOR CONDITIONS
WAS VARIED BETWEEN CONDITIONS
AND ACROSS UNDER THE INSTITUTES
AND CENTER AND THE NEEDS OF
WOMEN WAS LIMITED AND VIEWED
PROJECTS ON WOMEN AND -- FEW
PROJECTS ON MULTIMORBIDITY WERE
IDENTIFIED AND WHAT THE PUBLIC
COMMENTED FREQUENTLY ON IN
RESPONSES TO OUR REQUEST FOR
INFORMATION AROUND THE WOMEN'S
HEALTH CONFERENCE OF THE 247
COMMENTS RECEIVED, 182 MENTIONED
CHRONIC DEBILITATING AND FEMALE
SPECIFIC DISEASES FOLLOWED BY
THOSE THAT ARE POTENTIALLY UNDER
STUDIED AND THOSE MOST COMMON IN
WOMEN WITH THE FEWEST NUMBER OF
COMMENTS ON CONDITIONS WITH HIGH
MORBIDITY IN WOMEN.
ON THE SLIDE WE SEE THE MOWORDS
WERE ENDOMETRIOSIS, FIBROIDS AND
MENSTRUATION AND MENOPAUSE AND
FOR DISORDERS MORE COMMON IN
WOMEN WITH GREATER MORBIDITY IN
WOMEN WERE MENTAL HEALTH,
AUTOIMMUNE DISEASE AND HPV AND
TRAU
TRAUMA.
FOR THOSE DISEASES POTENTIALLY
UNDER STUDIED OUT WAS PAIN,
ENVIRONMENTAL EXPOSURES,
COVID-19 AND INFECTION.
AND AMONGST CONDITIONS THAT HAVE
HIGH MORBID AMONGST WOMEN, THE
MOST FREQUENTLY USED TERMS WERE
HEART DISEASE, SUBSTANCE USE,
HYPERTENSION AND OBESITY.
ON THE DAY AFTER THE WOMEN'S
HEALTH CONFERENCE THE ADVISORY
COMMITTEE MET AND SUMMARIZED THE
PROCEEDINGS AND VOTED ON THIS
SET OF OPPORTUNITIES FOR NIH
RESEARCH ON CHRONIC DEBILITATING
CONDITIONS AMONGST WOMEN.
I HILTED SEVERAL THAT RESEARCH
SCHAUBED LINED WITH THE NEEDS OF
WOMEN AND THAT INCLUDES STUDY
OBJECTIVES AND END POINTS AND
THERE COULD BE AN INCREASE IN
RESEARCH ACTIVITY SPECIFIC TO
DISEASES THAT ARE FEMALE FIFK
AND MEN PAUSE AND AGING AND
RESEARCH COULD BE ENCOURAGED
AROUND MULTIMORBIDITY IN WOMEN.
OVER THE FOUR YEARS OF THE U3
SUPPLEMENT PROGRAM, ACTUALLY
THERE HAS BEEN A FAIR AMOUNT OF
SUPPORT AMONGST THE 71 SUPPORTED
PROJECTS FOR MANY OF THESE
CONDITIONS THAT ARE UNDER
STUDIED AMONGST WOMEN.
AND LISTED HERE ARE SUBJECTS
THAT HAVE BEEN SUPPORTED ON
MENOPAUSE, TRAUMA AND MENTAL
HEALTH, MUSCULOSKELETAL DISEASE
AND MULTIMORBIDITY AND
FEMALE-SPECIFIC CONDITIONS AND
INFLAMMATION AND IMMUNITY.
AND WE'RE LOOKING AT CONDITIONS
RELATIVE TO THE HEALTH OF WOMEN
USING THE U3 FRAMEWORK WHICH WAS
DEVELOPED FOR THE SUPPLEMENT
PROGRAM AND DEVELOP A NEW
FUNDING OPPORTUNITY TO SUPPORT
RESEARCH ON UNDER STUDIED
CONDITIONS THAT AFFECT WOMEN.
THE SPECIFIC CONDITIONS OF
INTEREST INCLUDE MENOPAUSE,
MUSCULOSKELETAL DISEASE,
INFLAMMATION AND IMMUNITY AND
FEMALE-SPECIFIC CONDITIONS AND
AS WE HOPEFULLY DEMONSTRATED,
THESE ARE BUILDING UPON OUR OWN
EXPERIENCE WITH OUR U-3
SUPPLEMENT PROGRAM AS WELL AS
THE CURRENT REVIEW OF THE NIH
ACTIVITY IN THE SPACE AND THE
PUBLIC COMMENTS.
WE'D LIKE TO ENCOURAGE
PARTICIPATION OF U3 POPULATIONS
AND SUPPORT IN THE POPULATIONS
WITH THE HIGHEST BURDENS OF
UNDER STUDIED CONDITIONS.
OUR PLAN WITH THIS PROPOSAL IS
TO PARTNER WITH INTERESTED
INSTITUTES AND CENTER AND
ENCOURAGE RESEARCH ON THE
CONDITIONS WHICH HAVE BEEN
IDENTIFIED AS UNDER STUDIED AS
WELL AS ON POPULATIONS THAT
TRADITIONALLY HAVE FALLEN INTO
THE U3 DEFINITION.
I'M HAPPY TO TAKE ANY QUESTION
OR COMMENTS ON THIS PROPOSAL.
>> FEEL FREE TO UTILIZE THE
CHAT.
>> GREAT PRESENTATION AND AN
IMPORTANT PROJECT.
I JUST WANTED TO CLARIFY
SOMETHING AND MAYBE IF I DIDN'T
UNDERSTAND, I'M SORRY.
THE CROSS SECTION BETWEEN
FEMALE-SPECIFIC CONDITIONS AND
OTHER CONDITIONS SUCH AS
INFLAMMATION AND IMMUNITY, YOU
TALKED ABOUT CHRONIC CONDITIONS
BUT THESE TWO INTER SESECT
INFLAMMATION IS A MORE CHRONIC
CONDITION AND WHEN INFLAMMATION
WORSENS DUE TO PREGNANCY BECAUSE
OF BIOLOGY WOULD THAT QUALIFY TO
BE PART OF THE U3 PROJECT OR
NOT?
>> I'LL TAKE A STAB AT THIS AND
THANK YOU FOR THE QUESTION.
THE ORIGINAL FRAMEWORK FOR THE
U3 SUPPLEMENT PROGRAM DID
INCLUDE PREGNANCY RELATED
RESEARCH AND THERE'S BEEN A FAIR
AMOUNT OF FUNDING FOR PREGNANCY
RELATED CONDITIONS IN
POPULATIONS UNDER STUDIED AND
UNDER REPRESENTED AND UNDER
SERVED.
IN BUILDING THE WOMEN'S HEALTH
CONFERENCE CONDITIONS WERE A
SEPARATE CATEGORY THAN
PREGNANCY.
THOUGH WE CAN HAVE A LONG
CONVERSATION ABOUT PREGNANCY
LASTING TO ONE-YEAR POST PARTUM,
WE DEFINED THOSE CHRONIC
CONDITIONS AS LASTING OVER ONE
YEAR AND SO WE CAN HAVE A
DISCUSSION TO INCLUDE PREGNANCY
IN THE PROGRAM HOWEVER, I DON'T
THINK THAT WAS THE ORIGINAL --
THE WAS THE IDEA OF THIS.
>> I JUST THINK IF YOU DON'T
THINK IT'S THE RIGHT IDEA IT
SHOULD BE INCLUDED SPECIFICALLY
>> THE SPECIFIC CONTEXT OF
PREGNANCY YOU WERE ASKING WOULD
THAT BE EXCLUDED FROM THE NEW
FUNDING OPPORTUNITY?
>> SHE WAS TALKING ABOUT FIVE
CONDITIONS IN ONE OF HER SLIDES
AND I DON'T CALL MY QUESTION IS
INTERSECTS WITH INFLAMMATORY
DISEASE AND MANY IMMUNE
DISORDERS WORSENS OR IMPROVES
DURING PREGNANCY AND IF YOU WANT
TO EXCLUDE IT OR NOT IT'S FINE.
>> I APPRECIATE THAT AND LOOKS
LIKE SARAH WANTS TO RESPOND.
>> I THINK THE LIST OF
CONDITIONS IS NOT MEANT TO BE
EXHAUSTIVE OR EXCLUSIVE.
THOSE ARE THE CONDITIONS WE
IDENTIFIED IN THE WOMEN'S HEALTH
ACTIVITIES AND FROM PUBLIC
COMMENTS AS SPECIFIC PLACES OF
NEED.
IF AN INVESTIGATOR WERE ABLE TO
MAKE A PROVIDER RATIONALE BY A
PREGNANCY RELATED RESEARCH
PROJECT MAY FIT THE DEFINITION.
I WOULD NOT PLAN TO SPECIFICALLY
EXCLUDE IT.
>> CONSISTENT WITH THE LIFE
COURSE PERSPECTIVE WE HAVE FOR
THE HEALTH OF WOMEN, DISSECTING
THE STAGES LIKE THAT IS NOT HOW
WE LIVE OUR LIVES.
EVERYTHING THAT WE HAVE BEFORE
AFFECTS OUR HEALTH AND THE MORE
WE CAN HAVE A MORE INTEGRATED
FRAMEWORK AS DR. GIBBON SAID
EARLIER HAVE THE OPPORTUNITY TO
INTERRUPT OR PREVENT THAT'S A
POU
POWERFUL APPROACH.
>> WE'RE IN GOOD TIME IF THERE
ARE ANY QUESTIONS TO DR. TEMKIN,
BEFORE WE MOVE ON TO VOTE, THIS
IS A GOOD TIME TO ASK.
I DON'T SEE ANYTHING IN THE
CHAT.
THANK YOU FOR YOUR QUESTION.
WE CAN MOVE ON.
WE WILL MOVE ON TO THE VOTE TO
APPROVE THE CONCEPT CLEARANCE
FOR THE ORWH U3 RESEARCH PROGRAM
EXTENSION TO EMPHASIZE UNDER
STUDIED CONDITIONS RELEVANT TO
THE HEALTH OF WOMEN.
IS THERE A MOTION ON THE TABLE
TO APPROVE THE CONCEPT CLEARANCE
FOR THE ORWH PROGRAM EXTENSION
TO EMPHASIZE UNDER STUDIED
CONDITIONS RELEVANT TO THE
HEALTH OF WOMEN?
>> SO MOVED.
>> THE MOTION IS SUBMITTED.
DO I HEAR A SECOND?
>> SECOND.
>> THANK YOU, DR. ANDERSON.
THE POLL HAS NOW BEEN RESPOND.
YOU HAVE 30 SECONDS.
>> 12 IN FAVOR.
>> THE CONCEPT CLEARANCE HAS
BEEN ACCEPTED WITH 12 IN FAVOR.
THANK YOU.
THANK YOU, DR. TEMKIN.
I'D LIKE TO TURN IT BACK TO THE
CHAIR OF THE COMMITTEE,
DR. JANINE CLAYTON.
>> THANK YOU SO MUCH, SAMIA.
THANK YOU, EVERYONE.
ALL THE PRESENTERS FOR THE CON
CONSEPTS AND TO THE ADVISORY
MEMBERS FOR ROBUST DISCUSSION.
WE RELY ON YOUR EXPERTISE TO
MAKE SURE WE'RE GOING IN THE
RIGHT DIRECTION AS WE APPRECIATE
THE AWESOME DISCUSSION THIS
AFTERNOON.
NOW IS THE TIME ON THE AGENDA
FOR OPEN DISCUSSION OF ANY
TOPICS AND ISSUES RELATED TO
ORWH WE WANT TO MAKE SURE YOU
HAVE AN OPPORTUNITY TO WEIGH IN.
WE APPRECIATE YOUR SUPPORT OF
THE ADVISORY COMMITTEE FOR THE
RESEARCH ON WOMEN'S HEALTH AT
NIH AND YOU'VE DONE A TREMENDOUS
AMOUNT OF WORK IN THE LAST YEAR
OR SO WITH THE CONFERENCE AND
BIENNIAL REPORT AND WORKING
GROUP.
THE FLOOR IS OPEN.
YOU CAN PUT COMMENTS IN THE CHAT
IF YOU'D LIKE AND YOU CAN ALSO
RAISE YOUR HAND ON ZOOM AND ALSO
TURN YOUR CAMERA ON AND LET US
KNOW YOU HAVE A COMMENT.
>> THANK YOU.
SO ONE THING I HAVE FUND
INTERESTING IN THE PRESENTATIONS
AND THIS GOES BACK TO THE BIRCWH
AND A TABLE SHOWING THERE ARE
TWO INSTITUTES, LET ME KNOW IF
I'M INCORRECT, ENGAGED THIS.
WHEN I THINK OF WHAT A
SUCCESSFUL PROGRAM AND I'M BIAS.
WE HAVE A BIRCWH JOHNS HOPKINS
AND I'D LIKE TO GAIN KNOWLEDGE
ON HOW TO GET THE PROGRAM TO
GROW.
>> IT'S ORWH AND NIDA.
WE'VE HAD SEVERAL I.C.s WHO
SUPPORTED A BIRCWH AWARD HERE
AND THERE.
NIEHS AND OTHERS BUT IT'S A CASE
BY CASE BASIS.
REMEMBER THE PHRASING IS THE
BIRCWH AND TO CONSIDER SEX AND
GENDER IN HEALTH AND DISEASE.
THE MAJORITY ARE WOMEN BUT NOT
ALL WOMEN.
THE TOPICS ARE HIGHLY RANGING.
THE CAREER DEVELOPMENT AWARD.
I THINK THE CONTEXT YOU ARE
TOUCHING UPON IS WHAT
CONSTITUTES WOMEN'S HEALTH
RESEARCH AND WHO FEELS THEY'RE
PART OF WOMEN'S HEALTH RESEARCH
AND MAYBE WHAT ARE IN WOMEN'S
HEALTH RESEARCH.
>> AND WHO OWNS THE TRAINING OF
THE NEXT GENERATION OF
INVESTIGATORS.
>> RIGHT.
AND NOT ALL SUPPORT AND THE
MECHANISM MAY ALSO BE A BARRIER.
FROM THE BIRCWH PERSPECTIVE WE
HAVE SEEN THE MECHANISM WORK
WELL TO PROVIDER THE SUPPORT AND
COHORT AFFECT AND THE CONTINUITY
JUNIOR FACULTY NEED.
IT HAS BEEN EFFECTIVE AND THE
FOLKS ARE GETTING HIGHER RATES
OF RPGs THAN OTHER PROGRAMS AND
DOING WELL.
I AGREE AND WOULD LOVE TO HAVE
THE FLOOR OPEN FOR ANYONE TO
COMMENT BECAUSE THE CRUX OF THE
MATTER SO WHO THINK THEY'RE A
PRIORITY OF WOMEN'S HEALTH
RESEARCH AND DR. TEMKIN SHOWED
YOU THE AMOUNT OF INVESTMENT.
IN TOTAL IT'S ABOUT 10% OF THE
TOTAL NIH BUDGET BUT EVERYONE IS
DOING WOMEN'S HEALTH RESEARCH SO
THEORETICALLY EVERYONE CAN BE
PART OF THE PROGRAM IF THEY SAW
IT THAT WAY.
>> HOW TO LEVERAGE WHAT YOU JUST
SAID TO GIVE MORE OWNERSHIP.
>> DO YOU HAVE AN IDEA OR
THOUGHT?
>> A QUICK COMMENT WHICH IS WHEN
I LOOKED AT THE GRANT OF WHICH
I.C.s ARE DOING WHAT PERCENT OF
WOMEN'S HEALTH RESEARCH, IF THEY
DID SEX-SPECIFIC ANALYSIS IT
WOULD BE 100% UNLESS IT WAS A
SEX-SPECIFIC CONDITION.
WHAT DO WE MEAN BY THEY'RE DOING
WOMEN'S HEALTH RESEARCH?
ARE THEY DOING REPRODUCTIVE
HEALTH RESEARCH?
WHAT CONSTITUTES WOMEN'S HEALTH
RESEARCH.
DO YOU THINK PERFORMING
SEX-SPECIFIC -- DO YOU THINK
SEX-SPECIFIC RESULTS IS WOMEN'S
HEALTH RESEARCH.
REQUIRED FOR PHASE 3 CLINICAL
RESEARCH.
I WOULD ARGUE CREATING
SEX-SPECIFIC RESULTS DOES NOT
CONSTITUTE AND WE WORK WITH THE
27 INSTITUTES AND CENTERS AND WE
THOUGHT ABOUT THIS AND WE DON'T
INCLUDE IN THE UNIVERSE OF
WOMEN'S HEALTH RESEARCH STUDYING
BOTH SEXES IS NOT SUFFICIENT.
I THINK WHAT WE MEAN AND I
THINK -- PLEASE ALLOW HER TO
COME IN THE MEETING.
>> SARAH, SHE MAY BE IN THE
WAITING ROOM.
SHE'S JOINING NOW.
FINISH THE THOUGHT, ALLISON, DO
YOU THINK CONFORMING ANALYSIS
CONSTITUTES WOMEN'S HEALTH
RESEARCH?
>> I THINK IT'S A GREAT
QUESTION.
MY FIRST THOUGHT WAS YES BECAUSE
THAT'S CONTRIBUTING TO
DISCOVERING SEX DIFFERENCES
WHICH WOMEN WILL BENEFIT FROM
LOOKING AT WHY.
MY FIRST THOUGHT WAS YES, IT
WAS.
>> I THINK WE SHOULD PUT THAT IN
THE PARKING LOT BECAUSE IT'S
SOMETHING WE SHOULD COME BACK TO
AS A COUNCIL BUT LET'S LET LET
DR. KLEIN IN.
SHE ALWAYS CHALLENGES US AND
FIND A WAY TO LEVERAGE THE
SUCCESS OF THE BIRCWH AND
ENLARGE THE TENT SO WE HAVE MORE
STAKEHOLDERS AND DISCIPLINES
PLAYING.
>> THANK YOU, EVERYONE, GOOD
AFTERNOON AND THANK YOU,
DRDR.
DR. KLEIN FOR THE QUESTION.
THERE'S EIGHT INSTITUTES AND
CENTERS THAT PARTICIPATE IN
BIRCWH.
WE HAVE TWO RFAs.
IN TERMS OF THE ROUNDS THEY'RE
BASICALLY CONTRIBUTING ABOUT 20%
TO 25% OF OUR FUNDING.
I'D LIKE TO GET THAT CORRECTED.
NICHD IS THE LEAD ADMINISTRATIVE
INSTITUTE AND NIDA HAS ONE OF
OUR PROGRAMS.
WE BASICALLY WORK WITH PAID
I.C.s.
IN TERMS OF EXPANDING THEM,
THERE'S SOME INSTITUTES THAT
HAVE K12s OF THEIR OWN AND
BECAUSE THEY'RE EXPENSIVE
PROJECTS, HOURS $648,000 PER
YEAR TOTAL COST AND THEY'RE
SIMILAR FOR THE INSTITUTES AND
CENTERS.
THEY HAVE ELECTED NOT TO JOIN US
BUT CONTRIBUTE AT LEAST SOME
MONEY FOR ONE SCHOLAR.
THAT'S HOW WE GET GREATER
PARTICIPATION.
I READ YOUR REPORT PUBLISHED IN
THE JOURNAL OF WOMEN'S HEALTH.
IT ALSO CLEARLY DOCUMENTED DATA
ABOUT THE DISPROPORTIONATE
AFFECT THE PANDEMIC HAS HAD ON
FEMALE FACULTY.
WHEN I THINK ABOUT THESE EARLY
AWAR
AWARDS AND SUPPORTING FACULTY
ESPECIALLY JUNIOR FEMALE FACULTY
I CAN'T HELP BUT THINK THERE MAY
BE WAYS TO LEVERAGE AND
INCREASE, ENGAGEMENT FROM THE
INSTITUTES IN THIS TYPE OF
PROGRAM IN A MOMENT WHEN MANY OF
US ARE TALKING ABOUT THE EXACT
ISSUE IN VERY DIVERSE AREAS OF
HEALTH SCIENCE.
>> I'LL REFER BACK TO COVID AS
THE MORE GENERAL ISSUE.
>> IN YOUR INSTITUTION, ABOUT
WHAT WOULD BE HELPFUL TO YOU TO
WITHIN YOUR INSTITUTION HELPING
OTHER DEPARTMENTS TO UNDERSTAND
THIS IS AN OPPORTUNITY?
MAYBE WE CAN FLIP IT AROUND AND
THEN SEE HOW TO GET THERE.
WHAT WOULD RAISE THEIR AWARENESS
AS AN OPPORTUNITY.
>> WHAT RAISES AWARENESS THIS AS
AN OPPORTUNITY IS HOW FAMILIAR
PROGRAMS ARE WITH K12 PROGRAMS.
I HAVE FOUND THE SCHOOL OF
MEDICINE IS AWARE AND
ACCOMPLISHED AT MANAGING K12
PROGRAMS AND SEES HOW THIS LIFTS
JUNIOR FACULTY PROVIDING THEM
WITH THE INFRASTRUCTURE.
THEY RELY ON US AS MENTORS IN A
PLACE LIKE THE SCHOOL OF PUBLIC
HEALTH WHERE I AM WHICH IS NOT
AS FAMILIAR WITH THE K12
PROGRAMS, A LITTLE MORE
LUKEWARM.
WE PARTICIPATE BUT WE EVEN HAVE
MATCHED FUNDS SO MAY MATCH
DOLLAR PER DOLLAR WHAT YOU GUYS
GIVE US SO WE CAN DOUBLE THE
NUMBER OF SCHOLARS.
THAT'S HOW MUCH AT JOHNS HOPKINS
WE BELIEVE IN THE PROGRAM I HOPE
THERE ARE WAYS TO INCREASE
INSTITUTE SUPPORT.
IT'S A SUCH A RICH PROGRAM AND
ONE THE DOLLAR AMOUNT DOESN'T
ADEQUATELY REFLECT WHAT THE
PROGRAM IS CAPABLE OF.
I'M GOING STOP BECAUSE JUDY HAS
HAD HER HAND UP.
>> THANK YOU FOR THE CHALLENGE,
SABRA, THANK YOU FOR THE
CHALLENGE AND THANK YOU FOR
BEING AVAILABLE.
>> I HAVE SEEN SO MUCH GOOD COME
FROM IT AND IF WE CAN CONTINUE
TO GROW THAT PROGRAM IT'S A GEM.
IT'S UNBELIEVABLE.
I WANTED TO ASK, LISA, I WAS
THINKING OF NHLBI CONTRIBUTE TO
BIRCWH AND I WONDERED ABOUT
THAT.
HAVE THEY AND HAVE I MISSED
THAT?
>> I DON'T WANT TO SPEAK FOR THE
INSTITUTE BUT IT HAS A LARGE K12
PROGRAM OF ITS OWN.
THAT'S THE FOCUS THEY WISH TO
CONTINUE.
>> EVACUATE -- HAVING BEEN TRE
TRAINING OFFICER OF NHLBI THEY
HAVE SET PRIORITIES AND NHLBI
HAS A TREMENDOUS NUMBER OF K
AWARDS BUT IN RECENT YEARS THE
K12 PROGRAMS IN THE MORE RECENT
YEARS HAVE BEEN FOCUSSED ON
IMPLEMENTATION SCIENCE RATHER
THAN ON THE SPECIFIC SCIENCE
AREA THAT IS WITHIN THE SCOPE OF
NHLBI.
MAYBE IN THE COMING YEARS
THEY'LL BE INTERESTED AGAIN
INVESTING IN A K12 BUT RIGHT NOW
I THINK THEIR BUDGET TIED UP FOR
THE NEXT FIVE YEARS ON PROGRAMS
THEY ALREADY HAVE IN PLACE.
>> THANK YOU FOR THE RICH
DISCUSSION.
I DO SEE THAT DR. TEMPLETON ALSO
ADDED A PLUS-1 TO ALLISON'S
COMMENT AND KIM, ARE YOU ABLE TO
UNMUTE AND MAKE YOUR COMMENT
YOURSELF?
>> I APPRECIATE THAT.
I APPRECIATE ALISON'S COMMENT
AND AGREE.
I THINK A SHIFT IN FOCUS IN WHAT
WE MEAN BY WOMEN'S HEALTH
RESEARCH BECAUSE IT HAS TO START
SOMEWHERE.
EVEN IF IT'S JUST COUNTING
INCIDENTS AND PREVALENCE AND
SEEING A DIFFERENCE USING THAT
AS THE WATCH TO START LOOKING AT
WHY.
LOOKING AT THE ISSUES WITH METAL
ON METAL ARTHROSCOPY AND WE SAW
ALMOST ALL THE FAILURES WERE IN
WOMEN AND YOU START EXPLORING
WHY.
THOUGH THERE WAS INCIDENTS OF
PREVALENCE IN FAILURE, THAT WAS
A TRUE WOMEN'S HEALTH RESEARCH
BECAUSE IT SHOWS THERE WAS A
DIFFERENCE AMONG WOMEN.
WHEN YOU TAKE IT TO THE NEXT
STEP THAT MAY GET MORE INTO WHAT
IS CONSIDERED WOMEN'S HEALTH
RESEARCH BUT I THINK IF THERE'S
A WAY TO EXPAND WHAT WE MEAN BY
THAT TO BE MORE INCLUSIVE OF
OTHER STUDIES.
DO OTHERS HAVE THOUGHTS TO WEIGH
IN ON HOW WE CONCEPTUALIZE
WOMEN'S HEALTH AND SEX AND
GENDER INFLUENCES IN HEALTH AND
DISEASE?
I PUT THAT TOGETHER IN ONE
PHRASE LIKE THAT OFTEN AND OFTEN
SAY WE UNDERSTAND SEX AND GENDER
INFLUENCES IN HEALTH AND DISEASE
WE CAN INFORM AND IMPROVE THE
HEALTH OF WOMEN.
THEY'RE ALL LINKED IN MY MIND IN
THAT WAY AS WELL BUT HOW WE
THINK THERE'S DIFFERENT WAYS TO
DO THAT.
I WELCOME ANYONE ELSE'S THOUGHTS
ON THAT.
>> THE EARLY STAGE IS IMPORTANT
IN A NEW AND SOMETHING VERY
MATURE.
A TOPIC THAT'S MATURE I PROBABLY
WOULDN'T FEEL LOOKING AT THE
GENDER DIFFERENCE WAS VERY
COMPELLING WITH WOMEN'S
RESEARCH.
I THINK THERE'S NUANCE IN THE
TOPIC.
>> THANKS FOR ADDING THAT.
AND WE HAVE THE RESPONSIBILITY
TO DESIGN THE TRIALS MORE
APPROPRIATELY TO LOOK FOR
AFFECTS IN MEN AND WOMEN.
THERE ARE NUANCES.
>> DR. CLAYTON, IN YOUR
DIRECTOR'S REPORT, WHICH I HAVE
TO AGREE WITH THE PERSON THAT
TALKED ABOUT THE BREADTH OF
INFORMATION WE GET FROM THAT
REPORT, BUT I LOVED HOW YOU IN
COR RATED WHAT SOME OF US THINK
OF AS A WELLNESS COMPONENT AND
THAT WAS SLEEP.
I WASN'T EXPECTING THAT BUT
THAT'S SO IMPORTANT TO WOMEN'S
HEALTH AND THERE'S OTHER MORE
RELATED TO WELLNESS LIKE SLEEP
AND BECAUSE OF THE IMPACT THAT
HAS ON WOMEN'S HEALTH AND
BECAUSE SLEEP PATTERNS ARE
DIFFERENT FOR MEN VERSUS WOMEN
BECAUSE SLEEP ISSUES CAN ALSO
DEVELOP DURING PREGNANCY, I WAS
WONDERING IF IT'S GOING TO BE
MORE FOCUSSED ON SOME OF THOSE
ASPECTS THAT WE DON'T NORMALLY
TALK ABOUT I WAS HAPPY STE THAT
AND GOING FORWARD ESPECIALLY
POST PANDEMIC IS OF INTEREST TO
THE PUBLIC HEALTH.
THANK YOU.
IT'S NOW BEING LED BY DR. BROWN.
>> THERE'S A NEW RESEARCH PLAN
WITH EXPLICIT ARTICULATION AND
ORWH SCIENTIFIC STAFF ARE
SPEAKING SO I EXPECT CONTINUED
CONNECTIONS WITH THE SLEEP
CENTER AS WE MOVE FORWARD.
WE HAVE SPONSORED SEVERAL
MEETINGS WITH THEM AND THERE'S A
COUPLE PUBLICATIONS BUT WE
GREATLY APPRECIATE THE FEEDBACK
ON WHAT IS OF INTEREST TO YOU
AND ALSO SLEEP IS EASILY
OVERLOOKED.
THAT'S ONE OF THE REASONS I KEPT
IT IN.
I COUNT HAVE PUT SOMETHING ON
THE SEX DIFFERENCES AND THE
CLOCK GENE EXPRESSION WHICH
EXISTS BUT I WANTED TO FOCUS ON
THE LIVED EXPERIENCE OF MANY
PEOPLE AND IT'S A COMMON
CHALLENGE AND IT'S A
QUINTESSENTIAL SEX DIFFERENCE
AND WOMEN'S TOPIC.
>> WE'RE COLLABORATING FOR NCCIH
ON THEIR WHOLE PERSON HEALTH
INITIATIVE.
MAY REMEMBER DR. LANGEVIN SPOKE
ON THAT IN A PREVIOUS MEETING.
THERE MAY BE FOLLOW-UP BUT WE'RE
COLLABORATING WITH HER ON THAT
AS WELL.
OTHER COMMENTS AND QUESTIONS.
I'M LOOKING AT HANDS UP.
ANYTHING YOU'D LIKE TO SEE AT A
FUTURE MEETING I APPRECIATE
DR. ROBINSON WEIGHING IN ON
THAT.
DR. NOURSI DO YOU HAVE FOLLOW-UP
AND YOU TOLD FOLKS TO E-MAIL YOU
DIRECTLY FOR THE WORKING GROUP?
>> YES.
THANK YOU FOR BRINGING THIS BACK
UP.
I MENTIONED WE WILL BE REACHING
OUT TO YOU ALL TO SERVE ON A
WORKING GROUP.
FOR THOSE THAT JOINED THE
WOMEN'S HEALTH CONFERENCE
WORKING GROUP WHERE IT HAD A
COMBINATION OF MEMBERS FROM
CCRWH AND OTHER ORGANIZATIONS
AND IT WILL BE A SIMILAR
COMPOSITION OF DIFFERENT
MEMBERS.
I ALREADY RECEIVED ONE VOLUNTEER
VIA E-MAIL WHO WANTS TO JOIN.
WE'LL BE REACHING OUT TO YOU AND
WE'RE HOPING SO WE ARE RIGHT NOW
IN THE PROCESS OF JUST PUTTING
THE FOUNDATION FOR HOW WE'RE
GOING TO APPROACH THE NEXT NIH
WIDE STRATEGIC PLAN AND IT WILL
INCLUDE SEVERAL COMPONENTS
CLEARLY AND IT WILL BE USING ALL
THE INFORMATION AND THE
IMPLEMENTATION ACROSS NIH.
I BELIEVE WE'LL REACH OUT TO YOU
NEXT WEEK WITH THE HOPE TO
CONVENE THE FIRST MEETING
SOMETIMES AT THE END OF MAY OR
BEGINNING OF JUNE.
SO WE CAN START BRAIN STORMING
HOW YOU PERCEIVE THE STRATEGIC
PLAN TO BE AND WHICH APPROACH TO
TAKE AND WHERE THE INFORMATION
WILL BE COMING.
WE'LL NEED IT TO BE DONE BY THE
END OF 2023.
BEHAVE TIME BUT THIS IS A TIME
TO START I'LL REACH OUT AND THE
BURDEN WOULD BE SPREAD OUT SO
YOU WOULD NOT BE EXPECTED TO DO
ANYTHING IMMEDIATELY.
LOOK FOR AN E-MAIL FROM US AND
MAINLY ONE FOCUS IS ON THE I.C.
REPORT IS THE BIENNIAL REPORT
INCLUDES REPORTS FROM THE
VARIOUS INSTITUTES ABOUT THE
WORK THEY'RE DOING TO WOMEN'S
HEALTH.
WE RELY ON YOUR EXPERTISE TO AN
WE'LL DIVIDE THE SECTIONS
ACCORDING TO YOUR EXPERTISE AND
HOPING YOU'LL SHED LIGHT ON WHAT
GAPS THE NIH INSTITUTES SHOULD
FOCUS ON FOR NEXT STRATEGIC
PLAN.
THAT'S THE FIRST THING WE WOULD
BE SEEKING YOUR HELP WITH.
LOOK FOR AN E-MAIL FROM ME OR
ONE OF MY SCIENCE POLICY
PLANNING AND SECTION STAFF AND I
HOPE YOU'LL JOIN US.
>> THANK YOU, I WILL ACKNOWLEDGE
YOU'RE STARTING EARLIER THAN
EVER BEFORE AND I APPRECIATE
THAT AND KNOW EVERYONE ELSE WILL
AS WELL.
THAT GIVES US MORE TIME TO THINK
CAREFULLY AND NOT BE RUSHED ON
IT.
AS YOU HIGHLIGHTED IN YOUR
PRESENTATION, WE HAVE SO MANY
SOURCES OF DATA AND WE HAVE DATA
FROM THE INSTITUTES AND CENTERS
BECAUSE OF THE NEW REPORTING
MODULE AND HAVE MORE TO INFORM
THIS PARTICULAR STRATEGIC PLAN.
I THINK IT'S GOING TO BE VERY
EXCITING TO HELP LAY OUT THE
FUTURE FOR NIH.
AND WE STARTED TO WORK ON THE
NIH WIDE STRATEGIC PLAN AND
WE'LL BE MAKE SURE THERE'S
SYNERGY BETWEEN THE TWO AND
WE'LL BUILD ON AND TRY TO INFUSE
AS MUCH AS WE CAN IN THE NIH
WIDE STRATEGIC PLAN.
IT WILL BE A GOAL.
YOU'RE RIGHT.
AS ALL OF YOU MAY KNOW, THIS IS
THE FIRST TIME I.C.s ARE
REPORTING AND WE HAVE NEVER HAD
THIS BEFORE AS WE DEVELOP THE
STRATEGIC PLAN SO THAT WOULD BE
AN INVALUABLE RESOURCE FOR US TO
SEE WHAT THEY HAVE DONE AND THE
MEETINGS THEY CONVENED AND THE
FOAs THEY'VE DEVELOPED.
>> THERE'S A NEW PROVISION THE
INSTITUTE AND CENTERS STRATEGIC
PLANS THEY DEVELOP ON THEIR OWN
MISSION AREAS MUST INCLUDE AN
ARTICULATION OF WHAT THEY'LL DO
TO ADVANCE WOMEN'S HEALTH AND
HEALTH DISPARITIES AND ADDRESS
HEALTH DISPARITY.
AS THOSE ARE COMING OUT AS WELL,
YOU'LL SEE INCREASED LANGUAGE IN
THE INSTITUTE SPECIFIC STRATEGIC
PLANS.
WE ALSO HAD JAMIE WHITE PUT IN
THE CHAT FOR THOSE WHO CAN
ACCESS THE LINK TO THE NHLBI-LED
SLEEP DISORDERS ADVISORY BOARD
MEETING.
IT'S THE PUBLIC MEETING THAT IS
TOMORROW WHERE THEY'LL BE
PRESENTATIONS FROM ORWH
COLLEAGUES AND WOMEN'S HEALTH IS
INCLUDED.
I'D LIKE TO TAKE A LOOK AND SEE
IF WE HAVE HANDS FOR ADDITIONAL
COMMENTS OR SUGGESTIONS THAT
ANYONE WOULD LIKE TO MAKE AND
FOR MANY PRESENTATIONS TODAY OR
PRESENTATIONS ORR IRI IRIC -- OR TOPICS
YOU'D LIKE TO SEE IN THE FUTURE.
PLEASE LET US KNOW.
SEEING NONE.
I DON'T SEE ANY OTHER QUESTIONS
IN THE CHAT.
DO WE HAVE ANYTHING ELSE TO
COVER BEFORE WE ADJOURN.
WE CAN CERTAINLY ADJOURN EARLY.
>> WE COVERED IT ALL.
>> ARE YOU OKAY WITH THAT,
DR. NOURSI.
>> YES, PEOPLE ASKED ABOUT THE
OCTOBER MEETING IF IT WILL BE IN
PERSON OR HYBRID AND WE'LL SHARE
INFORMATION AS WE GET GUIDANCE
FROM NIH.
THINGS ARE MOVING SO HOPEFULLY
NOTHING HITS OUR NATION WITH
REGARD TO ANY PANDEMIC OR ANY
OTHER THING SO MAYBE WE'LL BE IN
PERSON BUT YOU'LL KNOW WAY IN
ADVANCE AND AS DR. CLAYTON SAID
AND YOU ALL KNOW AND I SHARED
WITH YOU, WE ALL SHARED WITH YOU
EVERYTHING ON ACTIVITY ARE
HAPPENING AND TAKE THAT
OPPORTUNITY TO COMMUNICATE
ANYTHING YOU'D LIKE TO SEE IN
THE REPORTS OR AGENDA AS WE'RE
TRYING TO PUT THE AGENDA FOR
OCTOBER, SHARE IDEAS OR TOPIC
YOU'D LIKE TO SEE AND WE'LL
DISCUSS IT INTERNALLY AND
INDEFINITELY TAKE IT INTO
ACCOUNT AS WE ARE MOVING FORWARD
WITH THE AGENDA FOR THE FALL.
>> SO BEFORE WE CLOSE I DO WANT
TO THANK ALL OF THE EXCELLENT
PRESENTERS.
ALL OF THEM ARE NOT ON BUT THANK
THEM FOR THEIR PARTICIPATION IN
TODAY'S MEETING.
THIS PRESENTATIONS ARE CRITICAL
TO SHARING INFORMATION WITH OUR
ADVISORY COMMITTEE MEMBERS AND
WITH THE GENERAL PUBLIC ABOUT
THE VAST COMMITMENT THAT IS NIH
WIDE RELATED TO WOMEN'S HEALTH
AND SEX AND GENDER INFLUENCES IN
HEALTH AND DISEASE AND THANK YOU
ALL AS ADVISORY MEMBERS.
WE KNOW THIS IS EXTRA ON TOP OF
YOUR DAY JOB AND SOME HAD TO POP
IN FROM DOING VARIOUS THINGS AND
WE APPRECIATE EACH AND EVERY ONE
OF YOU AND YOUR WORK AND SUPPORT
OF ORWH AND BECAUSE OF YOU WE'RE
ABLE TO MOVE FORWARD IN NEW
DIRECTIONS.
AND SO BEFORE I END I ALSO WANT
TO THANK OUR AMAZING TEAM ORWH
FOLKS BEHIND THE SCENES AND OUR
CONTRACTORS AND COMMUNICATION
STAFF AND ALL TEAM ORWH.
THERE'S A LOT OF WORK THAT GOES
INTO ORGANIZING THESE MEETINGS
AND EVEN ON TOP OF THAT THERE'S
AN INCREDIBLE AMOUNT OF WORK
THAT GOES INTO THE SIGNATURE
PROGRAMS AND THE WORK THAT I WAS
ABLE TO PRESENT.
IT'S MY PLEASURE AND A PRIVILEGE
TO BE ABLE TO PRESENT THAT
DIRECT'S REPORT.
IT REALLY REPRESENTS AN AMAZING
AMOUNT OF WORK DONE BY
INCREDIBLE PEOPLE AT TEAM ORWH
AND SPECIAL THANKS TO DR. NOURSI
WHO HAS STOOD BY ME AS EXEC SEC
OF THE ORWH.
NOT A JOB SHE WAS ORIGINALLY
ASSIGNED SO SHE'S DONE AN
OUTSTANDING JOB.
THANK YOU VERY VERY MUCH AND HER
PARTNER, SARAH HEILMAN, SPECIAL
THANKS TO HER TOO.
ON BEHALF OF ORWH, THANK YOU
SARAH.
WE WILL SEE YOU ON OCTOBER 18
FOR THE 57th MEETING OF THE NIH
ADVISORY COMMIT FOR COMMITTEE ON
RESEARCH ON WOMEN'S HEALTH.
STAY SAFE AND HEALTHY ALL.
TODAY'S MEETING IS NOW
ADJOURNED.
THANK YOU.